PDS Biotechnology Corp - Annual Report: 2018 (Form 10-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to ________
Commission file number 001-37568
|
Edge Therapeutics, Inc.
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
26-4231384
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922
|
|
(Address of principal executive offices)
|
|
(800) 208-3343
|
|
(Registrant’s telephone number)
|
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulations S-K (§ 229.405 of this chapter) is not contained herein and
will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or
an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller Reporting Company ☒
|
|
Emerging growth company ☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☒ No ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates (without admitting that any person whose shares are not
included in such calculation is an affiliate) of the registrant on June 30, 2018, was $32.3 million (based on the closing price for shares of the registrant’s common stock as reported on the Nasdaq Global Select Market on that date).
The number of shares of the registrant’s common stock, par value $0.00033 per share, outstanding as of February 14, 2019 was 31,509,822.
Edge Therapeutics, Inc.
FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2018
|
PAGE
|
||
|
PART I
|
||
|
Item 1
|
4
|
|
|
Item 1A
|
8
|
|
|
Item 1B
|
28
|
|
|
Item 2
|
28
|
|
|
Item 3
|
28
|
|
|
Item 4
|
28
|
|
|
PART II
|
||
|
Item 5
|
29
|
|
|
Item 6
|
Selected Financial Data |
29 |
|
Item 7
|
30 |
|
|
Item 8
|
38 |
|
|
Item 9
|
38
|
|
|
Item 9A
|
38
|
|
|
Item 9B
|
38
|
|
|
PART III
|
||
|
Item 10
|
39
|
|
|
Item 11
|
45
|
|
|
Item 12
|
51
|
|
|
Item 13
|
52
|
|
|
Item 14
|
53
|
|
|
PART IV
|
||
|
Item 15
|
55
|
|
|
Item 16
|
55
|
|
|
59
|
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements that involve substantial risks and
uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future
operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors”
contained in Item 1A of this Annual Report. In light of these risks, uncertainties and assumptions, actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements in this Annual Report and
you should not place undue reliance on these forward-looking statements.
These forward-looking statements include, but are not limited to, statements about:
| ● |
the expected benefits of and potential value created by the proposed merger among Edge Therapeutics, Inc., a Delaware corporation, or Edge, Echos Merger Sub, Inc., a
Delaware corporation and a wholly-owned subsidiary of Edge, or Merger Sub, and PDS Biotechnology Corporation, a Delaware corporation, or PDS, for the stockholders of Edge;
|
| ● |
the likelihood of the satisfaction of certain conditions to the completion of the merger and whether and when the merger will be consummated;
|
| ● |
Edge’s ability to control and correctly estimate its operating expenses and its expenses associated with the merger;
|
| ● |
the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings;
|
| ● |
the plans to develop and commercialize additional products;
|
| ● |
the attraction and retention of highly qualified personnel;
|
| ● |
the ability to protect and enhance the combined company’s products and intellectual property;
|
| ● |
developments and projections relating to the combined company’s competitors or industry;
|
| ● |
the combined company’s financial performance;
|
| ● |
expectations concerning Edge’s or PDS’s relationships and actions with third parties;
|
| ● |
future regulatory, judicial and legislative changes in Edge’s or PDS’s industry; and
|
| ● |
other risks and uncertainties, including those listed under Item 1A. Risk Factors.
|
Any forward-looking statements in this Annual Report reflect our current views with respect to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any
reason, even if new information becomes available in the future.
In this Annual Report, unless otherwise stated or the context otherwise indicates, references to “Edge,” “Edge Therapeutics,” “the
Company,” “we,” “us,” “our” and similar references refer to Edge Therapeutics, Inc., a Delaware corporation.
PART I
Pending Merger Agreement with PDS
On November 23, 2018, Edge, Merger Sub and PDS, a privately-held clinical-stage cancer immunotherapy company, entered into an Agreement
and Plan of Merger and Reorganization, or the Merger Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into PDS, with PDS
surviving the merger as the wholly-owned subsidiary of the combined company.
If the merger is completed, the business of Edge will become the business of PDS. If the merger is not completed, Edge will reconsider
its strategic alternatives and may pursue one of the following courses of action, which Edge currently believes are the most likely alternatives if the merger with PDS is not completed:
| ● |
Pursue another strategic transaction similar to the merger. Edge may resume its process of evaluating other companies interested in pursuing a strategic transaction with
Edge and, if a candidate is identified, focus its attention on negotiating and completing such a transaction with such candidate.
|
| ● |
Dissolve and liquidate its assets. If Edge is unable, or does not believe that it is able, to find a suitable candidate for another strategic transaction, Edge may dissolve
and liquidate its assets. In the event of dissolution, Edge would be required to pay all of its debts and contractual obligations and to set aside certain reserves for potential future claims. If Edge dissolves and liquidates its
assets, there can be no assurance as to the amount or timing of available cash that will remain for distribution to Edge’s stockholders after paying Edge’ debts and other obligations and setting aside funds for its reserves.
|
Overview
Edge is a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming
treatment paradigms in the management of medical conditions.
On March 28, 2018, Edge announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first 210
subjects randomized and treated in the Phase 3 multi-center, randomized, double-blind, placebo-controlled, NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage demonstrated a low probability of achieving a
statistically-significant difference compared to the standard of care in the study’s primary endpoint, if the study were to be fully enrolled. The independent Data Monitoring Committee, or the DMC, for the NEWTON 2 study recommended that the study
be stopped based on this demonstration. The DMC also reported that there were no safety concerns attributed to EG-1962.
Based on the DMC recommendation, Edge decided to discontinue the NEWTON 2 study and took steps to notify health authorities and clinical
investigators participating in the study.
The NEWTON 2 study was designed to detect a 15% absolute improvement in favorable outcomes at Day 90 for the EG-1962 treatment group
with a target enrollment of 374 subjects with WFNS grades 2-4 and an external ventricular drain, or EVD. Prior to discontinuation of the study, 289 subjects were randomized and 282 were treated. The final analysis showed that overall in the study’s
primary endpoint, 46% (64/138) of subjects treated with a single intraventricular injection of EG-1962 experienced a favorable outcome (a score of 6 to 8 on the extended Glasgow Outcome Scale, or GOSE) at Day 90, compared to 43% (62/144) of
subjects treated with oral nimodipine. The GOSE is a clinically validated scale to assess recovery for patients who have suffered a brain injury.
In the NEWTON 2 study, at randomization, subjects were stratified by baseline severity as measured by the World Federation of
Neurological Surgeons, or WFNS, grade. Results of a logistic regression analysis of Day 90 GOSE outcomes including interactions revealed a statistically significant treatment by WFNS group interaction (p=0.0381). In the pre-specified subgroup of
subjects with WFNS grade 3 or 4 (i.e., severe aSAH subjects), 46% (32/69) of subjects treated with EG-1962 experienced a favorable outcome as measured by
GOSE, compared to 32% (24/75) of subjects treated with oral nimodipine. While these results did not achieve statistical significance (as the NEWTON 2 study was not powered to provide statistical significance for subgroups), they suggest a
clinically meaningful potential benefit for EG-1962 in subjects with WFNS grade 3 or 4. Further, these results are consistent with results from Edge’s Phase 1/2 NEWTON study. In that study, EG-1962 demonstrated a similar efficacy trend in favorable
outcome rate compared to oral nimodipine in severe aSAH subjects with WFNS grades 3 or 4, with 37% (10/27) of the subjects treated with EG-1962 experiencing a favorable outcome, compared to 23% (3/13) of the subjects treated with oral nimodipine.
In the WFNS grade 2 subgroup (i.e., moderate
aSAH subjects), favorable outcome rates from the NEWTON 2 study were inconsistent with those observed in the Phase 1/2 NEWTON study in both the EG-1962 and oral nimodipine treatment groups. In addition, the favorable response rate in the control
group in NEWTON 2 was higher than, and inconsistent with, that reported in the medical literature.
Edge did not identify any safety concerns that would have halted the NEWTON 2 study or precluded further development of EG-1962.
Notably, the incidence of vasospasm was significantly lower in the EG-1962 treatment group compared to the standard of care, oral nimodipine. In addition, there was a lower incidence of both mortality and hypotension in the EG-1962 treatment group.
Based on the overall findings of the NEWTON 2 study, Edge has explored whether any third party(ies) would be interested in acquiring
rights to EG-1962. To date, there has been no significant interest expressed by any third party.
On April 17, 2018, the Edge Board of Directors, or the Edge Board, established a committee of convenience, the Transactions Committee,
to explore strategic alternatives for Edge in order to maximize both near and long-term value for Edge shareholders, which might have included, without limitation, an acquisition of another company, acquisitions or in-licensing of products or
product candidates, technologies or other assets, the sale of all or substantially all of the assets of Edge, a sale of stock, a strategic merger or other business combination transaction or other transaction between Edge and a third party.
In April 2018, the Edge Board retained Piper Jaffray & Co., or Piper Jaffray, to serve as its financial advisor in certain aspects
of the strategic review process. Throughout the strategic alternatives review and selection process, Edge has continued to finance its operations with its existing cash. In addition, Edge has reduced the scope of its operations, including the size
of its workforce, in order to preserve cash resources. Edge has ceased research and development on EG-1962, including the completion of the NEWTON 2 study, and all of Edge’s other product candidates.
After a comprehensive review of strategic alternatives, on November 23, 2018, Edge, Merger Sub and PDS entered into the Merger
Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into PDS, with PDS surviving the merger as the wholly-owned subsidiary of
the combined company. PDS is a private company with a growing pipeline of clinical-stage immunotherapies that are expected to treat various early-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, breast
cancer and other cancers. Following the merger, the combined company expects to focus on developing PDS’s growing pipeline of next-generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology
platform, the development of PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers, and multiple preclinical programs developing Versamune®-based cancer
immunotherapies in combination with checkpoint inhibitors for various late-stage cancers.
Intellectual Property
The protection of Edge’s product candidates, Edge’s manufacturing methods, delivery systems and patient treatment protocols, and
associated trade secrets and know-how are important to Edge’s business. Edge has sought patent protection in the United States and internationally relating to EG-1962, a microparticulate formulation of nimodipine. Edge’s policy is to seek, maintain
and defend patent rights, whether developed internally or in-licensed, and to protect technologies, improvements and trade secrets that may be important to Edge’s business.
Edge’s commercial success will depend in part upon obtaining and maintaining patent and trade secret protection for Edge’s product
candidates, including components of Edge’s proprietary formulations, methods of manufacturing Edge’s product candidates, delivery systems, and methods of treating patients with Edge’s product candidates, as well as successfully defending Edge’s
patent rights against third party challenges. Edge’s ability to prevent or stop third parties from making, using, selling, offering to sell or importing Edge’s product candidates will depend in part upon whether Edge has valid and enforceable
patent rights that cover the activities of third parties.
Patent Rights
Edge has been building Edge’s patent portfolio. Where possible, Edge has pursued multi-tiered patent protection for Edge’s product
candidates and their manufacture, delivery and use. In addition to filing and prosecuting patent applications in the United States, Edge has filed counterpart patent applications in various countries and regions where Edge thinks such foreign
filing is likely to be cost-effective.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which Edge files, the patent term is 20 years from the earliest date of filing of a non-provisional patent application, with up to an additional five-year patent term extension available for regulatory delay. In the United States, a patent’s
term may also be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office, or USPTO, in granting a patent. However, the term of a United States patent may be
shortened, if the patent term for a patent is terminally disclaimed by its owner, over another patent.
Patent Rights Associated with EG-1962
Edge wholly-owns one issued U.S. patent (expected to expire in 2029 if
all maintenance fees are paid) directed to a method of treating a cerebral vasospasm in a human by administering a pharmaceutical composition via surgical injection into the subarachnoid space in a cistern closest to a cerebral artery at risk for
vasospasm. Edge also has been granted patent protection for this invention in Australia (3), Canada, China, Germany, Great Britain, France, Switzerland, Spain, Israel,
Japan, Korea (3), New Zealand (2) and Singapore.
Edge has wholly-owned patents (expected to expire in 2032 if all
maintenance fees are paid) directed to a method of treating, and a microparticulate delivery system for treating, a delayed complication associated with brain injury where the brain injury includes interruption of at least one cerebral artery in
Germany, Spain, France, United Kingdom, Italy and Hong Kong; a notice of allowance has issued in Israel.
Edge also has a wholly-owned U.S. patent (expected to expire in 2029 if
all maintenance fees are paid) claiming a method of treating a cerebral artery in the subarachnoid space of a human at risk of interruption due to a brain injury by administering locally a microparticulate composition into a cerebral ventricle.
Patent protection for these inventions has been granted in Australia, China, Switzerland, Germany, France, United Kingdom, Japan, New Zealand, Russia and Singapore.
Edge also has a wholly-owned U.S. patent (expected to expire in 2029 if
all maintenance fees are paid) claiming a method for treating a delayed complication of a brain injury that deposits blood in a subarachnoid space of the brain, wherein the brain injury is mediated by decreased cerebral perfusion, comprising
providing a flowable particulate composition comprising a microparticulate suspension containing a calcium channel antagonist and a pharmaceutically acceptable carrier comprising an agent that affects viscosity of the microparticulate suspension
of claimed release characteristics, and a drug load of at least 40%; and administering the composition locally either intracisternally, intraventricularly or intrathecally. Patent protection for this invention has been granted in New Zealand and
United Kingdom.
In addition to the foregoing, Edge has used Edge’s Precisa development
platform, in collaboration with Evonik Industries, or Evonik, to seek to develop pharmaceutical compositions that contain particular polymorphic forms of nimodipine. Based on the collaboration, Edge co-owns, together with Evonik, two issued U.S.
patents claiming a process for producing microparticles encapsulating a particular polymorphic form of nimodipine, a semisolid delivery system containing microparticles comprising the particular polymorphic form of nimodipine, and a method of
treating a cerebral artery in a subarachnoid space at risk of interruption due to a brain injury using such a delivery system. These patents are expected to expire in 2033 if all maintenance fees are paid. Edge also co-owns, with Evonik, related
patents granted in Australia, Canada, Japan, Korea, New Zealand and Singapore. The issued U.S. patents cover the microparticulate formulation used in the NEWTON study. Evonik, as successor to SurModics Pharmaceuticals, Inc., or SurModics, under
Edge’s license agreement initially with SurModics, has granted Edge an exclusive, field-restricted, worldwide, royalty-bearing license under its patent rights together with enforcement rights against infringers, all pursuant to Edge’s license
agreement with Evonik relating to the co-owned patent rights.
Manufacturing
Edge has no present intention to manufacture EG-1962 or any other product. Edge currently has (1) an amended and restated master
formulation development agreement and (2) a manufacturing and supply agreement, each for EG-1962 and each with Oakwood Laboratories, or Oakwood, but no work is being performed under either agreement.
Competition
Edge has no current plans to further develop or commercialize its portfolio of products. However, to the extent the merger with PDS
results in the further development of the candidates in its portfolio, potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies
and research institutions. The pharmaceutical industry is highly competitive and subject to rapid and significant technological change. Key competitive factors are likely to be efficacy, safety and tolerability profile, convenience of dosing, price
and reimbursement. Many of these potential competitors have substantial financial, technical and human resources and significant experience in the discovery and development of product candidates, obtaining United States Food and Drug
Administration, or FDA, approval and other regulatory approvals of products and the commercialization of those products. Further, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being
concentrated among a small number of competitors. Accordingly, competitors may be more successful in obtaining FDA approval for therapies and achieving widespread market acceptance. Competitors’ products may also be more effective, or more
effectively marketed and sold, than any product candidate that may be commercialized and may render Edge’ therapies obsolete or non-competitive before development and commercialization expenses can be recovered.
Government Regulation
Government authorities in the United States at the federal, state and local levels, and in other countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of new drugs.
A number of different regulatory agencies may be involved, depending on the product at issue, and the type and stage of activity. These
include the FDA, the Drug Enforcement Administration, the Centers for Medicare and Medicaid Services, other federal agencies, state boards of pharmacy, state-controlled substance agencies and more.
U.S. Government Regulation
Drug Development Process
In the United States, the FDA is a primary regulator of drugs under the Federal Food, Drug, and Cosmetic Act and implementing
regulations. The process of obtaining regulatory approvals and other compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with
applicable requirements at any time during the drug development process, approval process, or after approval, may subject Edge to adverse consequences and administrative or judicial sanctions, any of which could have a material adverse effect on
Edge. These sanctions could include refusal to approve pending applications; withdrawal or restriction of an approval; imposition of a clinical hold or other limitation on research; warning letters; product seizures; total or partial suspension of
development, production, or distribution; or injunctions, fines, disgorgement, or civil or criminal payments or penalties.
The process required before a drug may be marketed in the United States generally involves the following:
| ● |
completion of preclinical laboratory tests, animal trials and formulation trials conducted according to Good Laboratory Practices, animal welfare laws and other applicable
regulations;
|
| ● |
submission to the FDA of an Investigational New Drug, or IND, application which must become effective before clinical trials (trials in human subjects) in the United States
may begin, obtaining similar authorizations in other jurisdictions where clinical research will be conducted and maintaining these authorizations on a continuing basis throughout the time that trials are performed and new data are
collected;
|
| ● |
performance of adequate and well-controlled clinical trials according to Good Clinical Practices to demonstrate whether a proposed drug is safe and effective for its
proposed intended use;
|
| ● |
preparation and submission to the FDA of a marketing authorization application, such as a new drug application, or NDA, and submitting similar marketing authorization
applications in other jurisdictions where commercialization will be pursued;
|
| ● |
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product will be produced to assess compliance with cGMP to assure that
the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity; and
|
| ● |
FDA review and approval of the NDA or other marketing authorization application.
|
The development, testing and approval process requires substantial time, effort and financial resources, as well as bearing inherent
risk that individual products will not exhibit relevant safety, effectiveness, or quality characteristics. Edge cannot be certain that any approvals for its product candidates will be granted on a timely basis, or with the specific terms that Edge
desires, if at all.
Foreign Regulation
In addition to regulations in the United States, Edge is subject to a variety of foreign regulations governing clinical trials, and
governing any future distribution and commercial sales, if any, of Edge’ products. Whether or not FDA approval is obtained for a drug candidate, the comparable regulatory authorities of foreign countries or economic areas, such as the European
Union, must approve commencement of clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place
to place, and the time may be longer or shorter than that required for FDA approval.
Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or
decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other immune
dysfunction, viral diseases or orphan medicinal products, and optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization based on the favorable scientific opinion of the European Medicines
Agency that is valid for all European Union member states and the European Economic Area Countries (Norway, Iceland and Liechtenstein) through the EEA Treaty. The decentralized procedure provides for national approval to be granted in more than two
or more member states based on an assessment of an application performed by the Member State leading the scientific evaluation, known as the “reference” member state. Under the decentralized approval procedure, an applicant submits an application,
or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90
days of receiving the reference member state’s assessment report, each concerned member state must decide whether or not to approve the assessment report and related materials. If a member state does not accept the assessment of the reference
member state on grounds relating to potential serious risk to public health, the points of disagreement are first referred to the coordination group on mutual recognition and decentralized procedures where all the member states are required to use
their best endeavors to reach agreement on the action to be taken. If the Member States fail to reach an agreement within 60 days in the referral to the coordination group, the application will be referred to the European Medicines Agency for
arbitration which will lead to a binding decision to be adopted by the European Commission.
The above overview describes the current drug approval framework in the European Union. In 2016, the United Kingdom voted to leave the
European Union, commonly referred to as “Brexit”. The Brexit implementation process is complex and ongoing. When finalized, Brexit may have implications on the drug approval framework in the European Union. The specifics of the potential impact of
Brexit on the drug approval process are unclear at this time.
Employees
As of December 31, 2018, Edge had 10 full-time employees. Edge has no collective bargaining agreements with Edge’s employees and has not
experienced any work stoppages.
Corporate and Available Information
Edge was incorporated in Delaware in 2009. Edge completed the initial public offering of Edge’s common stock in October 2015. Edge’s
common stock is currently listed on The Nasdaq Global Select Market under the symbol “EDGE.” Edge is an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, and therefore Edge is currently subject to reduced public
company reporting requirements.
Edge’s principal executive offices are located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922, and Edge’s telephone number
is (800) 208-3343.
You may find on Edge’s website (http://www.edgetherapeutics.com) electronic copies of Edge’s annual report on Form 10-K, quarterly
reports on Form 10-Q, and current reports on Form 8-K (and any amendments thereto) filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. Such filings are placed on Edge’s website as soon as reasonably
possible after they are filed with the Securities and Exchange Commission, or SEC. Edge’s current charters for Edge’s audit, compensation, and nominating and corporate governance committees and Edge’s Code of Ethics are available on Edge’s website
as well. Any waiver of Edge’s Code of Ethics may be made only by Edge’s Board of Directors. You can read Edge’s SEC filings over the internet at the SEC’s web site at www.sec.gov.
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described
below, together with the other information contained in this Annual Report, including our financial statements and the related notes appearing elsewhere in this Annual Report, before making your decision to invest in shares of our common stock. We
cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and cash flows and our future prospects
would likely be materially and adversely affected. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.
Risks Related to the Merger
The ratio setting forth the number of shares of Edge common stock that will be issued in respect of each outstanding
share of PDS capital stock, or the Exchange Ratio, is not adjustable based on the market price of Edge common stock so the merger consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed.
The Merger Agreement has set the Exchange Ratio for the PDS common stock, and the Exchange Ratio is only adjustable upward or downward
based on increases or decreases in the number of shares of PDS’s issued and outstanding capital stock and the number of shares of PDS common stock issuable upon the exercise of all issued and outstanding equity awards, increases or decreases the
number of Edge’s issued and outstanding common stock, if the cash balances at closing of either Edge or PDS fall outside a pre-determined range, and the proposed reverse stock split, prior to the closing of the merger. The Exchange Ratio will
depend on the exact reverse stock split ratio that is ultimately mutually determined by Edge and PDS and certain changes in the capitalization of the two companies, as well as the cash balances of both companies relative to the agreed upon ranges.
If there is a significant divergence in the cash balances of either company relative to the agreed upon ranges there could be a material change to Exchange Ratio, which would affect the stockholders of one party at the expense of the other party.
The longer it takes to complete the merger, the greater the possibility there is for the Company’s cash balances to fall outside of the range. Any changes in the market price of Edge common stock before the closing of the merger will not affect the
number of shares PDS securityholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the closing of the merger the market price of Edge common stock declines from the market price on the date of the Merger
Agreement, then PDS stockholders could receive merger consideration with substantially lower value. Similarly, if before the closing of the merger the market price of Edge common stock increases from the market price on the date of the Merger
Agreement, then PDS stockholders could receive merger consideration with substantially more value for their shares of PDS common stock than the parties had negotiated for in the establishment of the Exchange Ratio. Because the Exchange Ratio does
not adjust as a result of changes in the value of Edge common stock, for each one percentage point that the market value of Edge common stock rises or declines, there is a corresponding one percentage point rise or decline, respectively, in the
value of the total merger consideration issued to PDS stockholders.
Failure to complete the merger may result in Edge paying a termination fee or expenses to PDS and could harm the
common stock price of Edge and future business and operations of each company.
If the merger is not completed, Edge and PDS are subject to the following risks:
| ● |
if the Merger Agreement is terminated under certain circumstances and certain events occur, Edge will be required to pay PDS a termination fee of $1.75 million;
|
| ● |
the price of Edge stock may decline and remain volatile; and
|
| ● |
costs related to the merger, such as legal, accounting and investment banking fees which Edge and PDS estimate will total approximately $5.3 million, of which $3.5 million must be paid even if the merger is not completed.
|
In addition, if the Merger Agreement is terminated and the Edge Board determines to seek another business combination, there can be no
assurance that Edge or PDS will be able to find a partner willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the merger.
If the conditions to the merger are not met, the merger may not occur.
Even if the proposals referred to herein are approved by the stockholders of Edge and PDS, specified other conditions must be satisfied
or waived to complete the merger. These conditions are set forth in the Merger Agreement. Edge and PDS cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the merger may not
occur or will be delayed, and Edge and PDS each may lose some or all of the intended benefits of the merger.
The merger may be completed even though material adverse changes may result from the announcement of the merger,
industry-wide changes or other causes.
In general, either Edge or PDS can refuse to complete the merger if there is a material adverse change affecting the other party between
November 23, 2018, the date of the Merger Agreement, and the closing. However, certain types of changes do not permit either party to refuse to complete the merger, even if such change could be said to have a material adverse effect on Edge or PDS,
including:
| ● |
any effect, change, event, circumstance or development in general economic or business conditions generally affecting the industries in which PDS or Edge operate;
|
| ● |
any act of war, armed hostilities or terrorism;
|
| ● |
any changes in financial, banking or securities markets;
|
| ● |
the taking of any action required to be taken by the Merger Agreement;
|
| ● |
any changes in accounting requirements or principles or any change in applicable laws, rules or regulations or the interpretation thereof;
|
| ● |
any effect resulting from the announcement or pendency of the merger or any related transactions;
|
| ● |
with respect to Edge, any change in the stock price or trading volume of Edge common stock; or
|
| ● |
with respect to Edge, any clinical trial programs or studies, including any adverse data, event or outcome arising out of or related to any such programs or studies.
|
If adverse changes occur and Edge and PDS still complete the merger, the combined company stock price may suffer. This in turn may
reduce the value of the merger to the stockholders of Edge and PDS.
The combined company will need to raise additional capital by issuing securities or debt or through licensing
arrangements, which may cause dilution to the combined company’s stockholders or restrict the combined company’s operations or proprietary rights.
The combined company may be required to raise additional funds sooner than currently planned. Additional financing may not be available
to the combined company when it needs it or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such an issuance may cause significant dilution to the combined
company’s stockholders’ ownership and the terms of any new equity securities may have preferences over the combined company’s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations.
These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company’s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make
investments. In addition, if the combined company raises additional funds through licensing or other strategic arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company or otherwise restrict its
operations.
Certain Edge and PDS executive officers and directors have interests in the merger that are different from yours and
that may influence them to support or approve the merger without regard to your interests.
Certain officers and directors of Edge and PDS will participate in
arrangements that provide them with interests in the merger that are different from yours, including, among others, the continued service as officers and/or directors of the combined company, severance and retention benefits, the acceleration of
stock options and continued indemnification.
Furthermore, in connection with the closing of the merger, all unvested options to acquire shares of Edge common stock and Edge RSUs
(including those held by Edge officers and the Edge Board members (including Edge RSUs for 10,000 shares of Edge common stock held by each of Robert Spiegel, M.D., FACP, and James J. Loughlin, who are expected to remain on the combined company’s
board of directors, and stock options for 220,607 and 64,286 shares of Edge common stock held by Dr. Spiegel and Mr. Loughlin, respectively)) will vest in full. The exercise price of all unvested stock option awards held by the Edge Board members
and officers was above the trading price of Edge common stock as of December 31, 2018. Additionally, the parties expect that Dr. Sol Barer will enter into a consulting arrangement in connection with serving as an advisor to the board of directors
of the combined company.
In addition, certain of Edge’s executive officers are expected to become executive officers of the combined company upon the closing of
the merger. Specifically, Andrew Saik is expected to serve as Chief Financial Officer of the combined company, and W. Bradford Middlekauff is expected to serve as Senior Vice President, General Counsel and Secretary of the combined company.
Additionally, James Loughlin and Robert Spiegel, each of whom is a current director of Edge, and Andrew Saik, the Chief Financial Officer of Edge, are expected to be designated to serve on the combined company’s board of directors following the
closing of the merger.
Additionally, certain of PDS’s directors and executive officers are expected to become directors and executive officers of the combined
company upon the closing of the merger. Specifically, Frank Bedu-Addo, Ph.D. is expected to serve as the Chief Executive Officer, Lauren Wood, MD is expected to serve as Chief Medical Officer and Gregory Conn, Ph.D. is expected to serve as the
Chief Scientific Officer of the combined company. Additionally, each of Frank Bedu-Addo, Ph.D., DeLyle Bloomquist, Sir Richard Sykes and Gregory Freitag, each of whom is a
current director of PDS, are expected to be designated to serve on the combined company’s board of directors following the closing of the merger.
In addition, certain of PDS’s executive officers and directors and affiliates of PDS’s directors currently hold shares of PDS common
stock and preferred stock. Affiliates of certain PDS directors and certain executive officers of PDS will convert their unsecured subordinated convertible promissory notes into shares of PDS common stock prior to the closing of the merger pursuant
to the note purchase agreement.
The market price of the combined company’s common stock following the merger may decline as a result of the merger.
The market price of the combined company’s common stock may decline as a result of the merger for a number of reasons including if:
| ● |
investors react negatively to the prospects of the combined company’s business and prospects from the merger;
|
| ● |
the effect of the merger on the combined company’s business and prospects is not consistent with the expectations of financial or industry analysts; or
|
| ● |
the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts.
|
Edge and PDS stockholders may not realize a benefit from the merger commensurate with the ownership dilution they
will experience in connection with the merger.
If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the merger, Edge and
PDS securityholders will have experienced substantial dilution of their ownership interests in their respective companies without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined
company is able to realize only part of the strategic and financial benefits currently anticipated from the merger.
During the pendency of the merger, Edge and PDS may not be able to enter into a business combination with another
party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect their respective businesses.
Covenants in the Merger Agreement impede the ability of Edge and PDS to make acquisitions, subject, in the case of Edge, to certain
exceptions relating to fiduciary duties, or complete other transactions that are not in the ordinary course of business pending the closing of the merger. As a result, if the merger is not completed, the parties may be at a disadvantage to their
competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating, encouraging or entering into certain extraordinary transactions, such as a merger, sale of assets
or other business combination outside the ordinary course of business, with any third-party, subject to, in the case of Edge, certain exceptions. Any such transactions could be favorable to such party’s stockholders.
Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover
proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement.
The terms of the Merger Agreement prohibit each of Edge and PDS from soliciting alternative takeover proposals or cooperating with
persons making unsolicited takeover proposals, except, with respect to Edge, in certain circumstances where the Edge Board determines in good faith, after consultation with its financial advisor and outside legal counsel, that an unsolicited
alternative takeover proposal constitutes or is reasonably likely to result in a superior takeover proposal. In addition, if Edge or PDS terminate the Merger Agreement under certain circumstances, including terminating because of a decision of a
board of directors to recommend an alternative proposal, Edge would be required to pay a termination fee of $1.75 million to the other party. These termination fees and reimbursement obligations described above may discourage third parties from
submitting alternative takeover proposals to Edge and its stockholders, and may cause the Edge Board to be less inclined to recommend an alternative proposal.
The lack of a public market for PDS shares makes it difficult to determine the fair market value of the PDS shares, and PDS stockholders
may receive consideration in the merger that is less than the fair market value of the PDS shares and/or Edge may pay more than the fair market value of the PDS shares.
PDS is privately held and its capital stock is not traded in any public market. The lack of a public market makes it extremely difficult
to determine PDS’s fair market value. Because the percentage of Edge equity to be issued to PDS stockholders was determined based on negotiations between the parties, it is possible that the value of the Edge common stock to be received by PDS
stockholders will be less than the fair market value of PDS, or Edge may pay more than the aggregate fair market value for PDS.
Risks Related to the Merger and Edge’s Evaluation of Strategic Alternatives
If the merger is not completed, Edge may be unsuccessful in completing an alternative transaction on terms that are
as favorable as the terms of the proposed transaction with PDS, or at all, and Edge may be unable to reestablish an operating business. The Edge Board may decide to pursue a dissolution and liquidation of Edge. In such an event, the amount of cash
available for distribution to Edge’s stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.
On March 28, 2018, Edge announced that an independent Data Monitoring Committee, or the DMC, for Edge’s NEWTON 2 clinical trial for
EG-1962 recommended that the NEWTON 2 study be stopped based on the DMC’s conclusion that the study has a low probability of meeting its primary endpoint. Based on the DMC recommendation, Edge decided to discontinue the NEWTON 2 study and has taken
steps to notify health authorities and clinical investigators participating in the study. Edge has ceased all further development of EG-1962 and Edge’s other product candidates and has implemented operating cost reductions and organizational
restructurings, including a reduction in Edge’s workforce, to preserve Edge’s cash resources. Edge’s strategic focus shifted to the identification and evaluation of a range of potential strategic alternatives designed to maximize stockholder value.
In April 2018, Edge engaged Piper Jaffray as Edge’s advisor to assist with the exploration of strategic alternatives. Edge devoted
substantial time and resources to exploring such strategic alternatives.
To date, Edge’s current assets consist primarily of cash, cash equivalents and marketable securities, Edge’s clinical assets, Edge’s
listing on the Nasdaq Global Market and the Merger Agreement with PDS. While Edge has entered into the Merger Agreement with PDS, the closing of the merger with PDS may be delayed or may not occur at all and there can be no assurance that the
merger will deliver the anticipated benefits Edge expects or enhance shareholder value.
If Edge is unable to consummate the merger with PDS, the Edge Board may elect to pursue an alternative strategy, one of which may be a
strategic transaction similar to the proposed merger with PDS. Attempting to complete an alternative transaction will be costly and time consuming, and Edge can make no assurances that such an alternative transaction would occur at all.
Alternatively, the Edge Board may elect to continue operations to conduct another study of EG-1962 or decide to pursue a dissolution and liquidation of the company. In such an event, the amount of cash available for distribution to Edge’s
stockholders will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as Edge continues to fund its operations. In addition, if the Edge Board was to approve and
recommend, and Edge’s stockholders were to approve, a dissolution and liquidation of the company, Edge would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision for contingent and
unknown obligations, prior to making any distributions in liquidation to Edge’s stockholders. Edge’s commitments and contingent liabilities may include severance obligations, regulatory and clinical obligations remaining under Edge’s NEWTON 2
study, fees and expenses related to the merger and liabilities relating to investigations of or litigation against Edge and other various claims and legal actions. As a result of this requirement, a portion of Edge’s assets may need to be reserved
pending the resolution of such obligations. In addition, Edge may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, the Edge Board, in consultation with its advisors,
would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of Edge common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or
winding up of the company.
Failure to obtain stockholder approval for the proposed reverse stock split may result in the combined company being
unable to obtain compliance with minimum bid price requirements for an initial listing on any Nasdaq market tier and may result in Edge common stock being delisted from the Nasdaq Global Select Market.
Edge is required pursuant to the terms of the Merger Agreement to submit to its stockholders a proposal to approve an amendment to its
certificate of incorporation to authorize the Edge Board to effect a reverse stock split of all outstanding shares of its common stock, or the Reverse Stock Split Proposal. If the Reverse Stock Split Proposal is not approved by Edge’s stockholders,
the combined company will likely not be able to obtain compliance with the minimum bid price requirement for an initial listing on any Nasdaq market tier and, as a consequence, to the extent the merger is consummated under such circumstances,
Nasdaq will immediately provide the combined company with written notification that the combined company’s common stock will be delisted.
Upon receipt of such delisting letter, the combined company will likely appeal the determination to the Nasdaq hearings panel, or the
Hearing Panel. If the combined company has not regained compliance with Nasdaq listing requirements prior to such hearing, and the Hearing Panel decides to continue with delisting of the combined company, the Hearing Panel’s decision may be
appealed to the Nasdaq Listing and Hearing Review Council but such appeal would not stay the delisting process.
The issuance of shares of Edge common stock to PDS stockholders in the merger will dilute substantially the voting
power of Edge’s current stockholders.
If the merger is completed, each outstanding share of PDS common stock will be converted into the right to receive a number of shares of
Edge common stock equal to the Exchange Ratio determined pursuant to the Merger Agreement. Immediately following the merger, Edge securityholders are expected to own approximately 30% of the outstanding capital stock of the combined company on a
fully diluted basis, and PDS securityholders are expected to own approximately 70% of the outstanding capital stock of the combined company on a fully diluted basis. Accordingly, the issuance of shares of Edge common stock to PDS stockholders in
the merger will reduce significantly the relative voting power of each share of Edge common stock held by Edge’s current securityholders. Consequently, Edge securityholders as a group will have significantly less influence over the management and
policies of the combined company after the merger than prior to the merger.
If the combined company after the merger is unable to realize the strategic and financial benefits currently anticipated from the
merger, the Edge stockholders and the PDS stockholders will have experienced substantial dilution of their ownership interests in their respective companies without receiving the expected commensurate benefit, or receiving only part of the
commensurate benefit to the extent the combined company is able to realize only part of the expected strategic and financial benefits currently anticipated from the merger.
The pendency of the merger could have an adverse effect on the trading price of Edge common stock and Edge’s
business, financial condition, results of operations or business prospects.
While there have been no significant adverse effects to date, the pendency of the merger could disrupt Edge’s businesses in the
following ways, including:
| ● |
the attention of Edge’s management may be directed toward the closing of the merger and related matters and may be diverted from the day-to-day business operations; and
|
| ● |
third parties may seek to terminate or renegotiate their relationships with Edge as a result of the merger, whether pursuant to the terms of their existing agreements with
Edge or otherwise.
|
Should they occur, any of these matters could adversely affect the trading price of Edge common stock or harm Edge’s financial
condition, results of operations or business prospects.
Stockholder litigation and regulatory inquiries and investigations are expensive and could harm Edge’s business,
financial condition and operating results and could divert management attention.
In the past, securities class action litigation and/or stockholder derivative litigation and inquiries or investigations by regulatory
authorities have often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, such as the merger, or the announcement of negative events, such as negative results from
clinical trials. Edge is currently and may in the future be the target of this type of litigation as a result of changes in Edge’s stock price, past transactions, results of clinical trials or other matters. Any stockholder litigation and/or
regulatory investigations against Edge, whether or not resolved in Edge’s favor, could result in substantial costs and divert Edge’s management’s attention from other business concerns, which could adversely affect Edge’s business and cash
resources and Edge’s ability to consummate a potential strategic transaction or the ultimate value Edge’s stockholders receive in any such transaction.
Edge is substantially dependent on Edge’s remaining employees to facilitate the consummation of a strategic
transaction.
On May 1, 2018, Edge announced that it planned to reduce its workforce by 29 to a total of eight full-time employees. Edge’s ability to
successfully complete a strategic transaction depends in large part on Edge’s ability to retain certain of its remaining personnel. Despite Edge’s efforts to retain these employees, one or more may terminate their employment with Edge on short
notice. The loss of the services of any of these employees could potentially harm Edge’s ability to consummate the merger, to run Edge’s day-to-day operations, as well as fulfill Edge’s reporting obligations as a public company.
There is no assurance that the proposed merger will be completed in a timely manner or at all. If the merger is not
consummated, Edge’s business could suffer materially and its stock price could decline.
The closing of the proposed merger is subject to a number of closing conditions, including the approval by Edge’s stockholders of the
issuance of shares of Edge common stock pursuant to the Merger Agreement and the proposed reverse stock split of Edge common stock and other customary closing conditions. If the conditions are not satisfied or waived, the merger will not occur or
will be delayed.
If the proposed merger is not consummated, Edge may be subject to a number of material risks, and Edge’s business and stock price could
be adversely affected, as follows:
| ● |
Edge has incurred and expects to continue to incur significant expenses related to the proposed merger even if the merger is not consummated;
|
| ● |
Edge could be obligated to pay PDS a termination fee of up to $1.75 million under certain circumstances pursuant to the Merger Agreement;
|
| ● |
the market price of Edge common stock may decline to the extent that the current market price reflects a market assumption that the proposed merger will be completed; and
|
| ● |
Edge may not be able to pursue an alternate merger transaction if the proposed merger with PDS is not completed.
|
Risks Related to Development and Regulatory Approval
Edge may not be able to successfully develop or obtain regulatory approval for EG-1962 or any other product
candidate.
Edge has ceased all research and development activities for EG-1962 and its other product candidates. Edge currently has no drug
products for sale and may never be able to develop marketable drug products. If Edge were to resume research and development activities, EG-1962 will require substantial additional clinical development, testing, and regulatory approval before Edge
will be permitted to commence its commercialization. No clinical studies have been undertaken with respect to Edge’s only other product candidates, EG-1964 and EG-1965. If Edge were to resume research and development activities, the clinical
studies of Edge’s product candidates will be, and the manufacturing and marketing of Edge’s product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other
countries where Edge intends to investigate and, if approved, market any product candidate. If Edge were to resume research and development activities, before obtaining regulatory approvals for the commercial sale of any product candidate, Edge
would have to successfully meet a number of critical developmental milestones. For example, for EG-1962, these would include:
| ● |
providing adequate and well-controlled data that the product candidate is safe and effective and shows a significant benefit over the active comparator in patients for the
intended indication;
|
| ● |
demonstrating that the product candidate formulation is reproducible and can meet the relevant release specifications for each market Edge intends to commercialize in; and
|
| ● |
completing the development and scale-up to permit manufacture of Edge’s product candidates in commercial quantities and at acceptable prices.
|
The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain.
If Edge were to resume research and development activities, Edge may not be able to finalize the design or formulation of any product
candidate. In addition, if Edge were to resume research and development activities, Edge may select components, solvents, excipients or other ingredients to include in its product candidates that have not previously been used in approved
pharmaceutical products, which may require Edge to perform additional studies and may delay clinical testing and regulatory approval of its product candidates. If Edge were to resume research and development activities, Edge may not be able to
complete development of any product candidates that will be safe and effective and that will have a commercially reasonable treatment and storage period, and may not be able to commercialize and earn revenue from any products candidates. Moreover,
even if a product candidate can be approved, it could be blocked by competitor patents or exclusivities.
The regulatory approval processes of the FDA and comparable foreign regulatory authorities are inherently
unpredictable, and, to the extent Edge resumes research and development activities, if Edge’s product candidates are subject to multiple cycles of review or Edge is ultimately unable to obtain regulatory approval for its product candidates, Edge’s
business will be substantially harmed. In addition, the regulatory approval processes can delay clinical trials, which can jeopardize the ability to generate revenues from the sale of products.
Of the large number of drugs in development in the United States, only a small percentage successfully complete the FDA regulatory
approval process and are commercialized. Edge has ceased all research and development activities for EG-1962 and its other product candidates but to the extent that Edge resumes research and development activities, Edge will not be permitted to
market any of product candidates in the United States or in other global markets unless and until Edge receives approval of an NDA from the FDA or the requisite approval from such other global regulatory authorities. Successfully completing
clinical studies and obtaining approval of an NDA is complex, lengthy, and expensive. The FDA or a comparable foreign regulatory authority may delay, limit or deny approval of product candidates for many reasons, including, among others:
| ● |
disagreement with, or disapproval of, the design of, procedures for, or implementation of, clinical trials;
|
| ● |
the inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;
|
| ● |
disagreement with the sufficiency of the final content and data included in a marketing application;
|
| ● |
feedback from the FDA or a comparable foreign regulatory authority on results from earlier stage or concurrent preclinical and clinical studies, that might require
modification to the protocol;
|
| ● |
a decision by the FDA or a comparable foreign regulatory authority to suspend or terminate clinical trials at any time for safety issues or for any other reason;
|
| ● |
challenges in meeting regulatory requirements to commence clinical trials in countries outside the United States;
|
| ● |
failure to conduct the trial in accordance with regulatory requirements;
|
| ● |
failure to demonstrate that the product candidate provides an overall benefit to risk or significant enough improvement over the comparator in the proposed indication;
|
| ● |
failure of the product candidate to demonstrate efficacy at the level of statistical significance required for approval;
|
| ● |
a negative interpretation of the data from preclinical studies or clinical trials;
|
| ● |
deficiencies in the manufacturing processes or failure of third party manufacturing facilities to effectively and consistently manufacture product or to pass FDA
pre-approval facility inspection;
|
| ● |
failure to demonstrate adequate and reproducible product stability to support product commercialization;
|
| ● |
failure to adequately demonstrate process performance qualification prior to product commercialization;
|
| ● |
inability to validate analytical and microbiological methods consistent with industry and government agency expectations; or
|
| ● |
changes in governmental regulations or administrative actions.
|
Further, if Edge were to resume research and development activities and experiences delays in the completion of, or termination of, any
clinical trial of product candidates, the commercial prospects of those product candidates will be harmed, and Edge’s ability to generate product revenues will be delayed or may not happen at all, which circumstances may significantly harm Edge’s
business, financial condition and prospects.
Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials and non-head-to-head analysis (e.g., historical comparisons) may not be predictive of future trial results.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any
time during the clinical trial process. The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Many companies in the biotechnology industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy, failure by the study drug to demonstrate sufficiently improved efficacy over a comparator arm, or adverse safety profiles, notwithstanding promising results in
earlier trials. If Edge were to resume research and development activities, Edge’s future clinical trials may not be successful.
To the extent Edge were to resume research and development activities, even if a product candidate receives
regulatory approval, it may still face future development and regulatory challenges and any approved products will be subject to extensive post-approval regulatory requirements.
To the extent Edge were to resume research and development activities and in the future obtains regulatory approval for a product
candidate, Edge would be subject to extensive ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety
surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory
authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of Edge’s product candidates, these regulatory authorities may require labeling changes or, depending
on the nature of the safety information, establishment of a Risk Evaluation and Mitigation Strategy, impose significant restrictions on a product’s indicated uses or marketing, impose ongoing requirements for potentially costly post-approval
studies or post-market surveillance, cause a recall or even move to withdraw the marketing approval for the product.
In addition, manufacturers of therapeutic products and their facilities are subject to continual review and periodic inspections by the
FDA and other regulatory authorities for compliance with applicable regulations, including a focused pre-approval inspection in connection with any regulatory submission for approval. If Edge or a regulatory agency discover previously unknown
problems with a product, such as problems with the facility where the product is manufactured, a regulatory agency may take regulatory actions against the manufacturing facility or Edge, leading to a product recall or withdrawal, or suspension of
manufacturing.
If Edge, Edge’s product candidates or the manufacturing facilities for Edge’s product candidates fail to comply with applicable
regulatory requirements, Edge’s ability to commercialize Edge’s products and generate revenue may be significantly limited.
Advertising and promotion of any product candidate that obtains approval in the United States may be heavily scrutinized by the FDA,
including the Office of Prescription Drug Promotion, the Department of Justice, or the DOJ, the Department of Health and Human Services, Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including
promotion of products for unapproved (or off-label) uses, may be subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA. Additionally, advertising and promotion of any product candidate that
obtains approval outside of the United States will be heavily scrutinized by comparable foreign regulatory authorities.
In the United States, engaging in impermissible promotion of products, including for off-label uses, can also subject companies to false
claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which a company can promote or distribute a drug product. These false claims statutes
include the False Claims Act, or FCA, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or
fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these FCA lawsuits against pharmaceutical companies
have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements based on certain sales practices promoting off-label drug uses. This growth in litigation has increased the risk that a pharmaceutical
company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from the Medicare, Medicaid, and other federal and state healthcare
programs. If Edge does not lawfully promote any approved products, Edge may become subject to such litigation and, if Edge is not successful in defending against such actions, those actions may have a material adverse effect on Edge’s business,
financial condition and results of operations.
Failure to obtain regulatory approval in international jurisdictions would prevent Edge’s product candidates from
being marketed abroad.
To the extent Edge were to resume research and development activities, and in the future obtains regulatory approval for a product
candidate, in order to market and sell Edge’s products in the EU, Canada, Japan and other international jurisdictions, Edge would have to obtain separate and distinct marketing approvals and comply with the respective regulatory requirements of
each of these jurisdictions. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval, but can involve additional testing or safety surveillance. Edge may need to partner
with third parties in order to obtain regulatory approvals outside the United States. Approval by the FDA does not necessarily guarantee approval by regulatory authorities in other countries or jurisdictions. Nor does the approval by one regulatory
authority outside the United States ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Edge may not be able to file for marketing approvals and may not receive necessary approvals to commercialize Edge’s
products in any market. If Edge is unable to obtain approval of any product candidates by regulatory authorities in the EU, Canada, and other international jurisdictions, the commercial prospects of those product candidates may be significantly
diminished and Edge’s business prospects could dramatically decline.
Risks Related to Edge’s Business and Industry
To the extent Edge were to resume research and development activities, Edge’s future success will depend on Edge’s
ability to attract, retain and motivate qualified personnel.
Edge does not have the resources or the required expertise to develop any of its potential product candidates. To the extent Edge were
to seek to resume research and development activities, because of the specialized scientific nature of Edge’s business, it would need to hire additional qualified scientific personnel. The competition for qualified personnel in the pharmaceutical
field is intense and, as a result, Edge may be unable to attract qualified personnel necessary for the future development of Edge’s business.
The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change,
which could render Edge’s technologies and products obsolete or uncompetitive.
If Edge were to resume research and development activities, there is no assurance that Edge’s product candidates will be the most
effective, the safest, the first to market, or the most economical to make or use. The introduction of competitive therapies as alternatives to any of Edge’s product candidates could dramatically reduce the value of those development projects or
chances of successfully commercializing those product candidates, which could have a material adverse effect on Edge’s long-term financial success.
Edge’s business and operations would suffer in the event of system failures.
Despite the implementation of security measures, the servers of Edge’s cloud-based computing providers and other systems, and those of
other third parties on which Edge relies, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions
in Edge’s operations, it could result in a material disruption of Edge’s drug development programs if Edge were to resume research and development activities. For example, the loss of clinical trial data from completed or ongoing or planned
clinical trials could result in delays in Edge’s regulatory approval efforts and significantly increase Edge’s costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to
Edge’s data or applications, or inappropriate disclosure of confidential or proprietary information, Edge could incur liability and the further development of Edge’s product candidates could be delayed.
Any future collaborators may compete with Edge or have interests which conflict with Edge’s. This may restrict any
future research and development efforts.
If Edge were to resume research and development activities, large pharmaceutical companies with whom Edge may seek to collaborate may
have internal programs or enter into collaborations with Edge’s competitors for products addressing the same medical conditions targeted by Edge’s technologies. Thus, such collaborators may pursue alternative technologies or product candidates in
order to develop treatments for the diseases or disorders targeted by Edge’s collaborative arrangements. Such collaborators may pursue these alternatives either on their own or in collaboration with others, including Edge’s competitors. Depending
on how other product candidates advance, a corporate partner may slow down or abandon its work on Edge’s product candidates or terminate its collaborative arrangement with Edge in order to focus on these other prospects.
If any conflicts arise, Edge’s future collaborators may act in their own interests, which may be adverse to Edge. In addition, in Edge’s
future collaborations, Edge may be required to agree not to conduct any research that is competitive with the research conducted under Edge’s future collaborations. Edge’s future collaborations may have the effect of limiting the areas of research
that Edge may pursue. Edge’s collaborators may be able to develop products in related fields that are competitive with the products or potential products that are the subject of these collaborations.
Business disruptions could seriously harm Edge’s financial condition and increase Edge’s costs and expenses.
Edge’s operations could be subject to natural disasters, power shortages, telecommunications failures, water shortages, fires, medical
epidemics and other manmade disasters or business interruptions, for which Edge or they are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm Edge’s financial condition and increase Edge’s costs
and expenses.
Edge’s employees may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements, which could have a material adverse effect on Edge’s business.
Edge is exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply
with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with federal and state healthcare fraud and abuse laws and
regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to Edge. Edge has adopted, implemented,
and is enforcing a code of conduct, or Code of Conduct, and other compliance-based policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions Edge takes to detect and prevent this activity,
such as employee training on enforcement of the Code of Conduct and other policies and procedures, may not be effective in controlling unknown or unmanaged risks or losses or in protecting Edge from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against Edge, and Edge is not successful in defending itself or asserting Edge’s rights, those actions could have a significant
impact on Edge, including the imposition of significant fines or other sanctions.
Risks Related to Edge’s Intellectual Property
If Edge is unable to protect Edge’s intellectual property rights, Edge’s competitive position could be harmed.
If Edge were to resume research and development activities, Edge will depend on its ability to protect its proprietary technology. Edge
relies on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. If Edge were to resume research and development
activities, Edge’s success will depend in large part on its ability to obtain and maintain patent protection in the United States and other countries with respect to Edge’s proprietary technology and products.
The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual
questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of Edge’s patents are highly uncertain.
The steps Edge has taken to police and protect Edge’s proprietary rights may not be adequate to preclude misappropriation of Edge’s
proprietary information or infringement of Edge’s intellectual property rights, both inside and outside the United States. The rights already granted under any of Edge’s currently issued/granted patents and those that may be granted under future
issued/granted patents may not provide Edge with the proprietary protection or competitive advantages Edge may seek in the future. If Edge is unable to obtain and maintain patent protection for Edge’s technology and products, or if the scope of the
patent protection obtained is not sufficient, Edge’s competitors could develop and commercialize technology and products similar or superior to Edge’s, and Edge’s ability to successfully commercialize Edge’s technology and products may be adversely
affected.
Although Edge has a number of issued/granted patents, the issuance/grant of a patent is not conclusive as to its inventorship, scope,
validity or enforceability, and issued/granted patents that Edge owns or has licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection,
the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit Edge’s ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the
patent protection for Edge’s technology and products.
Protecting against the unauthorized use of Edge’s patented technology, trademarks and other intellectual property rights is expensive,
difficult and, may in some cases not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of Edge’s intellectual property rights, even in relation to issued/granted patent claims, and
proving any such infringement may be even more difficult.
Edge could be required to incur significant expenses to obtain Edge’s intellectual property rights, and Edge cannot
ensure that Edge will obtain meaningful patent protection for its products.
The patent prosecution process is expensive and time-consuming, and Edge or any future licensors may not be able to file and prosecute
all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, if Edge were to resume research and development activities, it is also possible that Edge or Edge’s licensors will fail to identify patentable
aspects of further inventions made in the course of Edge’s development and commercialization activities before they are publicly disclosed, making it too late to obtain patent protection on them. Further, given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Changes in either the patent laws or interpretation of the patent laws
in the United States and other countries may diminish the value of Edge’s patents or narrow the scope of Edge’s patent protection. The laws of foreign countries may not protect Edge’s rights to the same extent as the laws of the United States, and
these foreign laws may also be subject to change.
Obtaining and maintaining Edge’s patent protection depends on compliance with various procedural, document
submissions, fee payment and other requirements imposed by governmental patent agencies, and Edge’s patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees on any issued/granted patent are due to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an
inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If Edge or Edge’s licensors fail to maintain the patents and patent applications covering any of Edge’s product candidates,
Edge’s competitors might be able to enter the market, which would have a material adverse effect on Edge’s business.
Edge may become involved in lawsuits to protect or enforce Edge’s intellectual property, which could be expensive,
time consuming and unsuccessful.
Competitors may infringe Edge’s patents or misappropriate or otherwise violate Edge’s intellectual property rights. To counter
infringement or unauthorized use, litigation may be necessary in the future to enforce or defend Edge’s intellectual property rights, to protect Edge’s trade secrets or to determine the validity and scope of Edge’s own intellectual property rights
or the proprietary rights of others. This can be expensive and time consuming and results can be uncertain. Many of Edge’s current and potential competitors have the ability to dedicate substantially greater resources to defend their intellectual
property rights than Edge can. Accordingly, despite Edge’s efforts, Edge may not be able to prevent third parties from infringing upon or misappropriating Edge’s intellectual property, particularly in certain parts of the world. Litigation could
result in substantial costs and diversion of management resources, which could harm Edge’s business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by, or licensed to, Edge is invalid or
unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that Edge’s patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of Edge’s
patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Edge’s
confidential information could be compromised by disclosure during this type of litigation. If any of these occur, Edge’s business could be materially and adversely affected.
From time to time Edge may need to rely on licenses to proprietary technologies, which may be difficult, expensive
or not possible to obtain or Edge may lose certain licenses which may be difficult or not possible to replace.
If Edge were to resume research and development activities, Edge may need to obtain licenses to patents and other proprietary rights
held by third parties to develop, manufacture and market Edge’s product candidates. If Edge is unable to timely obtain these licenses on commercially reasonable terms and maintain these licenses, Edge’s ability to commercially market Edge’s product
candidates may be inhibited or prevented, which could have a material adverse effect on Edge’s business, results of operations, financial condition and cash flows.
Third parties may initiate legal proceedings alleging that Edge is infringing their intellectual property rights,
the outcome of which would be uncertain and could have a material adverse effect on the success of Edge’s business.
If Edge were to resume research and development activities, Edge’s commercial success will depend upon Edge’s ability to develop,
manufacture, market and sell Edge’s product candidates, and to use Edge’s proprietary technologies without infringing the proprietary rights of third parties. Edge may become party to, or threatened with, future adversarial proceedings or
litigation regarding intellectual property rights with respect to Edge’s products and technology, including interference (for patents with an effective date before March 16, 2013) and various post grant proceedings before the USPTO, and opposition
proceedings at other patent offices. Third parties may assert infringement claims against Edge based on existing patents or patents that may be granted in the future. In the event a third party were to assert an infringement claim against Edge and
Edge were ultimately found to infringe the third party’s intellectual property rights, Edge could be required to obtain a license from such third party to continue developing and commercializing Edge’s products and technology. However, Edge may not
be able to obtain an appropriate license on commercially reasonable terms or at all. Even if Edge is able to obtain a license, it may be non-exclusive, thereby giving Edge’s competitors access to the same technologies licensed to Edge. Edge could
be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, Edge could be found liable for monetary damages. A finding of infringement could prevent Edge
from commercializing Edge’s product candidates or force Edge to cease some of Edge’s business operations, which could materially harm Edge’s business. Any claims by third parties that Edge has misappropriated their confidential information or trade
secrets could have a similar negative impact on Edge’s business.
Edge’s trade secrets are difficult to protect.
Confidentiality agreements with employees and others may not adequately prevent disclosure of Edge’s trade secrets and other proprietary
information and may not adequately protect Edge’s intellectual property.
If Edge were to resume research and development activities, Edge’s success will depend upon the skills, knowledge and experience of
Edge’s scientific and technical personnel, Edge’s consultants and advisors as well as Edge’s partners, licensors and contractors. Because Edge operates in a highly competitive technical field of drug discovery, Edge relies in part on trade secrets
to protect Edge’s proprietary technology and processes. However, trade secrets are difficult to protect. Edge enters into confidentiality and invention assignment agreements with Edge’s employees and certain of Edge’s corporate partners,
consultants, sponsored researchers and other advisors. These agreements generally require that the receiving party keep confidential and not disclose to third parties all confidential information developed by the receiving party or made known to
the receiving party by Edge during the course of the receiving party’s relationship with Edge. These confidentiality and assignment agreements may be breached and may not effectively assign intellectual property rights to Edge.
Edge’s trade secrets also could be independently discovered by competitors, in which case Edge would not be able to prevent use of such
trade secrets by Edge’s competitors. The enforcement of a claim alleging that a party illegally obtained and was using Edge’s trade secrets could be difficult, expensive and time consuming and the outcome would be unpredictable. In addition, courts
outside the United States may be less willing to protect trade secrets. The failure to obtain or maintain meaningful trade secret protection could adversely affect Edge’s competitive position.
Edge may be subject to claims that Edge’s employees or consultants have wrongfully used or disclosed alleged trade
secrets of their former employers or other third parties.
Many of Edge’s employees and consultants were previously employed at other biotechnology or pharmaceutical companies, including Edge’s
competitors or potential competitors. Some of these employees, including each member of Edge’s senior management, and consultants executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous
employment. Although Edge tries to ensure that Edge’s employees and consultants do not use the proprietary information or know-how of others in their work for Edge, Edge may be subject to claims that Edge or these employees and consultants have
used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s or consultant’s former employer. Edge is not aware of any threatened or pending claims related to these matters or concerning
the agreements with Edge’s senior management, but in the future, litigation may be necessary to defend against such claims. If Edge fails in defending any such claims, in addition to paying monetary damages, Edge may lose valuable intellectual
property rights or personnel. Even if Edge is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.
Intellectual property disputes could cause Edge to spend substantial resources.
Even if resolved in Edge’s favor, litigation or other legal proceedings relating to intellectual property claims may cause Edge to incur
significant expenses. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a
substantial adverse effect on the market price of Edge’s common stock. Such litigation or proceedings could substantially increase Edge’s operating losses and reduce the resources available for development activities or any future sales, marketing
or distribution activities. Edge may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of Edge’s competitors may be able to sustain the costs of such litigation or proceedings more
effectively than Edge can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on Edge’s ability to compete in the
marketplace.
Edge may not be able to protect Edge’s intellectual property rights throughout the world.
Filing, prosecuting and defending patents on all of Edge’s product candidates throughout the world could be prohibitively expensive.
Competitors may use Edge’s technologies in jurisdictions where Edge has not obtained patent protection to develop their own products and
further, may export otherwise infringing products to territories where Edge has patent protection, but where enforcement is not as strong as that in the United States. These products may compete with any of Edge’s future products, to the extent
Edge resumes research and development activities, in jurisdictions where Edge does not have any issued/granted patents and Edge’s patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so
competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for Edge to stop the infringement of Edge’s
patents or marketing of competing products in violation of Edge’s proprietary rights generally. Proceedings to enforce Edge’s patent rights in foreign jurisdictions could result in substantial cost and divert Edge’s efforts and attention from other
aspects of Edge’s business and will have uncertain outcomes.
Risks Related to Edge’s Financial Position and Capital Needs
Edge has incurred significant losses since Edge’s inception and anticipates that Edge will continue to incur losses
for the foreseeable future.
Edge is a clinical-stage biotechnology company. Investment in biotechnology product development is highly speculative because it entails
substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. Edge has not generated any revenue from product sales to date, and Edge continues to incur
expenses related to Edge’s ongoing operations. As a result, Edge is not profitable and has incurred losses in each period since inception in 2009. For the years ended December 31, 2018 and December 31, 2017, Edge reported a net loss of $40.9
million and $50.9 million, respectively.
Edge expects to continue to incur losses for the foreseeable future. Edge may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect Edge’s business. Edge’s prior losses and expected future losses have had and will continue to have an adverse effect on Edge’s stockholders’ (deficit) equity and working
capital.
Edge has not generated any revenues since inception and may never become profitable.
Edge has not generated any revenues since Edge’s inception. If Edge were to resume research and development activities, even if Edge is
able to successfully achieve regulatory approval for any product candidates, Edge does not know when any of these products will generate revenue for Edge, if at all.
If Edge were to resume research and development activities, Edge will require additional capital to fund Edge’s
operations and if Edge fails to obtain necessary financing, Edge will not be able to complete the development and commercialization of Edge’s product candidates.
Edge’s operations have consumed substantial amounts of cash since inception. If Edge were to resume research and development activities,
Edge will require additional capital for the further development and commercialization of Edge’s product candidates.
Under such circumstances Edge cannot be certain that additional funding will be available on acceptable terms, or at all. If Edge is
unable to raise additional capital in sufficient amounts or on terms acceptable to Edge, Edge may have to significantly delay, scale back or discontinue the development or commercialization of one or more of Edge’s products or product candidates or
one or more of Edge’s other research and development initiatives.
Raising additional capital may cause dilution to Edge’s stockholders, restrict Edge’s operations or require Edge to
relinquish rights to Edge’s technologies or product candidates.
If Edge were to resume research and development activities, Edge may seek additional capital through a combination of private and public
equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that Edge raises additional capital through the sale of equity or convertible debt securities, Edge’s then-existing stockholders’
ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of then-existing stockholders. Debt financings may be coupled with an equity component, such as warrants to purchase
stock, which could also result in dilution of Edge’s then-existing stockholders’ ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as
limitations on Edge’s ability to incur additional debt, limitations on Edge’s ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact Edge’s ability to conduct Edge’s business and may
result in liens being placed on Edge’s assets and intellectual property. If Edge were to default on such indebtedness, Edge could lose such assets and intellectual property. If Edge raises additional funds through strategic partnerships and
alliances and licensing arrangements with third parties, Edge may have to relinquish valuable rights to Edge’s product candidates, or grant licenses on terms that are not favorable to Edge.
Risks Related to Ownership of Edge’s Common Stock
The trading market in Edge’s common stock has been extremely limited and substantially less liquid than the
average trading market for a stock quoted on the Nasdaq Global Select Market.
Prior to Edge’s initial public offering, or IPO, there was no market for shares of Edge’s common stock. Since Edge’s initial listing
on the Nasdaq Global Select Market on October 1, 2015, the trading market in Edge’s common stock has been limited and substantially less liquid than the average trading market for companies quoted on the Nasdaq Global Select Market. The quotation
of Edge’s common stock on the Nasdaq Global Select Market does not assure that a meaningful, consistent and liquid trading market currently exists. Edge cannot predict whether a more active market for Edge’s common stock will develop in the
future. An absence of an active trading market could adversely affect Edge’s stockholders’ ability to sell Edge’s common stock at current market prices in short time periods, or possibly at all. Additionally, market visibility for Edge’s common
stock may be limited and such lack of visibility may have a depressive effect on the market price for Edge’s common stock. As of December 31, 2018, approximately 41% of Edge’s outstanding shares of common stock was held by Edge’s officers,
directors, beneficial owners of 5% or more of Edge’s capital stock and their respective affiliates, which adversely affects the liquidity of the trading market for Edge’s common stock, inasmuch as federal securities laws restrict sales of Edge’s
shares by these stockholders under certain circumstances. If Edge’s affiliates continue to hold their shares of common stock, there will be limited trading volume in Edge’s common stock, which may make it more difficult for investors to sell
their shares or increase the volatility of Edge’s stock price.
Edge’s common stock is listed on The Nasdaq Global Select Market. In order to maintain Edge’s listing, Edge must meet minimum financial
and other requirements, including requirements for a minimum amount of capital, a minimum price per share and continued business operations so that Edge is not characterized as a “public shell company.” Edge has received written notice from Nasdaq
stating that, at present, Edge is not in compliance with the audit committee requirements for continued listing on The Nasdaq Global Select Market, because Edge currently has an audit committee comprised of two members. If Edge does not regain
compliance with audit committee requirements in a timely manner, Nasdaq will provide written notification to Edge that Edge’s securities will be subject to delisting. In addition, Edge has received written notice from Nasdaq stating that, at
present, Edge is not in compliance with the bid price requirements for Edge’s common stock because the bid price for Edge’s common stock had closed below $1.00 per share for 30 consecutive business days. If Edge does not regain compliance with the
bid price requirements in a timely manner, Nasdaq will provide written notification to Edge that Edge’s securities will be subject to delisting.
Nasdaq has notified Edge that, in connection with the Merger, Edge will be required to submit a new listing application and meet
Nasdaq’s initial listing requirements, as opposed to Nasdaq’s more lenient continued listing requirements. Edge cannot provide any assurance that it will meet the initial listing requirements at the closing of the Merger. If the merger is
consummated, the combined company following such transaction will need to meet Nasdaq’s initial listing standards. If Edge is unable to comply with Nasdaq’s listing standards, Nasdaq may determine to delist Edge’s common stock from The Nasdaq
Global Select Market or other of Nasdaq’s trading markets. If Edge’s common stock is delisted for any reason, it could reduce the value of Edge’s common stock and its liquidity.
Market volatility may affect Edge’s stock price and the value of Edge’s stockholders’ investment.
The trading price of Edge’s common stock, similar to other biotechnology companies, is likely to be highly volatile and could be subject
to wide fluctuations in response to various factors, some of which are beyond Edge’s control, including, among others:
| ● |
regulatory actions with respect to Edge;
|
| ● |
the recruitment or departure of key personnel;
|
| ● |
announcements by Edge or Edge’s competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;
|
| ● |
regulatory or legal developments in the United States and other countries;
|
| ● |
developments or disputes concerning patent applications, issued/granted patents or other proprietary rights;
|
| ● |
the level of Edge’s expenses;
|
| ● |
actual or anticipated changes in estimates as to financial results;
|
| ● |
variations in Edge’s financial results or those of companies that are perceived to be similar to Edge;
|
| ● |
fluctuations in the valuation of companies perceived by investors to be comparable to Edge;
|
| ● |
share price and volume fluctuations attributable to inconsistent trading volume levels of Edge’s shares;
|
| ● |
announcement or expectation of additional financing efforts;
|
| ● |
sales of Edge’s common stock by Edge, Edge’s insiders or Edge’s other stockholders;
|
| ● |
market conditions in the pharmaceutical and biotechnology sectors; and
|
| ● |
general economic, industry and market conditions.
|
In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of Edge’s common stock, regardless of Edge’s actual operating
performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors,” could have a dramatic and material adverse impact on the market price of Edge’s common stock.
Future sales of a substantial number of shares of Edge’s common stock in the public market or other issuances of
Edge’s common stock or rights to purchase common stock, including pursuant to equity incentive plans could result in additional dilution of the percentage ownership of Edge’s stockholders and could cause Edge’s stock price to fall.
Edge’s stock price could also decline as a result of sales of a large number of shares of Edge’s common stock, including shares issuable
upon exercise of stock options and warrants, or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for Edge to sell equity securities in the future at a time
and at a price that Edge deems appropriate.
As of December 31, 2018, the holders of up to 3,290,905 shares, or 10.4%, of Edge’s common stock outstanding, will have rights, subject
to some conditions, to require Edge to file registration statements covering the sale of their shares or to include their shares in registration statements Edge may file for itself or other stockholders. Once Edge registers the offer and sale of
shares for the holders of registration rights, they can be freely sold in the public market.
In addition, in the future, Edge may issue additional shares of common stock or other equity or debt securities convertible into common
stock in connection with a financing, acquisition, litigation settlement, employee arrangements, or otherwise. Any such issuance could result in substantial dilution to Edge’s then-existing stockholders and could cause Edge’s stock price to
decline.
Future issuances of Edge’s common stock or rights to
purchase common stock, including pursuant to Edge’s equity incentive plans, could result in additional dilution of the percentage ownership of Edge’s stockholders and could cause Edge’s stock price to fall.
Any future issuances of common stock or common stock-related securities,
together with the exercise of outstanding options and warrants to purchase 7,632,383 shares of common stock as of December 31, 2018 and any additional shares issued in connection with acquisitions, if any, may result in material dilution to
Edge’s then-existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of Edge’s common stock.
Edge’s principal stockholders and management own a significant percentage of Edge’s stock and will be able to exert
significant control over matters subject to stockholder approval.
As of December 31, 2018, Edge’s executive officers, directors, holders of 5% or more of Edge’s capital stock and their respective
affiliates beneficially owned approximately 41% of Edge’s outstanding voting stock (assuming no exercise of outstanding stock options). These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For
example, these stockholders may be able to control elections of directors, amendments of Edge’s organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited
acquisition proposals or offers for Edge’s common stock that Edge’s then-existing stockholders’ may feel are in their best interest. The interests of this group of stockholders may not always coincide with your interests or the interests of other
stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for Edge’s common
stock.
Some provisions of Edge’s charter documents and Delaware law may have anti-takeover effects that could discourage an
acquisition of Edge by others, even if an acquisition would be beneficial to Edge’s stockholders and may prevent attempts by Edge’s stockholders to replace or remove Edge’s current management.
Provisions in Edge’s amended and restated certificate of incorporation, or certificate of incorporation, and amended and restated
bylaws, or bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire Edge or increase the cost of acquiring Edge, even if doing so would benefit Edge’s stockholders, or remove Edge’s current
management. These provisions include:
| ● |
authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;
|
| ● |
prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates;
|
| ● |
prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of Edge’s stockholders;
|
| ● |
eliminating the ability of stockholders to call a special meeting of stockholders;
|
| ● |
establishing a staggered board of directors; and
|
| ● |
establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.
|
These provisions may frustrate or prevent any attempts by Edge’s stockholders to replace or remove Edge’s current management by making
it more difficult for stockholders to replace members of Edge’s board of directors, who are responsible for appointing the members of Edge’s management. Because Edge is incorporated in Delaware, Edge is governed by the provisions of Section 203 of
the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring Edge or merging with Edge whether or not it is desired by or beneficial to Edge’s stockholders. Under Delaware law, a corporation may not, in
general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of Edge’s
amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for Edge’s stockholders to receive a premium for their
shares of Edge’s common stock, and could also affect the price that some investors are willing to pay for Edge’s common stock.
Because Edge does not anticipate paying any cash dividends on Edge’s capital stock in the foreseeable future,
capital appreciation, if any, will be Edge’s stockholders’ sole source of gain.
Edge has never declared or paid cash dividends on Edge’s capital stock. Edge currently intends to retain all of Edge’s future earnings,
if any, to finance Edge’s business. In addition, any future debt agreements may preclude Edge from paying dividends. As a result, capital appreciation, if any, of Edge’s common stock will be Edge’s stockholders’ sole source of gain for the
foreseeable future.
Edge is an “emerging growth company” and Edge intends to take advantage of reduced disclosure and governance
requirements applicable to emerging growth companies, which could result in Edge’s common stock being less attractive to investors.
Edge is an “emerging growth company,” as defined in the JOBS Act, and Edge intends to take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in Edge’s periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of
any golden parachute payments not previously approved. Edge cannot predict if investors will find Edge’s common stock less attractive because Edge will rely on these exemptions. Edge may take advantage of these reporting exemptions until Edge is no
longer an emerging growth company, which could potentially be for up to five years after the date of Edge’s IPO, which occurred on October 1, 2015. If investors find Edge’s common stock less attractive as a result of Edge’s reduced reporting
requirements, there may be a less active trading market for Edge’s common stock and Edge’s stock price may be more volatile. Edge may also be unable to raise additional capital as and when Edge needs it.
If Edge fails to maintain an effective system of internal control over financial reporting in the future, Edge may
not be able to accurately report Edge’s financial condition, results of operations or cash flows, which may adversely affect investor confidence in Edge and, as a result, the value of Edge’s common stock.
The Sarbanes-Oxley Act requires, among other things, that Edge maintain effective internal controls for financial reporting and
disclosure controls and procedures. Edge’s annual report on Form 10-K includes a report by management on, among other things, the effectiveness of Edge’s internal control over financial reporting. This assessment includes disclosure of any material
weaknesses identified by Edge’s management in Edge’s internal control over financial reporting. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting that results in more
than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 of the Sarbanes-Oxley Act also generally requires an attestation from Edge’s
independent registered public accounting firm on the effectiveness of Edge’s internal control over financial reporting. However, for as long as Edge remains an emerging growth company as defined in the JOBS Act, Edge intends to take advantage of
certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public
accounting firm attestation requirement.
Edge’s compliance with Section 404 requires that Edge incur additional accounting expense and management efforts. Edge currently does
not have an internal audit group. Edge may not be able to complete any required Section 404 evaluation, testing and remediation in a timely fashion. During the evaluation and testing process, if Edge identifies one or more material weaknesses in
Edge’s internal control over financial reporting, Edge will be unable to assert that Edge’s internal control over financial reporting is effective. Edge cannot assure Edge’s stockholders that there will not be material weaknesses or significant
deficiencies in Edge’s internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit Edge’s ability to accurately report Edge’s financial condition, results of
operations or cash flows. If Edge is unable to conclude that Edge’s internal control over financial reporting is effective, or if Edge’s independent registered public accounting firm determines Edge has a material weakness or significant deficiency
in Edge’s internal control over financial reporting, Edge could lose investor confidence in the accuracy and completeness of Edge’s financial reports, the market price of Edge’s common stock could decline, and Edge could be subject to sanctions or
investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in Edge’s internal control over financial reporting, or to implement or maintain other effective control systems required of public
companies, could also restrict Edge’s future access to the capital markets.
Edge’s disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Edge’s disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by Edge in reports
Edge files or submits under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms
of the SEC. Edge believes that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are
met.
These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because
of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in
Edge’s control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.
Risks Related to the Combined Company
If the merger with PDS closes, the combined company will be subject to additional risks, including each of those described below.
The combined company’s stock price is expected to be volatile, and the market price of its common stock may drop
following the merger.
The market price of the combined company’s common stock following the merger could be subject to significant fluctuations following the
merger. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of the combined company’s common
stock to fluctuate include:
| ● |
the ability of the combined company or its partners to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and
effective;
|
| ● |
the ability of the combined company or its partners to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;
|
| ● |
failure of any of the combined company’s product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;
|
| ● |
failure by the combined company to maintain its existing third-party license, manufacturing and supply agreements;
|
| ● |
failure by the combined company or its licensors to prosecute, maintain, or enforce its intellectual property rights;
|
| ● |
changes in laws or regulations applicable to the combined company’s product candidates;
|
| ● |
any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;
|
| ● |
adverse regulatory authority decisions;
|
| ● |
introduction of new or competing products by its competitors;
|
| ● |
failure to meet or exceed financial and development projections the combined company may provide to the public;
|
| ● |
the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;
|
| ● |
announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by the combined company or its competitors;
|
| ● |
disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company’s ability to obtain intellectual property
protection for its technologies;
|
| ● |
additions or departures of key personnel;
|
| ● |
significant lawsuits, including intellectual property or stockholder litigation;
|
| ● |
if securities or industry analysts do not publish research or reports about the combined company, or if they issue an adverse or misleading opinions regarding its business
and stock;
|
| ● |
changes in the market valuations of similar companies;
|
| ● |
general market or macroeconomic conditions;
|
| ● |
sales of its common stock by the combined company or its stockholders in the future;
|
| ● |
trading volume of the combined company’s common stock;
|
| ● |
adverse publicity relating to the combined company’s markets generally, including with respect to other products and potential products in such markets;
|
| ● |
changes in the structure of health care payment systems; and
|
| ● |
period-to-period fluctuations in the combined company’s financial results.
|
Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating
performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company’s common stock.
In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class
action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm the combined company’s profitability and
reputation.
Edge and PDS do not anticipate that the combined company will pay any cash dividends in the foreseeable future.
The current expectation is that the combined company will retain its future earnings, if any, to fund the development and growth of the
combined company’s business. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.
Future sales of shares by existing stockholders could cause the combined company’s stock price to decline.
If existing stockholders of Edge and PDS sell, or indicate an intention to sell, substantial amounts of the combined company’s common
stock in the public market after legal restrictions on resale lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of December 31, 2018 and shares expected to be issued upon the closing
of the merger, the combined company is expected to have outstanding a total of approximately 101 million shares of common stock (prior to giving effect to the proposed reverse stock split) immediately following the closing of the merger.
Approximately 36 million of such shares of common stock (prior to giving effect to the proposed reverse stock split) will be freely tradable, without restriction, in the public
market. Approximately 65 million of such shares of common stock (prior to giving effect to the proposed reverse stock split) will be held by directors, executive officers of the combined company and other affiliates and will be subject to volume
limitations under Rule 144 under the Securities Act and various vesting agreements.
If the ownership of the combined company common stock is highly concentrated, it may prevent you and other
stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause the combined company stock price to decline.
Executive officers and directors of the combined company and their affiliates are expected to beneficially own or control approximately
59.6% of the outstanding shares of the combined company common stock following the closing of the merger. Accordingly, these executive officers, directors and their affiliates, acting as a group, will have substantial influence over the outcome of
corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of the combined company assets or any other significant corporate transactions. These stockholders
may also delay or prevent a change of control of the combined company, even if such a change of control would benefit the other stockholders of the combined company. The significant concentration of stock ownership may adversely affect the trading
price of the combined company’s common stock due to investors’ perception that conflicts of interest may exist or arise.
Because the merger will result in an ownership change under Section 382 of the Code for Edge, pre-merger U.S. net
operating loss carryforwards and certain other tax attributes will be subject to limitations.
As of December 31, 2018, Edge had federal and state net operating loss carryforwards, or NOLs, of $128.6 million and $27.2 million,
respectively, due to prior period losses. If a corporation undergoes an “ownership change” within the meaning of Section 382 of the Code, the corporation’s U.S. net operating loss carryforwards and certain other tax attributes arising from before
the ownership change are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation’s equity ownership by certain stockholders that exceeds fifty percentage
points over a rolling three-year period. Similar rules may apply under state and foreign tax laws. Edge believes that it may have already undergone one or more ownership changes prior to the merger. The merger will also result in an ownership
change for Edge and, accordingly, Edge’s U.S. net operating loss carryforwards and certain other tax attributes will be subject to limitations on their use after the merger.
Changes in tax laws and regulations or in the combined company’s operations may impact the combined company’s
effective tax rate and may adversely affect the combined company’s business, financial condition and operating results.
Changes in tax laws in any jurisdiction in which combined company operates, or adverse outcomes from any tax audits that the combined
company may be subject to in any such jurisdictions, could result in an unfavorable change in Edge’s effective tax rate, which could adversely affect Edge’s business, financial condition, and operating results.
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or
the Tax Act. The changes included in the Tax Act are broad and complex. The impact of these changes on how the combined company’s earnings are taxed include, among other items, (i) reducing the U.S. federal corporate tax rate from 35% to 21%; (ii)
repealing the corporate alternative minimum tax and changing how existing credits can be utilized; (iii) temporarily providing for elective immediate expensing for certain depreciable property; (iv) creating a new limitation on the deductibility of
interest expense; and (v) changing rules related to uses and limitations of net operating losses created in tax years beginning after December 31, 2017. Edge and PDS continue to evaluate the Tax Act and its impact on the combined company’s
businesses. It is possible that the Tax Act will be subject to further changes either in a technical corrections bill or entirely new legislation. The overall impact of the Tax Act also depends on the future interpretations and regulations that may
be issued by U.S. tax authorities. Edge expects there will be further guidance provided by these authorities potentially having a material adverse effect on the combined company’s financial condition or results of operations. The impact of broad
proposals or of regulatory issuances on the combined company’s business can vary substantially depending upon the specific changes or further guidance made and how the changes or guidance are implemented by the authorities.
Anti-takeover provisions under Delaware law could make an acquisition of the combined company more difficult and may
prevent attempts by the combined company stockholders to replace or remove the combined company management.
Because the combined company will be incorporated in Delaware, it is governed by the provisions of Section 203 of the DGCL, which
prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although Edge and PDS believe these provisions collectively will provide for an opportunity to
receive higher bids by requiring potential acquirors to negotiate with the combined company’s board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or
prevent any attempts by the combined company’s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of
management.
None.
Our corporate headquarters consists of approximately 20,410 square feet of office space located at 300 Connell Drive, Berkeley Heights,
New Jersey, that we occupy under a 63 month lease which ends in November of 2021. We believe that our existing facilities are adequate for our near-term needs. We believe that
suitable additional or alternative space would be available if required in the future on commercially reasonable terms.
From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes.
On April 23, 2018, a purported securities class action complaint was filed against Edge, Brian Leuthner (Edge’s President and
Chief Executive Officer) and Andrew Saik (Edge’s Chief Financial Officer) in the United States District Court for the District of New Jersey, captioned Sanfilippo v. Edge Therapeutics, Inc., Case No. 2:18-cv-8236. The complaint alleged that Edge,
Mr. Leuthner and Mr. Saik violated Section 10(b) of the Securities Exchange Act of 1934 by making false and misleading statements concerning Edge’s business, operations and prospects by failing to disclose that Edge’s developmental product EG-1962
allegedly would likely fail a futility analysis. The complaint also asserted a “control” person claim against Mr. Leuthner and Mr. Saik pursuant to Section 20(a) of the Exchange Act. The complaint was brought on behalf of all purchasers of Edge’s
common stock between December 27, 2017, and March 27, 2018, and sought unspecified damages. On December 7, 2018, the court appointed Sam Kirkpatrick and Amos Bakouple lead plaintiffs for the putative class and appointed the firm Glancy, Prongay
& Murray LLP lead counsel for the putative class. On February 14, 2019, the lead plaintiffs voluntarily dismissed the action, without prejudice, as to all defendants.
Edge and the Edge Board have been named as defendants in two individual lawsuits and two putative class action lawsuits regarding the
potential merger, each of which alleges that the registration statement on Form S-4 (Registration No. 333-228937) filed by the Edge on December 21, 2018 omitted material information with respect to the proposed transaction, which rendered the
registration statement on Form S-4 false or misleading. The case captioned Michael Condon v. Edge Therapeutics et al., case no. 2:19-cv-00152, or the Condon Action, was filed on January 4, 2019 in the United States District Court for the District
of New Jersey. The case captioned Adam Franchi et al. v. Edge Therapeutics et al., case no. 1:19-cv-00058-UNA, or the Franchi Action, was filed on January 9, 2019 in the United States District Court for the District of Delaware. The case captioned
Jeffrey L. Prince v. Edge Therapeutics et al., case no. 1:19-cv-00280, or the Prince Action, was filed on January 10, 2019 in the United States District Court for the Southern District of New York. The case captioned Brian Foldenauer et al. v. Edge
Therapeutics et al., case no. 1:19-cv-00280, or the Foldenauer Action, was filed on January 22, 2019 in the United States District Court for the District of Delaware.
The causes of action set forth in each of the Condon Action, the Franchi Action, the Prince Action and the Foldenauer Action are (i) a
claim against Edge and the Board for violations of Section 14(a) of the Exchange Act, as well as (ii) a claim against the Board for violations of Section 20(a) of the Exchange Act. In the Franchi Action, PDS was also named as a defendant in respect
of the claim regarding violations of Section 20(a) of the Exchange Act. In each case, the plaintiffs seek, among other things, injunctive relief, rescissory damages, and an award of attorneys’ fees and expenses.
Edge has voluntarily accepted service of process in the Franchi Action and Prince Action, but has not yet been served with process in
the Condon Action or the Foldenauer Action. On January 18, 2019, the plaintiffs in the Prince Action filed a motion for a preliminary injunction barring any stockholder vote on the proposed merger until revised disclosures are made to Edge’s
stockholders, and withdrew the motion for a preliminary injunction on February 1, 2019. Edge believes the litigation is without merit and in any event has been rendered moot by amendment no. 1 to the Registration Statement on S-4 filed by Edge on
January 25, 2019 and subsequent disclosures. This litigation remains in the initial pleadings phase.
Not applicable.
PART II
ITEM 5. Market for Registrant’s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities Market Information
On October 1, 2015, our common stock began trading on the Nasdaq Global Market under the symbol “EDGE”. Prior to that time, there was no
public market for our common stock. Shares sold in our initial public offering on October 1, 2015 were priced at $11.00 per share.
On February 14, 2019, the closing price for our common stock as reported on the Nasdaq Global Market was $0.39. The following table sets forth the high and low sales prices per share of our common stock as reported on the Nasdaq Global Market for the period indicated.
|
Year Ended December 31, 2018
|
High
|
Low
|
||||||
|
Fourth Quarter
|
$
|
1.09
|
$
|
0.31
|
||||
|
Third Quarter
|
$
|
1.10
|
$
|
0.70
|
||||
|
Second Quarter
|
$
|
1.28
|
$
|
0.87
|
||||
|
First Quarter
|
$
|
17.47
|
$
|
1.18
|
||||
|
Year Ended December 31, 2017
|
High
|
Low
|
||||||
|
Fourth Quarter
|
$
|
11.16
|
$
|
9.07
|
||||
|
Third Quarter
|
$
|
11.51
|
$
|
9.20
|
||||
|
Second Quarter
|
$
|
10.72
|
$
|
8.81
|
||||
|
First Quarter
|
$
|
12.99
|
$
|
7.62
|
||||
Stockholders
As of February 14, 2019, there were 36 stockholders of record, which excludes stockholders whose shares were held in nominee or street
name by brokers.
We did not purchase any of our registered equity securities during the period covered by this Annual Report.
Use of Proceeds from Registered Securities
On April 21, 2017, we completed a registered direct common stock offering for gross proceeds of $18.0 million. We received
approximately $17.4 million in net proceeds after deducting the finder’s fee and other offering costs. We have invested the net proceeds in short-term, investment-grade,
interest-bearing cash equivalents.
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS AS OF DECEMBER 31, 2018
|
|
(A)
|
(B)
|
(C)
|
|||||||||
|
Plan category
|
Number of
securities
to be issued
upon exercise
of outstanding
options, warrants
and rights
|
Weighted-
average
exercise price
of outstanding
options, warrants
and rights
($)
|
Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column (A))
|
|||||||||
|
Equity compensation plans approved by security holders
|
7,238,787
|
5.41
|
136,228
|
|||||||||
|
Equity compensation plans not approved by security holders
|
315,003
|
8.35
|
-
|
|||||||||
|
Total
|
7,553,787
|
5.68
|
136,228
|
|||||||||
We are a smaller reporting company; as a result, we are not required to report selected financial data disclosures as required by Item 301 of Regulation S-K.
You should read the following discussion and analysis of our financial condition and results of operations
together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks,
uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences
below and elsewhere in this Annual Report, including those set forth under Item 1A. “Risk Factors” and under “Forward-Looking Statements” in this Annual Report.
The Company is a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of
transforming treatment paradigms in the management of medical conditions. On March 28, 2018, the Company announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first 210 subjects randomized and treated in
the Phase 3 multi-center, randomized, double-blind, placebo-controlled NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage demonstrated a low probability of achieving a statistically significant difference compared to the
standard of care in the study’s primary endpoint, if the study were to be fully enrolled. The independent Data Monitoring Committee (“DMC”) for the NEWTON 2 study recommended that the study be stopped based on this demonstration. The DMC also
reported that there were no safety concerns attributed to EG-1962. Based on the DMC recommendation, the Company decided to discontinue the NEWTON 2 study and took steps to
notify health authorities and clinical investigators participating in the study.
On April 30, 2018, the Company announced that it was exploring strategic alternatives that might have included, without limitation, an
acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the assets of the Company, a sale of stock, a strategic merger or other business
combination transaction or other transaction between the Company and a third party. The Company retained Piper Jaffray & Co. to serve as the financial advisor to its Board of Directors in certain aspects of the process. The Company has
reduced the scope of its operations, including the size of its workforce, in order to preserve its cash resources.
After a comprehensive review of strategic alternatives, on November 23, 2018, the Company, Merger Sub and PDS entered into the Merger
Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into PDS, with PDS surviving the merger as the wholly-owned subsidiary of
the combined company. PDS is a private company with a growing pipeline of clinical-stage immunotherapies that are expected to treat various early-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, breast
cancer and other cancers. Following the merger, the combined company expects to focus on developing PDS’s growing pipeline of next-generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology
platform, the development of PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers, and multiple preclinical programs developing Versamune®-based cancer
immunotherapies in combination with checkpoint inhibitors for various late-stage cancers.
The Company has never been profitable and has incurred net losses in each year since inception. The Company’s net losses were $40.9
million, and $50.9 million for the years ended December 31, 2018 and 2017 respectively. As of December 31, 2018, the Company had an accumulated deficit of $192.8 million. From the Company’s inception, it has devoted substantially all of its efforts
to business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital. The Company’s future operations are highly dependent on the success of
its transaction with PDS. The Company has ceased research and development on EG-1962, including the completion of
the NEWTON 2 study, and all of its other product candidates.
Furthermore, the Company expects to incur additional costs associated with operating as a public company. Accordingly, at least until
the Company can generate significant revenue from product sales, the Company will seek to fund its operations through public or private equity or debt financings or other sources. However, the Company may be unable to raise additional funds or
enter into such other arrangements when needed on favorable terms or at all.
As of December 31, 2018, the Company had $34.6 million in cash and cash equivalents.
Financial Operations Overview
Revenue
We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We
may generate revenue in the future from a combination of research and development payments, license fees and other upfront payments or milestone payments.
Research and Development Expenses
Research and development expenses include employee-related expenses, licensing fees to use certain technology in our research and
development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development
activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs
incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued expenses. Costs incurred in
connection with research and development activities are expensed as incurred.
The following table summarizes our research and development expenses incurred for the periods indicated (in thousands):
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
EG-1962 product candidate
|
$
|
9,504
|
$
|
22,075
|
||||
|
EG-1964 product candidate
|
5
|
640
|
||||||
|
Pipeline
|
188
|
371
|
||||||
|
Internal Operating Expenses
|
6,372
|
11,226
|
||||||
|
Total
|
$
|
16,069
|
$
|
34,312
|
||||
Following the DMC’s recommendation that the NEWTON 2 Trial for EG-1962 be stopped, we decided to discontinue the NEWTON 2 study and took
steps to notify health authorities and clinical investigators participating in the study. We have ceased all further research and development activities for EG-1962 and suspended research for our other product candidates and implemented operating
cost reductions and organizational restructurings, including a reduction in the our workforce, to preserve our cash resources and better align the organization with our current operating plan.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to
our executive, finance, legal, business development and support functions. Other general and administrative expenses include travel expenses, professional fees for auditing, tax and legal services and facility-related costs.
The following table summarizes our general and administrative expenses incurred for the periods indicated (in thousands):
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
General and administrative expenses
|
$
|
14,291
|
$
|
17,655
|
||||
As was mentioned in “Research and Development Expenses” above, we have implemented operating cost reductions and organizational
restructurings, including a reduction in the Company’s workforce, to preserve its cash resources and better align the organization with its current operating plan.
Restructuring Expenses
Restructuring expenses consist of charges related our company reorganization including severance, financial advisor fees, legal fees and
retention compensation. Restructuring expenses amounted to $9.9 million for the year ended 2018.
Impairment charges
Impairment charges reflects the charge to the write-down of machinery and equipment no longer needed as a consequence of ceasing
research and development on EG-1962.
Interest Income
Interest income consists of interest income earned on our cash and cash equivalents.
Interest Expense
Interest expense consists of interest expense on our borrowings under the Amended Loan Agreement with Hercules. The loan was repaid in
full in June 2018.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets
and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe
are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.
While our significant accounting policies are described in the notes to our financial statements appearing in this Annual Report, we
believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.
Income Taxes
We file U.S. federal income tax returns and New Jersey state tax returns. Our deferred tax assets are primarily comprised of federal
and state tax net operating losses and tax credit carryforwards and are recorded using enacted tax rates expected to be in effect in the years in which these temporary differences are expected to be utilized. At December 31, 2018, we had federal
net operating loss, or NOL, carryforwards of approximately $101.5 million, which expire at various dates between 2029 and 2038, and $27.1 million generated in 2018 will have an indefinite carryforward period. At December 31, 2018, we had federal
research and development credits carryforwards of approximately $2.3 million and Orphan Drug credit of approximately $24.4 million. We may be subject to the net operating loss utilization provisions of Section 382 of the Internal Revenue Code.
The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon our value immediately before the
ownership change, changes to our capital during a specified period prior to the change, and the federal published interest rate. Although we have not completed an analysis under Section 382 of the Code, it is likely that the utilization of the
NOLs will be limited.
On December 22, 2017, H.R. 1 (also known as the Tax Cuts and Jobs Act (the “Tax Act”)) was signed into law. Among its numerous changes
to the Internal Revenue Code, the Tax Act reduces U.S. federal corporate tax rate to 21%. As a result, the most significant impact on its consolidated financial statements was the reduction of approximately $13.6 million for the deferred tax
assets related to net operating losses and other assets. Such reduction was offset by changes to the Company’s valuation allowance as of December 31, 2017. We previously provided a provisional estimate of the effect of the Tax Act in our financial statements. In the fourth quarter of 2018, we completed our analysis to determine there was no
additional effect of the Tax Act as of December 31, 2018.
Accrued Clinical Expenses
When preparing our financial statements, we are required to estimate our accrued clinical expenses. This process involves reviewing open
contracts and communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or
otherwise notified of actual cost. Payments under some of the contracts we have with parties depend on factors, such as successful enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones.
When accruing clinical expenses, we estimate the time period over which services will be performed and the level of effort to be
expended in each period. If possible, we obtain information regarding unbilled services directly from our service providers. However, we may be required to estimate the cost of these services based only on information available to us. If we
underestimate or overestimate the cost associated with a trial or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued clinical expenses have
approximated actual expense incurred.
As of December 2018, we have agreed with our clinical research organization on the final wind-down costs of our EG-1962 study and have
recorded the expense in 2018.
Stock-based Compensation
We estimate the fair value of our stock-based option awards to employees and non-employees using the Black-Scholes option-pricing model,
which requires the input of assumptions, including: (1) the expected volatility of our stock, (2) the expected term of the award, (3) the risk-free interest rate and (4) expected dividends. In accordance with FASB ASC 505, we re-measure the fair
value of non-employee stock-based compensation as the awards vest, and recognize the resulting value, if any, as expense during the period the related services are rendered. We believe that all stock options issued under our stock option plans meet
the criteria of “plain vanilla” stock options. The expected term of the options outstanding was determined using the “simplified” method as prescribed by Staff Accounting Bulletin, No. 107, Share Based Payment. The risk-free interest rate is based on U.S. Treasury notes with remaining terms similar to the expected term of the option. The volatility was based on a representative group of small
publicly traded drug development companies. The dividend yield assumption is zero since we have never paid cash dividends and have no present intention to pay cash dividends.
The fair value of options granted for the periods indicated was estimated using the Black-Scholes option valuation model utilizing the following
assumptions:
|
|
Year Ended December 31,
|
|||||||
|
2018
|
2017
|
|||||||
|
Weighted Average
|
Weighted Average
|
|||||||
|
Volatility
|
86.33
|
%
|
88.87
|
%
|
||||
|
Risk-Free Interest Rate
|
2.23
|
%
|
1.88
|
%
|
||||
|
Expected Term in Years
|
6.00
|
6.00
|
||||||
|
Dividend Rate
|
0.00
|
%
|
0.00
|
%
|
||||
|
Fair Value of Option on Grant Date
|
$
|
5.08
|
$
|
6.93
|
||||
Basic and Diluted Net Loss Per Share of Common Stock
We compute basic and diluted net loss per share of common stock by
dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, common stock underlying the options, unvested RSUs and warrants have been excluded from the
calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.
Results of Operations
Comparison of the Years Ended December 31, 2018 and 2017
|
Year Ended December 31,
|
Increase (Decrease)
|
|||||||||||||||
|
2018
|
2017
|
$ |
%
|
|||||||||||||
|
(in thousands)
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development expenses
|
$
|
16,069
|
$
|
34,312
|
$
|
(18,243
|
)
|
(53
|
)%
|
|||||||
|
General and administrative expenses
|
14,291
|
17,655
|
(3,364
|
)
|
(19
|
)%
|
||||||||||
|
Restructuring expenses
|
9,914
|
–
|
9,914
|
100
|
%
|
|||||||||||
|
Impairment charges
|
2,823
|
–
|
2,823
|
100
|
%
|
|||||||||||
|
Total operating expenses
|
43,097
|
51,967
|
(8,870
|
)
|
(17
|
)%
|
||||||||||
|
Loss from operations
|
(43,097
|
)
|
(51,967
|
)
|
8,870
|
(17
|
)%
|
|||||||||
|
Interest income (expense), net
|
(553
|
)
|
(1,479
|
)
|
926
|
(63
|
)%
|
|||||||||
|
Loss before income taxes
|
(43,650
|
)
|
(53,446
|
)
|
9,796
|
(18
|
)%
|
|||||||||
|
Benefit for income taxes
|
2,782
|
2,586
|
196
|
8
|
%
|
|||||||||||
|
Net loss and comprehensive loss
|
$
|
(40,868
|
)
|
$
|
(50,860
|
)
|
$
|
9,992
|
(20
|
)%
|
||||||
Research and Development Expenses
Research and development expenses decreased to $16.1 million in the year ended December 31, 2018 from $34.3 million for the same period
in 2017. The decrease of $18.2 million in 2018 was primarily attributable to a decrease in external expenses for the clinical studies of $13.4 million and R&D internal department costs of $4.8 million resulting from the discontinuance of the
clinical studies and reduction in force.
General and Administrative Expenses
General and administrative expenses decreased to $14.3 million in the year ended December 31, 2018 from $17.7 million for the same
period in 2017. The $3.4 million decrease was due primarily to decreases in personnel costs of $0.8 million, facilities $0.2 million, travel $0.2 million, marketing of $1.1 million and legal and professional fees of $1.1 million.
Restructuring Expenses
Restructuring expenses amounted to $9.9 million for the year ended December 31, 2018, related to the previously announced discontinuance
of the NEWTON 2 study. The components consisted of $4.4 million for severance benefits, $2.3 million for financial advisory fees, $1.4 million for legal fees and $1.8 million for retention compensation.
Impairment Charges
The charge in 2018 reflects the impairment charge to the write-down of machinery and equipment no longer needed as a consequence of
ceasing research and development on EG-1962.
Interest Income and Expense, net
Interest income and expense, net decreased primarily due to reduced interest expense for our loan of $0.7 million resulting from paying
off the loan in June 2018 offset by an increase in interest income from interest earned on our cash and cash equivalents of $0.2 million.
Benefit for Income Taxes
Benefit for income taxes increased as a result of selling additional New Jersey Net Operating Losses in 2018 as compared to 2017.
Liquidity and Capital Resources
Since our inception and through December 31, 2018, we have raised
aggregate net proceeds of $207.9 million to fund our operations, primarily $82.8 million from the sale of common stock, $87.5 million from the sale of preferred stock, $17.4 million net proceeds from a registered direct common stock offering and
$20.0 million from a loan. As of December 31, 2018, we had total cash and cash equivalents of $34.6 million as compared to $88.1 million as of December 31, 2017. The $53.5 million
decrease in total cash and cash equivalents was due to repayment of debt totaling $20.9 million and to the funding of operations, which mainly consisted of research and development activities and general and administrative expenses offset by
proceeds from exercise of stock options.
On October 6, 2015, we completed the IPO of our common stock for aggregate gross proceeds of $92.5 million. We received $82.8 million in
net proceeds after deducting underwriting discounts and commissions and other offering costs of $9.7 million. In connection with the IPO, all preferred stock was converted into common stock. There is no preferred stock outstanding as of December
31, 2018.
On April 21, 2017, we completed a registered direct common stock offering for gross proceeds of $18.0 million. We received $17.4 million
in net proceeds after deducting the finder’s fee and other offering costs.
In April 2018, we announced that we plan to explore strategic alternatives for the Company in order to maximize both near and long-term
value for our shareholders, which might have included, without limitation, an acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the
assets of the Company, a sale of stock, a strategic merger or other business combination transaction or other transaction between the Company and a third party. In April 2018, the Edge Board retained Piper to serve as its financial advisor in
certain aspects of the strategic review process. Throughout the strategic alternatives process, we have financed our operations with our existing cash. Our ability to continue to support our operations is dependent, in the near-term, upon managing
our cash resources as we pursue such strategic alternatives. We have ceased research and development on EG-1962, other than the wind-down of the NEWTON 2 study, and all of our other product candidates.
On November 23, 2018, Edge, Merger Sub and PDS, a privately-held clinical-stage cancer immunotherapy company, entered into an Agreement
and Plan of Merger and Reorganization, or the Merger Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into PDS, with PDS
surviving the merger as the wholly-owned subsidiary of the combined company.
If the merger is completed, the business of Edge will become the business of PDS. If the merger is not completed, Edge will reconsider
its strategic alternatives and may pursue one of the following courses of action, which Edge currently believes are the most likely alternatives if the merger with PDS is not completed:
| ● |
Pursue another strategic transaction similar to the merger. Edge may resume its process of evaluating other companies interested in pursuing a strategic transaction with
Edge and, if a candidate is identified, focus its attention on negotiating and completing such a transaction with such candidate.
|
| ● |
Dissolve and liquidate its assets. If Edge is unable, or does not believe that it is able, to find a suitable candidate for another strategic transaction, Edge may dissolve
and liquidate its assets. In the event of dissolution, Edge would be required to pay all of its debts and contractual obligations and to set aside certain reserves for potential future claims. If Edge dissolves and liquidates its
assets, there can be no assurance as to the amount or timing of available cash that will remain for distribution to Edge’ stockholders after paying Edge’ debts and other obligations and setting aside funds for its reserves.
|
Hercules Loan and Security Agreement
On August 1, 2016, the Company entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”) with
Hercules Capital, Inc., formerly known as Hercules Technology Growth Capital, Inc. (“Hercules”). Pursuant to the Amended Loan Agreement, the Company was able to borrow up to $20,000,000. At closing, the Company borrowed $15,000,000 of the amount
available for draw under the Amended Loan Agreement (and received proceeds net of the amount then outstanding under the Original Loan Agreement, fees and expenses). On May 23, 2017, the Company elected to draw down the second tranche of $5
million. Pursuant to the Amended Loan Agreement, in March 2018, the Company made a payment of $90,000, which is equal to 1.5% of the total amounts funded under the Original Loan Agreement.
In June 2018, the Company paid off its entire outstanding debt under the Amended Loan Agreement. The payment consisted of $20.0 million
for the principal amount, an additional $0.9 million in back-end fees and $0.1 million in accrued and unpaid interest.
As of June 30, 2018, there were no future principal payments due under the Amended Loan Agreement.
Cash flows
The following table shows a summary of our cash flows for each of the periods indicated (in thousands):
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Net cash used in operating activities
|
$
|
(33,153
|
)
|
$
|
(40,697
|
)
|
||
|
Net cash used in investing activities
|
–
|
(188
|
)
|
|||||
|
Net cash (used in) provided by financing activities
|
(20,269
|
)
|
22,554
|
|||||
|
Net decrease in cash
|
$
|
(53,422
|
)
|
$
|
(18,331
|
)
|
||
Net Cash Used in Operating Activities
Net cash used in operating activities was $33.2 million and $40.7 million for the years ended December 31, 2018 and 2017, respectively.
The decrease in cash used in operating activities of $7.5 million was primarily due to the reduction of operating activities as compared to the prior year.
Net Cash Used in Investing Activities
Net cash used in investing activities in 2017 relates entirely to purchases of property and equipment.
Net Cash Provided by Financing Activities
Net cash used in financing activities of $20.3 million for the year ended December 31, 2018 was due to the repayment of debt and debt
fees totaling $21.0 million offset by receipt of net proceeds from exercise of stock options of $0.7 million.
Net cash provided by financing activities of $22.6 million for the year ended December 31, 2017 was primarily due to the receipt of net
proceeds from the issuance of common stock of $17.4 million and debt of $5.0 million.
Operating Capital Requirements
Our future capital requirements are difficult to forecast. We expect that our research and development expenses will decrease
significantly due to the discontinuation of the NEWTON 2 study for EG-1962 and further research and development activities for EG-1962 and our other product candidates, at least until the strategic review process is complete.
We believe that our existing cash and cash equivalents as of December 31, 2018 will be sufficient to meet our anticipated cash
requirements for at least the next 12 months.
Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking
statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital
resources sooner than we currently expect. Our future capital requirements are difficult to forecast and will depend on many factors, including:
| ● |
our ability to timely consummate the merger with PDS;
|
| ● |
the costs incurred in defending the class action civil litigation;
|
| ● |
the costs incurred in responding to disruptive actions by activist stockholders;
|
| ● |
the timing and nature of any strategic transactions that we undertake;
|
| ● |
personnel-related expenses, including salaries, benefits, severance, stock-based compensation expense and other compensation costs related to implementing our restructuring
plan;
|
| ● |
the scope and nature of activities we may pursue to advance clinical development for our product candidates, if any; and
|
| ● |
the number and characteristics of product candidates that we develop or may acquire or in-license;
|
Please see the section titled “Risk Factors” elsewhere in this Annual Report for additional risks associated with our operations.
Contractual Obligations and Commitments
The following is a summary of our contractual obligations as of the date indicated:
|
As of December 31, 2018
|
Total
|
Less than One Year
|
1-3 Years
|
3-5 Years
|
More than 5 Years
|
|||||||||||||||
|
(in thousands)
|
||||||||||||||||||||
|
Operating lease obligations
|
$
|
1,739
|
$
|
605
|
$
|
1,134
|
$
|
–
|
$
|
–
|
||||||||||
|
Total contractual obligations
|
$
|
1,739
|
$
|
605
|
$
|
1,134
|
$
|
–
|
$
|
–
|
||||||||||
This table above does not include (a) any milestone payments related to contingent events which may become payable to third parties
under our license agreements should we elect to conduct further development and potential commercialization of EG-1962, as the timing and likelihood of such payments are not known and may not occur at all, or (b) contracts that are entered into in
the ordinary course of business which are not material in the aggregate in any period presented above.
Purchase Commitments
We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase
order basis.
Milestone and Royalty-based Commitments
Pursuant to the Evonik Agreement, in exchange for the license, we agreed to make milestone payments totaling up to $14.75 million upon
the achievement of certain development, regulatory and sales milestones detailed in the Evonik Agreement. We paid $0.25 million upon execution of the Evonik Agreement. In August 2016, we paid a milestone of $1.0 million after we dosed the first
patient in the Phase 3 clinical trial of EG-1962. In addition, the Evonik Agreement calls for us to pay royalties on sales of certain products based on a mid-single digit percentage of net sales. The Evonik Agreement provides for the reduction of
royalties in certain circumstances. Following the discontinuation of the NEWTON 2 trial for EG-1962, we have ceased all research and development efforts related to EG-1962 and suspended our other product candidates. As such, unless we resume such
development activities, it is unlikely that we will have any additional milestones or royalty obligations to Evonik in the future.
Under the Restated Development Agreement, we agreed to pay Oakwood to perform services under agreed upon project plans and to pay
Oakwood up to an aggregate of $4.5 million. In July 2017 and April 2018, the Company paid $1.5 million and $0.5 million, respectively, of such aggregate amount in connection with entering into the Restated Development Agreement. The remaining
$2.5 million was payable no later than April 1, 2019. The remaining payment was discounted to $2.375 million pursuant to an accelerated payment agreement entered into in August 2018. As of September 30, 2018, there are no remaining payments under
the Restated Development Agreement. In addition, the Restated Development Agreement calls for us to pay royalties on sales of certain products based on a low single digit percentage of net sales of EG-1962, regardless of the manufacturer or
supplier thereof.
Following the discontinuation of the NEWTON 2 trial for EG-1962, we have ceased all research and development efforts related to EG-1962
and our other product candidates. As such, we may terminate the Supply Agreement immediately upon notice to Oakwood (which will also result in the automatic termination of the Restated Development Agreement); provided, that if we choose to do so
prior to completion of the most recent project plan attached to the Restated Development Agreement, we must pay to Oakwood a termination fee. While certain of our milestone payments to Oakwood will remain outstanding (including the termination fee
in the event the Restated Development Agreement is terminated), unless we resume such development activities for EG-1962, it is unlikely that we will be required to pay additional milestone or royalty payments to Oakwood in the future pursuant to
the Restated Development Agreement or the Supply Agreement.
JOBS Act
On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of
the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which
adoption of such standards is required for other public companies.
Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these
exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that
may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis.
Off-balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules
and regulations of the SEC.
The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial
statements is found in Item 15.
None.
Evaluation of Disclosure Controls and Procedures
An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive
Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Exchange Act as of the end of the period covered by this report. Based on the
evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under
the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is
defined in Rules 13a—15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer and effected by the Edge
Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting
principles.
Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent
all errors and all fraud. A control system, no matter how well conceived, operated, tested and monitored, can provide only reasonable, not absolute, assurance that the objectives of the control system are met because of inherent limitations.
Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be
circumvented by collusion or improper management override. As a result of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these
inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
Management evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (the 2013 Framework). Management, under the supervision
and with the participation of the principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2018 and concluded that it was effective.
Our independent registered public accounting firm has not performed an evaluation of our internal control over financial reporting
during any period in accordance with the provisions of the Sarbanes-Oxley Act. For as long as we remain an “emerging growth company” as defined in the JOBS Act, we intend to take advantage of the exemption.
Changes in Internal Control over Financial Reporting
There were no significant changes to our internal control over financial reporting that occurred during the period covered by this
Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Not applicable.
PART III
Board of Directors
All of our current directors bring to the Edge
Board executive leadership experience from their service as executives and/or directors of our Company and/or other entities. The biography of each of the Edge Board members below contains information regarding the person’s business experience,
director positions held currently or at any time during the last five years, and the experiences, qualifications, attributes and skills that caused the nominating and corporate governance committee and the Edge Board to determine that the person
should serve as a director, given our business and structure.
|
Name
|
Age
|
Director Since
|
||
|
(Class A − Term expiring at annual meeting of stockholders in 2019)
|
||||
|
Rose Crane
|
59
|
2017
|
||
|
Liam Ratcliffe, M.D., Ph.D.
|
55
|
2016
|
||
|
Robert Spiegel, M.D.
|
69
|
2013
|
||
|
(Class B − Term expiring at annual meeting of stockholders in 2020)
|
||||
|
Isaac Blech
|
69
|
2013
|
||
|
James Loughlin
|
75
|
2011
|
||
|
R. Loch Macdonald, M.D., Ph.D.
|
57
|
2009
|
||
|
(Class C − Term expiring at annual meeting of stockholders in 2021)
|
||||
|
Sol Barer, Ph.D.
|
71
|
2011
|
||
| Brian A. Leuthner | 54 |
2009 |
Sol Barer, Ph.D
Dr. Barer has served on our board of directors since September 2011 and has been Chairman of our board of directors since January 2013.
He is the Managing Partner of SJ Barer Consulting. Dr. Barer spent 24 years at Celgene as, among other positions, President, COO and CEO, as well as its Executive Chairman and Chairman before retiring in June 2011. Dr. Barer currently serves as
Chairman of the Board of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Lead Independent Director of the Board of ContraFect Corporation (Nasdaq: CFRX), a biotechnology company; and Chairman of the Board of Aevi Genomic Medicine, Inc. (Nasdaq:
GNMX), a genomic medicine company. He also serves on the boards of several privately-held companies. Dr. Barer holds a B.S. from Brooklyn College. He earned his Ph.D. in Organic Chemistry from Rutgers University.
Our board of directors believes Dr. Barer’s broad industry
experience, as well as his significant experience on the boards of other public companies, provide him with the qualifications and skills to serve as a director.
Brian A. Leuthner
Mr. Leuthner, one of our co-founders, has served on our board of directors and has been our President and CEO since our inception in
January 2009. He has more than 28 years of experience in the biotechnology and pharmaceutical marketplace, with a specific expertise in orphan products, critical care and diseases of the central nervous system. Mr. Leuthner has also worked in the
hematology and oncology, infectious disease and cardiology marketplaces. Prior to founding our company, Mr. Leuthner was the CEO of Fontus Pharmaceuticals, Inc. from 2007 to 2008, the Senior Head of Marketing for The Medicines Company (Nasdaq:
MDCO) from 2005 to 2007 and the Director of Market Development for ESP Pharma, Inc. from 2003 to 2005. He also held marketing and sales positions of significant responsibility at Burroughs Wellcome and Company, Glaxo Wellcome plc and Johnson &
Johnson (NYSE: JNJ). Mr. Leuthner received his B.S. and M.B.A. degrees from the University of North Carolina at Chapel Hill.
Our board of directors believes Mr. Leuthner’s perspective and
experience as our President and CEO, as well as his depth of operating and senior management experience in our industry and educational background, provide him with the qualifications and abilities to serve as a director.
Liam Ratcliffe, M.D., Ph.D.
Dr. Ratcliffe has served on our board of directors since June 2016. Dr. Ratcliffe is a Managing Director at New Leaf Venture Partners,
and concentrates on biopharmaceutical investing. Dr. Ratcliffe joined New Leaf in September 2008. Dr. Ratcliffe was previously Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and
Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. Dr. Ratcliffe received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. He completed his internal
medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa. Dr. Ratcliffe serves on several academic and industry advisory boards, as well as a director on the boards of
Deciphera Pharmacueticals (Nasdaq: DCPH), Aptinyx, Inc. (Nasdaq: APTX), Unum Therapeutics Inc. (Nasdaq: UMRX), Arvinas Holding Company, LLC (Nasdaq: ARVN), and several privately-held companies.
Our board of directors believes that Dr. Ratcliffe’s experience in
the biopharmaceutical industry and investing in life sciences companies, as well as his medical and scientific background, provide him with the qualifications and skills to serve as a director.
Robert Spiegel, M.D.
Dr. Spiegel has served on our board of directors since August 2013. He has been an Associate Professor at Weill Cornell Medical
College since 2012 and is an Advisor to Warburg Pincus, LLC and the Israeli Biotech Fund. He served as Consultant and Chief Medical Officer of PTC Therapeutics, Inc., (“PTC”) from 2011 to 2014. Prior to joining our board of directors, Dr. Spiegel spent over 25 years at Schering-Plough Corporation, retiring in 2009 from his position as Chief Medical
Officer and Senior Vice President of the Schering-Plough Research Institute. Dr. Spiegel serves as a member of the board of directors of Geron Corporation (Nasdaq: GERN), a biotechnology oncology company, where he also serves on the compensation
committee. He also serves on the board of directors of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), a biotechnology oncology company. He currently serves as Chairman of Vidac Pharma and on the boards of NexImmune and Ayala Pharmaceuticals,
private biotechnology companies. He was previously a director of Talon Therapeutics, Inc., a biopharmaceutical oncology company, where he also served on the audit committee, and Sucampo Pharmaceuticals where he served on the compensation and
nominating and governance committees and Clavis Pharma ASA, a pharmaceutical company based in Oslo, Norway. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. Following a residency in internal medicine,
he completed a fellowship in medical oncology at the National Cancer Institute and held academic positions at the National Cancer Institute and New York University Medical Center.
Our board of directors believes that Dr. Spiegel’s extensive
medical experience in biopharmaceutical product development, deep understanding of pharmaceutical research and development, and broad expertise in gaining regulatory approval for drug candidates provide him with the qualifications and skills to
serve as a director.
Isaac Blech
Mr. Blech has served as Vice Chairman of our board of directors since
January 2013. Mr. Blech serves as a director of Cerecor, Inc. (Nasdaq: CERC), a CNS company, a director of ContraFect Corporation (Nasdaq: CFRX), an infectious disease company and a director of Adhera Therapeutics, Inc. (OTC: ATRX). Mr. Blech
also serves as Vice Chairman on a number of privately held life sciences companies. Mr. Blech earned a B.A. degree from Baruch College in 1975.
Our board of directors believes that Mr. Blech’s broad
experiences as a founder, director and investor in numerous biotechnology companies provide him with the qualifications and skills to serve as a director.
Rose Crane
Ms. Crane has served on the board of directors since September of 2017. She has served as President and Chief Executive Officer of
MELA Sciences, Inc. from 2013 to 2014. Ms. Crane was Head of Commercialization and a partner at Appletree Partners from 2011 to 2013. From 2008 to 2011, she served as President and Chief Executive Officer of Epocrates Inc. Ms. Crane served in
various senior and executive positions at Johnson & Johnson from 2002 to 2008, including as Group Chairman, OTC & Nutritional Group from 2006 to 2008, as Group Chairman Consumer, Specialty Pharmaceuticals and Nutritionals from 2004 to
2006, and as Executive Vice President of Global Marketing for the Pharmaceutical Group from 2002 to 2004. Prior to that, she held various positions at Bristol-Myers Squibb from 1982 to 2002, including as President of U.S. Primary Care from 2000
to 2002 and as President of Global Marketing and Consumer Products from 1998 to 2000. Ms. Crane has served on the Board of Directors of Catalent (NYSE: CTLT) since 2018 and currently as Vice Chairman of the Board of Zealand Pharma A/S (Nasdaq:
ZEAL) and a member of the Board of Directors of Teva Pharmaceuticals (NYSE: TEVA) since 2015. Ms. Crane received an M.B.A. from Kent State University and a B.A. in communications and English from the State University of New York.
Our board of directors believes that Ms. Crane’s senior
management experience in the pharmaceutical industry and service as a director on the boards of other public companies provide her with the qualifications and skills to serve as a director.
James Loughlin
Mr. Loughlin has served on our board of directors since November of 2011. Since 2007, he has served on the board of Celgene
Corporation (Nasdaq: CELG), where he is Chairman of the audit committee and a member of the compensation committee. Mr. Loughlin retired in 2003 after 40 years at KPMG LLP, a leading professional accounting and business consulting firm. As a
partner at KPMG, he served for five years as a member of the board as well as National Director of the Pharmaceuticals Practice and as Chairman of the pension and investment committee of the KPMG Board from 1995 through 2001. Mr. Loughlin is a
certified public accountant and received his B.S. degree in Accounting from St. Peter’s University in 1964.
Our board of directors believes Mr. Loughlin’s valuable
experiences as national director of the pharmaceuticals practice at KPMG LLP, an extensive background in accounting and financial reporting, and prior service on the board of directors of other publicly-held biopharmaceutical companies, provide
him with the qualifications and skills to serve as a director.
R. Loch Macdonald, M.D., Ph.D.
Dr. Macdonald, one of our co-founders, has served on our board of directors since inception, and served as our Chief Scientific
Officer from inception through May 15, 2018. Dr. Macdonald is a scientist, researcher and neurosurgeon and a recognized expert on brain hemorrhage, including Delayed Cerebral Ischemia (“DCI”). For the past 20 years, his research interest has focused on improving patient outcome after brain hemorrhage, with a specific focus on developing a cure
for cerebral vasospasm and DCI. From 2007 to 2015, he served as Keenan Endowed Chair, Head, Division of Neurosurgery at St. Michael’s Hospital. He is currently Professor of
Neurosurgery at the University of Toronto. Prior to St. Michael’s Hospital, he was Professor of Surgery and Radiation & Cellular Oncology at the University of Chicago
Medical Center. Dr. Macdonald holds an M.D. from the University of British Columbia and a Ph.D. in Experimental Surgery from the University of Alberta. He completed his Neurosurgery residency at the University of Toronto.
Our board of directors believes Dr. Macdonald’s experience in the
field of neurosurgery, as well as his expertise in the area of brain hemorrhage, provide him with the qualifications and skills to serve as a director.
Executive Officers
The following table sets forth certain information regarding our executive officers as of
December 31, 2018.
|
Name
|
Age
|
Position
|
||
|
Brian A. Leuthner
|
54
|
President, Chief Executive Officer and Director
|
||
|
Andrew Saik
|
49
|
Chief Financial Officer
|
||
|
W. Bradford Middlekauff
|
57
|
Senior Vice President, General Counsel and Secretary
|
Brian A. Leuthner
Mr. Leuthner serves as our President and Chief Executive Officer. Mr. Leuthner’s biographical information is set forth above under the
header “Board of Directors”
Andrew Saik
Mr. Saik has been our Chief Financial Officer since October 2017. Mr. Saik was Chief Financial Officer at Vertice Pharma, LLC From
August 2015 to July 2017. From August 2014 to April 2015 he was Chief Financial Officer at Auxilium Pharmaceuticals, Inc., where Mr. Saik led all financial and information technology activities and relationships and played a critical leadership
role in executing Auxilium’s diversification and growth strategy. From February 2013 to August 2014 Mr. Saik was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he was responsible for internal and external
reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. During his tenure at Endo, he helped complete the acquisition of Paladin Labs. Prior to Endo, Mr. Saik served in senior financial
management roles with increasing responsibility at Valeant Pharmaceuticals International from January 2001 to July 2012, including Senior Vice President, Finance. In this post, he served as the overall finance lead for the acquisition and
integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada. From October 1999 to January 2001 he was a finance manager at Nexgenix, Inc. and prior to that, from 1996 to 1999, he was a senior
financial analyst at Atlantic Richfield Corporation. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.
W. Bradford Middlekauff
Mr. Middlekauff has been our Senior Vice President, General Counsel and Secretary since October 2015. Mr. Middlekauff has over 20 years
of experience in the life science industry. Prior to joining Edge, Mr. Middlekauff served as Executive in Residence at Princeton University from October 2014 to October 2015. Prior to assuming his position at Princeton, Mr. Middlekauff was a
freelance consultant from August 2013 to October 2014. Previously, Mr. Middlekauff was Chief Legal Officer, General Counsel and Secretary at Kolltan Pharmaceuticals, Inc. from December 2008 to August 2013, where he also ran the business development
function; Senior Vice President, General Counsel and Secretary of Medarex, Inc. from March 2000 to November 2007; and Senior Vice President, Strategic Planning of Medarex, Inc. from November 2007 to April 2008. Mr. Middlekauff was an associate with
the law firm of Cooley Godward, LLP from September 1993 to June 1998, where he advised life science companies on a broad range of business and legal matters. Mr. Middlekauff has served as Chairman of the Biotechnology Industry Organization (BIO)
General Counsels’ Committee and Vice President of the Yale Law School Executive Committee and has spoken at numerous conferences on legal and business issues relating to
biotechnology. Mr. Middlekauff received a bachelor’s degree from Brown University and a law degree from Yale Law School.
Corporate Governance
Independence of the Board of Directors
As required under the Nasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as
“independent,” as affirmatively determined by the board of directors. The Edge Board consults with our counsel to ensure that the Edge Board’s determinations are consistent with relevant securities and other laws and regulations regarding the
definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in
effect from time to time.
The Edge Board has undertaken a review of the independence of our directors and has determined that all of our directors, except Mr.
Leuthner and Dr. Macdonald, are independent within the meaning of Section 5605(a)(2) of the Nasdaq Stock
Market listing rules. Mr. Leuthner is not an independent director under these rules because he is our President and Chief Executive Officer, and Dr. Macdonald is not an independent director under these rules because he was our Chief Scientific
Officer for part of 2018.
Board Leadership Structure
The Edge Board has appointed Dr. Barer as Chairman of the Edge Board and Mr. Blech as Vice Chairman of the Edge Board. The Chairman
has the authority, among other things, to preside over Edge Board meetings, to set meeting agendas and to perform all other duties delegated to him from time to time by the Board. We believe that separation of the positions of the Chairman and
Chief Executive Officer reinforces the independence of the Edge Board in its oversight of our business and affairs. In addition, we believe that having an independent Chairman creates an environment that is more conducive to objective evaluation
and oversight of management’s performance, increasing management accountability and improving the ability of the Edge Board to monitor whether management’s actions are in our best interests and the best interests of our stockholders. As a result,
we believe that having an independent Chairman can enhance the effectiveness of the Edge Board as a whole.
Role of the Edge Board in Risk Oversight
One of the Edge Board’s key functions is informed oversight of our risk management process. The Edge Board does not have a standing
risk management committee, but rather administers this oversight function directly through the Edge Board as a whole, as well as through various Edge Board standing committees that address risks inherent in their respective areas of oversight. In
particular, the Edge Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to review and discuss with
management and KPMG LLP, as appropriate, our guidelines and policies with respect to risk assessment and risk management, including our major financial risk exposures and the steps taken by management to monitor and control these exposures. Our
Nominating and Corporate Governance Committee is responsible for developing our corporate governance principles, and periodically reviews these principles and their application. Our Compensation Committee reviews our practices and policies of
employee compensation as they relate to risk management and risk-taking incentives, to determine whether such compensation policies and practices are reasonably likely to have a material adverse effect on us.
Meetings of the Board of Directors
The Board met ten times during 2018. Except as set forth below, all current directors attended at least 75% of the aggregate number of meetings of the Edge Board and of
the committees on which they served during 2018 or the portion thereof for which they were directors or committee members. In 2018, Dr. Barer attended 56% of the aggregate
number of meetings of the Board and committees on which he served during such year.
Information Regarding Committees of the Board of Directors
The Board has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The
following table provides membership information as of December 31, 2018 for each of these standing Board committees. From time to time, our Board and committees also take action by written consent without a meeting. Each of our Board committees
has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.
|
Name
|
Audit
|
Compensation
|
Nominating
and Corporate
Governance
|
|||
|
Sol Barer, Ph.D.
|
X
|
X*
|
||||
|
Isaac Blech
|
X
|
|||||
|
Rose Crane
|
X
|
|||||
|
James Loughlin
|
X*
|
|||||
|
Liam Ratcliffe, M.D., Ph.D.
|
X
|
|||||
|
Robert Spiegel, M.D.
|
X
|
X*
|
X
|
| * |
Committee Chairperson
|
Audit Committee
Our Audit Committee consists of Mr. Loughlin and Dr. Spiegel, each of whom satisfies the independence requirements under Nasdaq Global Select Market listing standards
and Rule 10A-3(b)(1) of the Exchange Act. The chairperson of our Audit Committee is Mr. Loughlin, whom the Edge Board has determined to be an “audit committee financial expert” within the meaning of SEC regulations. Each member of our Audit
Committee can read and understand fundamental financial statements in accordance with Audit Committee requirements. In arriving at this determination, the Edge Board has examined each Audit Committee member’s scope of experience and the nature of
their employment in the corporate finance sector. The Audit Committee held seven meetings in 2018.
The primary purpose of our Audit Committee is to assist the Edge Board in the oversight of the integrity of our accounting and
financial reporting process, the audits of our financial statements, and our compliance with legal and regulatory requirements. The functions of our Audit Committee include, among other things:
| ● |
hiring an independent registered public accounting firm to conduct the annual audit of our financial statements and monitoring its independence and performance;
|
| ● |
reviewing and approving the planned scope of the annual audit and the results of the annual audit;
|
| ● |
pre-approving all audit services and permissible non-audit services provided by our independent registered public accounting firm;
|
| ● |
reviewing the significant accounting and reporting principles to understand their impact on our financial statements;
|
| ● |
reviewing our internal financial, operating and accounting controls with management and our independent registered public accounting firm;
|
| ● |
reviewing with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements and our compliance with
legal and regulatory requirements;
|
| ● |
reviewing potential conflicts of interest under and violations of our Code of Conduct;
|
| ● |
establishing procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters and confidential submissions
by our employees of concerns regarding questionable accounting or auditing matters;
|
| ● |
reviewing and approving related-party transactions;
|
| ● |
primary responsibility for overseeing our risk management function; and
|
| ● |
reviewing and evaluating, at least annually, our Audit Committee’s charter.
|
With respect to reviewing and approving related-party transactions, our Audit Committee reviews related-party transactions for
potential conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to which we are or may be a party in which the amount involved exceeds $120,000, and in which any of our directors or
executive officers or any other related person had or will have a direct or indirect material interest, excluding, among other things, compensation arrangements with respect to employment and board membership. Our Audit Committee could approve a
related-party transaction if it determines that the transaction is in our best interests. Our directors are required to disclose to the committee or the full Edge Board any potential conflict of interest or personal interest in a transaction that
the Edge Board is considering. Our executive officers are required to disclose any potential conflict of interest or personal interest in a transaction to the Audit Committee. We also poll our directors and executive officers on an annual basis
with respect to related-party transactions and their service as an officer or director of other entities. Whenever possible, the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as
promptly as practical.
On June 20, 2018, we received notice from Nasdaq stating that we are not in compliance with the audit
committee requirements for continued listing on The Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5605(c)(2)(A), as a result of Mr. James Healy’s decision not to seek reelection to the Edge Board at Edge’s 2018 Annual Meeting
of Stockholders on June 19, 2018 and Mr. Kurt Conti’s resignation from the Edge Board on the same date. We have until June 19, 2019 to regain compliance with the Nasdaq Listing Rules; we intend to regain compliance with the audit committee
requirements within this time frame.
The Edge Board has adopted a charter for the Audit Committee that complies with SEC and Nasdaq Stock Market listing rules. The charter is available on our website at www.edgetherapeutics.com.
Compensation Committee
Our Compensation Committee currently consists of Drs. Ratcliffe, Barer and Spiegel, each of whom the Edge Board has determined to be
independent under the Nasdaq listing
standards, a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act, and an “outside director” as that term is defined in Section 162(m) of the Internal Revenue Code. The chairperson of our Compensation Committee is
Dr. Spiegel. The Compensation Committee held four meetings in 2018.
The primary purpose of our Compensation Committee is to assist the Edge Board in exercising its responsibilities relating to
compensation of our executive officers and employees and to administer our equity compensation and other benefit plans. In carrying out these responsibilities, this committee reviews all components of executive officer and employee compensation
for consistency with its compensation philosophy, as in effect from time to time. The functions of our Compensation Committee include, among other things:
| ● |
designing and implementing competitive compensation policies to attract and retain key personnel;
|
| ● |
reviewing and formulating policy and determining the compensation of our executive officers and employees;
|
| ● |
reviewing and recommending to the Edge Board the compensation of our directors;
|
| ● |
administering our equity incentive plans and granting equity awards to our employees and directors under these plans;
|
| ● |
if required from time to time, reviewing with management our disclosures under the caption “Compensation Discussion and Analysis” and recommending to the full board its
inclusion in our periodic reports to be filed with the SEC;
|
| ● |
if required from time to time, preparing the report of the Compensation Committee to be included in our annual proxy statement;
|
| ● |
engaging compensation consultants or other advisors it deems appropriate to assist with its duties; and
|
| ● |
reviewing and evaluating, at least annually, our Compensation Committee’s charter.
|
The Edge Board has adopted a charter for the Compensation Committee
that complies with SEC and Nasdaq Stock Market listing rules. The charter is available on our website at www.edgetherapeutics.com.
Nominating and Corporate Governance Committee
Our Nominating and Corporate Governance Committee consists of Dr. Barer, Mr. Blech, Ms. Crane and Dr. Spiegel, each of whom the Edge
Board has determined to be independent under the Nasdaq
listing standards. The chairperson of our Nominating and Corporate Governance Committee is Dr. Barer. The Nominating and Corporate Governance Committee held two meetings in 2018.
The primary purpose of our Nominating and Corporate Governance Committee is to assist the Edge Board in promoting our best interests
and the best interests of our stockholders through the implementation of sound corporate governance principles and practices. The functions of our Nominating and Corporate Governance Committee include, among other things:
| ● |
identifying, reviewing and evaluating candidates to serve on the Edge Board;
|
| ● |
determining the minimum qualifications for service on the Edge Board;
|
| ● |
developing and recommending to the Edge Board an annual self-evaluation process for the Edge Board and overseeing the annual self-evaluation process;
|
| ● |
developing, as appropriate, a set of corporate governance principles, and reviewing and recommending to the Edge Board any changes to such principles; and
|
| ● |
periodically reviewing and evaluating our Nominating and Corporate Governance Committee’s charter.
|
The Edge Board has adopted a charter for the Nominating and Corporate Governance Committee that complies with SEC and Nasdaq Stock Market listing rules. The charter is
available on our website at www.edgetherapeutics.com.
While the Nominating and Corporate Governance Committee does not have a formal diversity policy, the Nominating and Corporate
Governance Committee recommends candidates based upon many factors, including the diversity of their business or professional experience, the diversity of their background and their array of talents and perspectives. We believe that the
Nominating and Corporate Governance Committee’s existing nominations process is designed to identify the best possible nominees for the Board, regardless of the nominee’s gender, racial background, religion, or ethnicity. The Nominating and
Corporate Governance Committee identifies candidates through a variety of means, including recommendations from members of the Edge Board and suggestions from our management, including our executive officers. In addition, the Nominating and
Corporate Governance Committee considers candidates recommended by third parties, including stockholders. The Nominating and Corporate Governance Committee gives the same consideration to candidates recommended by stockholders as those candidates
recommended by members of the Edge Board. Nominees should have a reputation for integrity, honesty and adherence to high ethical standards, should have demonstrated business acumen, experience and ability to exercise sound judgments in matters
that relate to our current and long-term objectives, should be willing and able to contribute positively to our decision-making process, should have a commitment to understand Edge and our industry and to regularly attend and participate in
meetings of the Edge Board and its committees, should have the interest and ability to understand the sometimes conflicting interests of the various constituencies of Edge, which include stockholders, employees, customers, creditors and the
general public, and to act in the interests of all stockholders, should not have, nor appear to have, a conflict of interest that would impair the nominee’s ability to represent the interests of all our stockholders and to fulfill the
responsibilities of a director. Nominees shall not be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. The value of diversity on the Edge Board should
be considered.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our officers (as defined under
Section 16(a) of the Exchange Act), directors and persons who own greater than 10% of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Based on our records and other information, we
believe that each of our executive officers, directors and certain beneficial owners of Edge’s common stock complied with all Section 16(a) filing requirements applicable to them during 2018 on a timely basis.
Code of Conduct
We have adopted a Code of Conduct, applicable to
all of our employees, executive officers and directors. The Code of Conduct is available on our website at www.edgetherapeutics.com. The
Nominating and Corporate Governance Committee of the Edge Board is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers or directors. We expect that any amendments to
the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.
Summary Compensation Table
The following table sets forth information for the years ended December 31, 2017 and December 31, 2018 concerning compensation of (i)
our principal executive officer, (ii) our most highly compensated executive officers, other than our principal executive officer, who were serving as executive officers as of December 31, 2018 and (iii) up to two additional individuals for whom
disclosure would have been made available in this table but for the fact that the individual was not serving as an officer of Edge at December 31, 2018. We refer to these executives as our named executive officers.
|
Name and Principal Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Option
Awards (1)
($)
|
Restricted
Stock Units
($)
|
All Other
Compensation (2)
($)
|
Total
($)
|
|||||||||||||||||||||
|
Brian A. Leuthner
Chief Executive Officer
|
2018
2017
|
530,000
500,000
|
318,000
255,000
|
3,356,300
1,761,831
|
143,846
-
|
10,800
10,800
|
4,358,946
2,527,631
|
|||||||||||||||||||||
|
R. Loch Macdonald, M.D., Ph.D.
Chief Scientific Officer (3)
|
2018
2017
|
150,750
402,000
|
-
153,765
|
11,578
724,493
|
8,510
-
|
272,179
10,800
|
443,017
1,291,059
|
|||||||||||||||||||||
|
Herbert J. Faleck
Chief Medical Officer (4)
|
2018
2017
|
416,000
400,000
|
187,200
724,493
|
646,945
153,000
|
50,918
-
|
10,800
10,800
|
1,311,863
1,288,293
|
|||||||||||||||||||||
|
Andrew Saik
|
2018
|
370,000
|
166,500
|
660,490
|
70,632
|
-
|
1,267,622
|
|||||||||||||||||||||
|
Chief Financial Officer
|
2017
|
61,667
|
-
|
1,594,402
|
-
|
-
|
1,656,069
|
|||||||||||||||||||||
|
W. Bradford Middlekauff
|
2018
|
347,700
|
156,470
|
791,426
|
42,351
|
10,800
|
1,348,747
|
|||||||||||||||||||||
|
SVP, General Counsel and Secretary
|
2017
|
328,000
|
97,580
|
345,782
|
-
|
10,800
|
782,162
|
|||||||||||||||||||||
| (1) |
Amounts shown in this column do not reflect actual compensation received by the named executive officers. The amounts reflect the grant date fair value of stock option
awards and are calculated in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718- Stock Compensation, and assume no forfeiture rate derived in the calculation of the grant
date fair value of these awards. Assumptions used in calculating the value of these awards are included in Note 7, “Stock Options” in the notes to Edge’s financial statements included in this Annual Report. The executive will only
realize compensation to the extent the trading price of Edge’s common stock is greater than the exercise price of such stock options at the time such options are exercised.
|
| (2) |
Amounts shown in this column reflect Edge’s matching contributions to Edge’s 401(k) plan in the amount of $10,800 except that, due to Dr. Macdonald’s termination on May 15,
2018, Edge’s contributions to the 401(k) plan for Dr. Macdonald in 2018 were $6,110. For Dr. Macdonald, the amount shown in this column also includes the dollar value of severance benefits paid through December 31, 2018, which is
comprised of continuation of Dr. Macdonald’s base salary ($251,250) and reimbursements of amounts paid for health care continuation under COBRA for Dr. Macdonald and his eligible dependents ($14,819).
|
| (3) |
Dr. Macdonald ceased employment with Edge on May 15, 2018.
|
| (4) |
Dr. Faleck ceased employment with Edge on December 31, 2018.
|
Narrative to Summary Compensation Table
Employment Agreements
The Company has entered into employment agreements with each of the named executive officers.
Other than with respect to Dr. Macdonald, whose employment with Edge terminated on May 15, 2018, and Dr. Faleck, whose employment with
Edge terminated on December 31, 2018, the term of employment for each named executive officer under his employment agreement will continue until the executive’s employment with
us terminates for any reason. Each employment agreement sets forth the named executive officer’s annual base salary and target bonus opportunity, and the named executive officer’s right to participate in our health insurance program and other benefit programs provided to our executives generally. Under the terms of these agreements, the named executive
officers’ base salaries are subject to annual review and adjustment by the Board. The base salaries for 2017 and 2018 for each of our named executive officers are reflected in
the table above.
Each employment agreement also provides for additional payments and benefits to be made in connection with the named executive officer’s termination of employment, as described below. In addition, in connection with their employment, each named executive officer entered into our standard confidentiality and
invention assignment agreement, which sets forth duties of confidentiality and certain intellectual property rights between us and our employees. Each executive’s employment
agreement also provides that his equity and incentive compensation is subject to any clawback policy of our company in effect from time to time, or otherwise required by law or applicable stock exchange.
2017 and 2018 Annual Cash Incentive Compensation
Expressed as a percentage of base salary, the target bonus opportunity for Mr. Leuthner, Dr. Macdonald, Dr. Faleck and
Mr. Middlekauff in 2017 was 60%, 45%, 45% and 35%. The ultimate determinations of cash bonuses for the named executive officers are based on the achievement of corporate goals, provided that the Compensation Committee and, for Mr. Leuthner, the Board, retain discretion to award a higher or lower bonus than warranted based on the achievement of the corporate goals. These goals are reviewed and approved by the
Compensation Committee and the Edge Board at the beginning of each year. At or after the end of such year, the Compensation Committee determines the extent to which these corporate goals have been attained and, based on such determination, the
Compensation Committee thereafter approve the annual cash bonus to be awarded. For 2017, the corporate goal categories (and weighting) were as follows: financial goals (15%); clinical/ medical affairs goals (25%); regulatory goals (20%);
manufacturing goals (15%); research goals (12%); commercial goals (5%) and corporate goals (8%). After reviewing performance for 2017, the Compensation Committee determined that the performance goals were achieved at 85% of target. The bonus earned
by Mr. Leuthner, Dr. Macdonald, Dr. Faleck and Mr. Middlekauff for 2017 is listed in the “Nonequity Incentive Plan Compensation” column in the 2018 Summary Compensation Table above. Mr. Saik was not eligible for any bonus opportunity in 2017 following his hiring on October 31, 2017.
The named executive officers of Edge were not entitled to cash bonus compensation for 2018. However, the named
executive officers other than Dr. Macdonald entered into certain retention arrangements described below under the header “Retention Arrangements.”
Equity Incentive Compensation - Option Awards
On November 3, 2014, Edge shareholders approved the Amended and Restated Edge Therapeutics, Inc. 2014 Equity Incentive
Plan, or the Current Plan. The Current Plan is the primary program through which Edge grants equity-based incentive compensation to its employees and Edge’s directors. Under the
Current Plan, Edge may grant awards of restricted stock, options, stock appreciation rights, restricted stock units (“RSUs”) and other types of equity-based awards, in each case, with respect to Edge common stock. As of the date of this Annual
Report, Edge has only made grants of stock options under the Current Plan and grants of RSUs in connection with the Retention Arrangements described below.
Other than the stock options granted in connection with the Retention Arrangements (as described below), all of the
outstanding options granted to Edge’s named executive officers are subject to time-based vesting, such that options vest with respect to one-fourth of the underlying shares on
the first anniversary of the grant date and in equal installments of 1⁄48 of the underlying shares thereafter for the subsequent 36 months. Under the employment agreements of
Edge’s named executive officers, all equity awards will become 100% vested upon a change in control. However, during 2016, the Compensation Committee reviewed the practice of “single trigger” vesting under Edge’s
named executive officers’ employment agreements. In light of such review, the Compensation Committee decided to use a new form of option award for Edge’s executives that eliminates automatic vesting on a change in control, and instead uses “double trigger” vesting (i.e., vesting does not automatically occur upon a change in control). This new vesting provision was adopted after Edge made stock option grants to Edge’s named executive officers in 2016, so none of their 2016 stock options contain double trigger vesting. However, the stock options granted to Edge’s
named executive officers in March 2017 contain double trigger vesting in connection with a change in control, and the double trigger vesting feature supersedes the provisions in Edge’s
named executive officers’ employment agreements that specify single trigger vesting upon a change in control. While the Compensation Committee intends to use a “double trigger” vesting approach for new option awards granted to Edge’s named executive officers, it will continue to analyze each separate option award to determine whether double trigger vesting is appropriate. Further, where double trigger vesting is utilized, Edge intends that
the double trigger vesting feature will supersede any provision in Edge’s named executive officers’
employment agreements that specifies single trigger vesting with respect to future stock option awards. The stock option awards granted to Edge’s named executed officers under
the Current Plan during 2018, including their vesting terms, are set forth in the Outstanding Equity Awards at Year-End table below.
Outstanding Equity Awards at Year-End
The table below sets forth the number of securities underlying outstanding plan awards for each named executive officer as of December
31, 2018.
|
Name
|
Number of Securities
Underlying Unexercised
Options Exercisable
|
Number of Securities
Underlying Unexercised
Options Unexercisable
|
Option
Exercise Price
|
Grant Date
|
Expiration Date
|
Number of Restricted
Stock Award Shares that
have not Vested
|
Market Value of Restricted
Stock Award Shares that
have not Vested
|
||||||||||||||||
|
Brian A. Leuthner (1) (2)
|
186,390
|
-
|
$
|
2.04
|
10/11/2013
|
10/11/2023
|
-
|
-
|
|||||||||||||||
|
69,440
|
-
|
$
|
8.28
|
3/27/2014
|
3/27/2024
|
-
|
-
|
||||||||||||||||
|
504,350
|
21,928
|
$
|
6.36
|
3/11/2015
|
3/11/2025
|
-
|
-
|
||||||||||||||||
|
162,916
|
67,084
|
$
|
6.99
|
2/16/2016
|
2/16/2026
|
-
|
-
|
||||||||||||||||
|
122,615
|
144,885
|
$
|
8.86
|
3/13/2017
|
3/13/2027
|
-
|
-
|
||||||||||||||||
|
-
|
280,000
|
$
|
14.98
|
3/1/2018
|
3/1/2028
|
-
|
-
|
||||||||||||||||
|
-
|
338,068
|
$
|
1.10
|
6/19/2018 (3)
|
6/19/2022
|
-
|
-
|
||||||||||||||||
|
-
|
-
|
-
|
8/14/2018 (4)
|
NA
|
169,032
|
$
|
54,090
|
||||||||||||||||
|
R. Loch Macdonald, M.D., PhD. (1) (2)
|
75,505
|
-
|
$
|
2.04
|
10/11/2013
|
3/1/2027
|
-
|
-
|
|||||||||||||||
|
63,958
|
-
|
$
|
8.28
|
3/27/2014
|
3/27/2024
|
-
|
-
|
||||||||||||||||
|
109,642
|
7,309
|
$
|
6.36
|
3/11/2015
|
3/11/2025
|
-
|
-
|
||||||||||||||||
|
178,166
|
41,116
|
$
|
11.00
|
9/30/2015
|
9/30/2025
|
-
|
-
|
||||||||||||||||
|
60,202
|
24,798
|
$
|
6.99
|
2/16/2016
|
2/16/2026
|
-
|
-
|
||||||||||||||||
|
50,420
|
59,580
|
$
|
8.86
|
3/13/2017
|
3/13/2027
|
-
|
-
|
||||||||||||||||
|
-
|
20,000
|
$
|
1.10
|
6/19/2018 (3)
|
6/19/2022
|
-
|
-
|
||||||||||||||||
|
-
|
-
|
-
|
8/14/2018 (4)
|
NA
|
10,000
|
$
|
3,200
|
||||||||||||||||
|
Herbert J. Faleck (1) (2)
|
148,341
|
-
|
$
|
8.28
|
3/27/2014
|
3/27/2024
|
-
|
-
|
|||||||||||||||
|
116,951
|
-
|
$
|
6.36
|
3/11/2015
|
3/11/2016
|
-
|
-
|
||||||||||||||||
|
77,914
|
32,086
|
$
|
6.99
|
2/16/2016
|
2/16/2026
|
-
|
-
|
||||||||||||||||
|
17,182
|
7,818
|
$
|
7.24
|
3/1/2016
|
3/1/2026
|
-
|
-
|
||||||||||||||||
|
50,420
|
59,580
|
$
|
0.00
|
3/13/2017
|
3/13/2027
|
-
|
-
|
||||||||||||||||
|
-
|
50,000
|
$
|
10.10
|
1/2/2018
|
1/2/2028
|
-
|
-
|
||||||||||||||||
|
-
|
90,000
|
$
|
14.98
|
3/1/2018
|
3/1/2028
|
-
|
-
|
||||||||||||||||
|
-
|
119,667
|
$
|
1.10
|
6/19/2018 (3)
|
6/19/2022
|
-
|
-
|
||||||||||||||||
|
-
|
-
|
-
|
8/14/2018 (4)
|
NA
|
59,833
|
$
|
19,147
|
||||||||||||||||
|
Andrew Saik (1) (2)
|
58,336
|
141,664
|
$
|
10.73
|
11/1/2017
|
11/1/2027
|
-
|
-
|
|||||||||||||||
|
-
|
50,000
|
$
|
14.98
|
3/1/2018
|
3/1/2028
|
-
|
-
|
||||||||||||||||
|
-
|
166,001
|
$
|
1.10
|
6/19/2018 (3)
|
6/19/2022
|
-
|
-
|
||||||||||||||||
|
-
|
-
|
-
|
8/14/2018 (4)
|
NA
|
82,999
|
$
|
26,560
|
||||||||||||||||
|
W. Bradford Middlekauff (1) (2)
|
63,328
|
16,672
|
$
|
14.92
|
11/16/2015
|
11/16/2025
|
-
|
-
|
|||||||||||||||
|
24,788
|
10,212
|
$
|
6.99
|
2/16/2016
|
2/16/2026
|
-
|
-
|
||||||||||||||||
|
24,065
|
28,435
|
$
|
8.86
|
3/13/2017
|
3/13/2027
|
-
|
-
|
||||||||||||||||
|
-
|
65,000
|
$
|
14.98
|
3/1/2018
|
3/1/2028
|
-
|
-
|
||||||||||||||||
|
-
|
99,534
|
$
|
1.10
|
6/19/2018 (3)
|
6/19/2022
|
-
|
-
|
||||||||||||||||
|
-
|
-
|
-
|
8/14/2018 (4)
|
NA
|
49,766
|
$
|
15,925
|
||||||||||||||||
| (1) |
Except as otherwise noted, options vest with respect to one-fourth of the underlying shares on the first anniversary of the grant date and in equal installments of 1⁄48 of
the underlying shares on each monthly anniversary of the grant date thereafter for the subsequent 36 months.
|
| (2) |
Options granted after November 3, 2014 were granted under the Current Plan. Options granted prior to such date were granted under the Edge Therapeutics, Inc. 2012 Equity
Incentive Plan.
|
| (3) |
Represents stock options granted in connection with the Retention Arrangements. These options vest on the earliest to occur of (i) the termination of the executive’s
employment with Edge other than for cause (as defined in the Current Plan), (ii) the consummation of a strategic transaction arising out of the strategic review discussed above and (iii) the one-year anniversary of the grant date.
|
| (4) |
Represents RSUs granted in connection with the Retention Arrangements. These RSUs have the same vesting terms as those described in note (3) above relating to retention
stock options.
|
Potential Payments Upon a Termination or Change in Control
Under the terms of their respective employment agreements, Mr. Leuthner, Dr. Faleck, Mr. Saik and Mr. Middlekauff, our named executive
officers as of December 31, 2018, are entitled to certain payments and benefits in connection with the termination of their employment with us under specified circumstances. As disclosed above, Dr. Macdonald received certain payments and benefits
in connection with the termination of his employment on May 15, 2018.
Generally, the employment agreements for our named executive officers state that if a named executive officer resigns without good
reason, is terminated for cause or, with respect to all of the named executive officers other than Mr. Leuthner, is terminated due to death or disability, the executive is only entitled to receive salary and benefits that were accrued but remain
unpaid through the date of termination.
The employment agreements provide severance benefits to be paid to each named executive officer, subject to the effectiveness of a
general release of claims, if the named executive officer terminates his employment for good reason or if we terminate the named executive officer’s employment without cause. Mr.
Leuthner’s employment agreement entitles him to severance benefits upon a termination due to death or disability as if such termination was without cause. The continued provision
of severance benefits is conditioned on each executive’s compliance with his release and the terms of our confidentiality and invention and assignment agreement such that if an
executive does not comply with such agreements, severance payments to the executive will cease and previously paid severance benefits must be repaid. The terms “cause” and “good reason” have the meanings set
forth in each named executive officer’s employment agreement with us.
Under Mr. Leuthner’s employment agreement, upon a termination of
Mr. Leuthner’s employment by Mr. Leuthner for good reason or by us without cause, in either case, not in connection with a change in control, Mr. Leuthner is entitled to receive
18 months of continued base salary to be paid in accordance with our normal payroll practices, plus 18 months of COBRA premium reimbursements for Mr. Leuthner and his eligible dependents. Under the employment agreements of Drs. Macdonald and Faleck
and Messrs. Saik and Middlekauff, if the executive terminates his employment for good reason or we terminate the executive’s employment without cause, and such termination was
not in connection with a change in control, such executives are entitled to receive 12 months of continued base salary, to be paid in accordance with our normal payroll practices, plus 12 months of COBRA premium reimbursements for the executive and
his eligible dependents.
The employment agreements for our named executive officers provide enhanced severance payments upon certain employment terminations that
occur in connection with a change in control. Mr. Leuthner’s employment agreement provides that if Mr. Leuthner terminates his employment for good reason within 12 months
following a change in control or if we terminate Mr. Leuthner’s employment other than for cause (i) within the 60-day period prior to a change in control or (ii) within the
12-month period following a change in control, then Mr. Leuthner would be entitled to receive the same severance benefits as provided above, plus a payment equal to 1.5 times his target bonus opportunity and accelerated vesting of all unvested
equity awards that do not provide for double-trigger vesting(with performance-based awards, if any, to vest at not less than target).
The employment agreements for Dr. Faleck and Messrs. Saik, Middlekauff and Leuthner provide that if they terminate their employment for
good reason within 12 months following a change in control or if we terminate the executive’s employment other than for cause (i) within the 60-day period prior to a change in
control or (ii) within the 12-month period following a change in control, then, in each case, the executive would be entitled to receive the same severance benefits as if such termination was not in connection with a change in control. In addition,
each executive would be entitled to accelerated vesting of all unvested equity awards that do not provide for double-trigger vesting (with performance-based awards, if any, to vest at not less than target). In addition, Dr. Faleck’s employment agreement provides that if his employment terminates for any reason (other than for cause) after attaining age 55 and having completed five consecutive years of service
to Edge, Dr. Faleck’s unvested options, stock appreciation rights and restricted stock (if any) will remain outstanding and continue to vest, according to the terms of such
equity awards, for three years following such termination or, if earlier, until such award is 100% vested.
Each named executive officer’s employment agreement also provides
for full vesting of all outstanding and unvested equity awards upon a change in control (with performance-based awards, if any, to vest at not less than target). However, as described above, our Compensation Committee has decided to utilize a “double trigger” vesting approach for option grants made to our named executive officers in March 2017 and
during the period from March 2017 to the present, and intends to use this approach for future grants (though it reserves the right to use a single trigger approach for any future equity awards). The stock option grants made to our named executive
officers in March 2017 and during the period from March 2017 to the present provide for accelerated vesting in connection with a change in control only if the named executive officer’s
employment is terminated due to his death or disability, by us without cause or by the executive for good reason, in each case, within 12 months immediately following the change in control, and the double trigger vesting feature in these option
grants supersedes any provision in the named executive officer’s employment agreement specifying single trigger vesting.
The following table sets forth potential payments payable to our named executive officers upon a termination of employment without cause
or resignation for good reason and a termination of employment without cause or resignation for good reason in connection with a change in control. The table below reflects amounts payable to our named executive officers assuming their employment
was terminated on December 31, 2018 and, if applicable, a change in control also occurred on such date:
|
Upon Termination Without Cause or Resignation for
|
||||||||||||||||
|
Good Reason—No Change in Control
|
||||||||||||||||
|
Cash
Payment ($)
|
Accelerated
Equity Vesting
|
Other ($) (1)
|
Total ($)
|
|||||||||||||
|
Brian A. Leuthner
|
|
795,000
|
|
-
|
38,105
|
|
833,105
|
|||||||||
|
Herbert J. Faleck, D.O. (2)
|
416,000
|
-
|
25,403
|
441,403
|
||||||||||||
|
Andrew Saik
|
370,000
|
-
|
25,403
|
395,403
|
||||||||||||
|
W. Bradford Middlekauff
|
347,700
|
-
|
25,403
|
373,103
|
||||||||||||
| (1) |
Reflects the value of COBRA premium reimbursements for the named executive officer and his eligible dependents.
|
| (2) |
Mr. Faleck became entitled to these payments upon the termination of his employment on December 31, 2018.
|
|
Upon Termination Without Cause or Resignation for
|
||||||||||||||||
|
Good Reason—With Change in Control
|
||||||||||||||||
|
Cash
Payment ($)
|
Accelerated
Equity Vesting ($) (1)
|
Other ($) (2)
|
Total ($)
|
|||||||||||||
|
Brian A.Leuthner
|
|
1,510,500
|
|
4,041,238
|
|
38,105
|
|
5,589,843
|
||||||||
|
Herbert J. Faleck, D.O.
|
416,000
|
1,770,053
|
25,403
|
2,211,456
|
||||||||||||
|
Andrew Saik
|
370,000
|
1,662,394
|
25,403
|
2,057,797
|
||||||||||||
|
W. Bradford Middlekauff
|
347,700
|
1,036,037
|
25,403
|
1,409,140
|
||||||||||||
| (1) |
Assumes all outstanding options vest upon termination.
|
| (2) |
Reflects the value of COBRA premium reimbursements for the named executive officer and his eligible dependents.
|
The following table sets forth potential payments payable to our named executive officers upon a change in control, regardless of
whether a termination of employment occurs. For purposes of this table, the change in control is assumed to occur on December 31, 2018.
|
Upon A Change in Control—No Termination of Employment
|
||||||||||||||||
|
Cash
Payment ($)
|
Accelerated
Equity Vesting ($) (1)
|
Other ($)
|
Total ($)
|
|||||||||||||
|
Brian A. Leuthner
|
|
-
|
1,361,534
|
|
-
|
|
1,361,534
|
|||||||||
|
Herbert J. Faleck, D.O.
|
-
|
1,072,108
|
-
|
1,072,108
|
||||||||||||
|
Andrew Saik
|
-
|
1,126,718
|
-
|
1,126,718
|
||||||||||||
|
W. Bradford Middlekauff
|
-
|
402,694
|
-
|
402,694
|
||||||||||||
| (1) |
Options granted in 2018 are not included in this column because such options have “double trigger” vesting.
|
On May 15, 2018, Edge terminated Dr. R. Loch Macdonald’s employment without cause outside the context of a change in control.
On December 31, 2018, Edge terminated Dr. Faleck’s employment without cause outside the context of a change in control.
Pursuant to a letter agreement dated February 3, 2019, Edge, PDS and Mr. Brian A. Leuthner agreed that, effective upon the close of the merger with PDS, Mr. Leuthner will resign as President and
Chief Executive Officer and such termination will be deemed to be a resignation for good reason in connection with a change in control. Concurrently, Mr. Leuthner will resign from the Edge Board.
Director Compensation
The Edge Board has adopted a formal non-employee director compensation plan.
Commencing October 1, 2017 and running through June 30, 2018, each non-employee director received a cash retainer covering such period in the
amount of $26,250 ($35,000 on an annualized basis), payable in three equal quarterly installments in arrears on the last day of the fiscal quarter in which such service occurred. Additional cash retainers were paid on the same schedule to (i)
the chair of the Edge Board in the amount of $22,500 ($30,000 annualized), (ii) the chair of the Audit Committee in the amount of $11,250 ($15,000 annualized), (iii) the chair of the Compensation Committee in the amount of $9,000 ($12,000
annualized), (iv) the chair of the Nominating and Corporate Governance Committee in the amount of $6,000 ($8,000 annualized), (v) each other member of the Audit Committee in the amount of $6,000 ($8,000 annualized), (vi) each other member of
the Compensation Committee in the amount of $5,250 ($7,000 annualized) and (vii) each other member of the Nominating and Corporate Governance Committee in the amount of $3,000 ($4,000 annualized).
Commencing July 1, 2018, each non-employee director receives an annual cash retainer in the amount of $40,000, payable in equal, quarterly
installments in arrears on the last day of the fiscal quarter in which such service occurred. The additional annual cash retainers that we provide are paid on the same schedule to (i) the chair of the Edge Board in the amount of $30,000,
(ii) the chair of the Audit Committee in the amount of $18,500, (iii) the chair of the Compensation Committee in the amount of $15,000, (iv) the chair of the Nominating and Corporate Governance Committee in the amount of $8,000, (v) each
other member of the Audit Committee in the amount of $8,000, (vi) each other member of the Compensation Committee in the amount of $7,000, and (vii) each other member of the Nominating and Corporate Governance Committee in the amount of
$4,500.
In addition to the payment of annual cash retainers, the plan provides for grants of options to
purchase shares of our common stock to non-employee directors pursuant to the terms and conditions of our Current Plan. Each non-employee new director will be granted an option covering 30,000 shares of our common stock on the date of his or
her initial election to the Edge Board. These options will vest 1⁄3 on the one year anniversary of the grant date, 1⁄3 on the two year anniversary of the grant date and 1⁄3 on the three year anniversary of the grant date, in all cases subject
to the non-employee director’s continuing service on the Edge Board. Each continuing non-employee director, other than the Chairman of the Edge Board, will be granted an option covering 15,000 shares of our common stock on the date of the
Annual Meeting. These options will vest fully on the one year anniversary of the grant date, subject to the non-employee director’s continuing service on the Edge Board. The Chairman of the Edge Board will be granted an option covering 30,000
shares of our common stock on the date of the Annual Meeting. These options will vest fully on the one year anniversary of the grant date, subject to the Chairman of the Edge Board’s continuing service on the Edge Board.
The table below summarizes the compensation paid by Edge to each non-employee director for the year
ended December 31, 2018.
|
Name
|
Fees Earned
or Paid in Cash
($)
|
Option
Awards
($) (1)
|
Total
($)
|
|||||||||
|
Sol Barer, Ph.D.
|
92,500
|
40,175
|
132,675
|
|||||||||
|
Isaac Blech
|
41,750
|
20,088
|
61,838
|
|||||||||
|
Kurt Conti (2)
|
21,500
|
-
|
21,500
|
|||||||||
|
Rose Crane
|
51,750
|
20,088
|
71,838
|
|||||||||
|
James I. Healy, M.D., Ph.D. (3)
|
21,500
|
-
|
21,500
|
|||||||||
|
James Loughlin
|
54,250
|
20,088
|
74,338
|
|||||||||
|
Liam Ratcliffe, M.D., Ph.D.
|
44,500
|
20,088
|
64,588
|
|||||||||
|
Robert Spiegel, M.D.
|
69,250
|
20,088
|
89,338
|
|||||||||
_____________________________
|
(1)
|
The amounts shown in this column do not reflect actual compensation received by our directors. The amounts reflect
the grant date fair value of option awards and are calculated in accordance with the provisions of FASB Accounting Standards Codification Topic 718 Compensation — Stock Options (“ASC Topic 718”), and assume no forfeiture rate
derived in the calculation of the grant date fair value of these awards. Assumptions used in calculating the value of these awards are included in Note 7, “Stock Options” in the notes to Edge’s financial statements included in
this Annual Report. The director will only realize compensation to the extent the trading price of Edge’s common stock is greater than the exercise price of such stock options at the time such options are exercised.
|
|
(2)
|
Mr. Conti resigned from the Edge Board on June 19, 2018.
|
|
(3)
|
Mr. Healy ceased to serve on the Edge Board following the 2018 annual meeting of the stockholders held on June 19,
2018.
|
The aggregate number of options held by our non-employee directors on December 31, 2018 was as
follows:
|
Name
|
Number of Options
|
|||
|
Sol Barer, Ph.D.
|
720,836
|
|||
|
Isaac Blech
|
828,950
|
|||
|
Rose Crane
|
60,000
|
|||
|
James Loughlin
|
119,939
|
|||
|
Liam Ratcliffe, M.D., Ph.D.
|
75,000
|
|||
|
Robert Spiegel, M.D.
|
120,668
|
|||
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table sets forth information with respect to the beneficial ownership of Edge common stock as of
December 31, 2018, by:
| ● |
each person, entity or group known to Edge to beneficially own more than 5% of its common stock;
|
| ● |
each of Edge’s named executive officers;
|
| ● |
each of Edge’s directors; and
|
| ● |
all of Edge’s executive officers and directors as a group.
|
The percentage of shares beneficially owned is based on 31,449,989 shares of Edge common stock outstanding as of
December 31, 2018. Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security,
including options that are exercisable within 60 days of December 31, 2018. Shares of Edge common stock issuable pursuant to stock options and restricted stock units, or RSUs, are deemed outstanding for computing the percentage of the person
holding such options and the percentage of any group of which the person is a member but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, Edge believes, based on the
information furnished to it, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable. The
information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section 13(d) and 13(g) of the Securities Act. The information set forth below is based upon information supplied by officers, directors
and principal stockholders and Schedules 13D and 13G, if any, filed with the SEC, which information may not be accurate as of December 31, 2018.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Edge Therapeutics,
Inc., 300 Connell Drive, Suite 4000, Berkeley Heights, New Jersey 07922.
|
Beneficial Ownership
|
||||||||
|
Name of Beneficial Owner
|
Shares
|
%
|
||||||
|
Greater than 5% Stockholders:
|
||||||||
|
Sofinnova Venture Partners IX, L.P.(1)
|
2,852,711
|
9.07
|
||||||
|
Entities affiliated with New Leaf Ventures III, L.P.(2)
|
2,379,668
|
7.57
|
||||||
|
Named Executive Officers and
Directors:
|
||||||||
|
Sol Barer, Ph.D.(3)
|
1,318,911
|
4.19
|
||||||
|
Isaac Blech(4)
|
798,950
|
2.54
|
||||||
|
Brian Leuthner(5)
|
1,622,719
|
5.16
|
||||||
|
Rosemary Crane(6)
|
9,900
|
0.03
|
||||||
|
James Loughlin(7)
|
115,564
|
0.37
|
||||||
|
R. Loch Macdonald, M.D., Ph.D.(8)
|
1,165,194
|
3.70
|
||||||
|
Liam Ratcliffe, M.D., Ph.D.(2)
|
2,379,668
|
7.57
|
||||||
|
Robert Spiegel, M.D., FACP(9)
|
129,329
|
0.41
|
||||||
|
W. Bradford Middlekauff(10)
|
145,406
|
0.46
|
||||||
|
Andrew Saik(11)
|
79,172
|
0.25
|
||||||
|
All current executive officers and directors as a group 10 persons)
|
7,764,816
|
24.69
|
||||||
| * |
all of Edge’s executive officers and directors as a group.
|
| (1) |
Represents shares held directly by Sofinnova Venture Partners IX, L.P., or SVP IX. Dr. James Healy, a former director of Edge together with Dr. Michael F. Powell and Dr.
Anand Mehra, are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Dr. Healy disclaims beneficial
ownership. The mailing address of SVP IX is c/o Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg. 4, Suite 250, Menlo Park, CA 94025.
|
| (2) |
New Leaf Venture Associates III, L.P., or NLVA-III LP, is the general partner of NLV-III and New Leaf BPO Associates I, L.P., or BPOA-I LP, is the general partner of New
Leaf Biopharma Opportunities I, L.P., or BPO-I. New Leaf Venture Management III, L.L.C., or NLVM-III LLC, is the General Partner of both NLVA-III LP and BPOA-I LP. Ronald M. Hunt, Vijay K. Lathi, and Liam Ratcliffe are individual
members of NLVM-III LLC, or collectively, the Individual Members. NLVA-III LP, BPOA-I LP and NLVM-III LLC disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. As one of three individual
members, each of the Individual Members disclaims beneficial ownership over the shares, and in all events disclaims pecuniary interest except to the extent of his economic interest. The mailing address of the beneficial owner is Times
Square Tower, 7 Times Square, Suite 3502, New York, NY 10036.
|
| (3) |
Includes 658,075 shares owned of record by Meryl Barer, Dr. Barer’s wife, all of which she may be deemed to have beneficial ownership of, and 660,836 shares for Dr. Barer
subject to stock options that are currently exercisable within 60 days of December 31, 2018.
|
| (4) |
Represents shares that are subject to outstanding options held by Mr. Blech that are currently exercisable with 60 days of December 31, 2018.
|
| (5) |
Includes 162,000 shares owned of record by Cristina Leuthner, Mr. Leuthner’s wife, 78,730 shares held directly by Mr. Leuthner and 223,622 shares held in trust for the
Leuthner children, to which Mr. Leuthner disclaims beneficial ownership, and 1,158,367 shares subject to outstanding options held by Mr. Leuthner that are currently exercisable with 60 days of December 31, 2018.
|
| (6) |
Represents shares that are subject to outstanding options held by Ms. Crane that are currently exercisable within 60 days of December 31, 2018.
|
| (7) |
Includes 25,625 shares held directly by Mr. Loughlin and 89,939 shares subject to outstanding options held by Mr. Loughlin that are exercisable within 60 days of December
31, 2018.
|
| (8) |
Includes 577,730 shares held directly by Dr. Macdonald and 587,464 shares subject to outstanding options held by Dr. Macdonald that are currently exercisable with 60 days
of December 31, 2018.
|
| (9) |
Includes 38,661 shares held directly by Dr. Spiegel and 90,668 shares subject to outstanding options held by Dr. Spiegel that are exercisable within 60 days of December 31,
2018.
|
| (10) |
Includes 10,000 shares held directly by Mr. Middlekauff and 135,409 shares subject to outstanding options held by Mr. Middlekauff that are exercisable within 60 days of
December 31, 2018.
|
| (11) |
Represents shares that are subject to outstanding options held by Mr. Saik that are currently exercisable within 60 days of December 31, 2018.
|
The following summary is a summary of transactions since January 1, 2017 and all currently proposed transaction, to which either Edge
has been a participant, in which:
| ● |
The amounts exceeded or will exceed $120,000; and
|
| ● |
Any of the directors, executive officers or holders of more than 5% of the respective capital stock, or any member of the immediate family of any of the foregoing persons,
had or will have a direct or indirect material financial interest.
|
Indemnification Agreements
On April 24, 2017, Edge entered into an indemnification agreement with Alyssa Wyant, Edge’s then-Senior Vice President of Regulatory Affairs.
On September 18, 2017, Edge entered into an indemnification agreement with Rose Crane in connection with her service
on the Edge Board.
On October 31, 2017, Edge entered into an indemnification agreement with Andrew Saik, Edge’s Chief Financial Officer.
Pursuant to these agreements, Edge has agreed to indemnify Ms. Wyant, Ms. Crane and Mr. Saik against any and all
expenses incurred by them resulting from their status as one of Edge’s executive officers or directors, as applicable, to the fullest extent permitted by Delaware law, Edge’s certificate of incorporation and Edge’s bylaws, except in limited circumstances. In addition, these
indemnification agreement provide that, to the fullest extent permitted by Delaware law, Edge will pay for all expenses incurred by Ms. Wyant, Ms. Crane and Mr. Saik in connection with a legal proceeding arising out of their service to Edge.
Similarly, prior to January 1, 2017, each of Edge’s directors and other officers entered into indemnification agreements on similar terms.
Employment Agreements
As discussed above, Edge has entered into employment agreements with each of its named executive officers.
In addition, on February 21, 2017, Edge entered into an at-will employment agreement with Ms. Wyant. Under her
agreement, Ms. Wyant received an annual base salary of $300,000, which may be increased, decreased or stay the same, depending on Ms. Wyant’s performance and the performance of
Edge. Under her employment agreement, Ms. Wyant was eligible to earn an annual discretionary performance-based bonus, with a target bonus opportunity equal to 35% of the base salary, as determined by the Edge Board or the Compensation Committee;
provided that Ms. Wyant remained employed with Edge on the last day of the relevant performance period. During her employment, Ms. Wyant was eligible to be granted equity awards by Edge, as may be determined by the Edge Board or the Compensation
Committee. The employment agreement could be terminated by Edge with or without cause, on the one hand, or by Ms. Wyant with or without good reason or upon her death or termination by reason of a disability, on the other hand. Under her employment
agreement, Ms. Wyant was also entitled to participate in the employee benefit plans, policies, practices and arrangements and was eligible for the same number of holidays and vacation days, in each case as are generally allowed to other similarly
situated executives of Edge. Edge and Ms. Wyant are parties to a separation agreement pursuant to which (i) Ms. Wyant received a cash payment in the amount of $125,400 on the first payroll date after February 1, 2019 and (ii) all of Ms. Wyant’s stock options and Edge RSUs, in each case, (99,534 stock options granted on June 14, 2018 and 49,766 Edge RSUs granted on August 14, 2018) became fully vested upon the
effectiveness of the release of claims in her separation agreement. All such stock options will remain exercisable for a period of three years following her termination date (which was December 14, 2018).
Retention Arrangements
On April 27, 2018, and June 19, 2018, in connection with the previous announcement by Edge of the determination by the Edge Board to
review strategic alternatives and to streamline its operations, the Compensation Committee approved certain retention compensation, which consists of grants to the executive officers named below of Edge of certain stock options and RSUs under the
Current Plan and cash compensation. Options, RSUs and cash compensation were granted to the named executive officers in the following amounts:
|
Recipient
|
Title
|
Stock Options with a
Grant Date of
June 19, 2018
|
RSUs with a
Grant Date of
August 14, 2018
|
Cash
Compensation
|
||||||||||
|
Brian A. Leuthner
|
President and Chief Executive Officer
|
338,068
|
169,032
|
$
|
318,000
|
|||||||||
|
Herbert J. Faleck
|
Former Chief Medical Officer
|
119,667
|
59,833
|
$
|
187,200
|
|||||||||
|
Andrew Saik
|
Chief Financial Officer
|
166,001
|
82,999
|
$
|
166,500
|
|||||||||
|
W. Bradford Middlekauff
|
Senior Vice President, General Counsel and Secretary
|
99,534
|
49,766
|
$
|
157,470
|
|||||||||
The stock options in the table above have an exercise price equal to the closing price of Edge common stock on the
applicable grant date.
All options and RSUs reflected in the table above shall vest upon the earliest to occur, for any executive officers,
of (i) the termination, other than for cause (as such term is defined in the Current Plan), of such executive officer by Edge, (ii) the consummation of a strategic transaction arising out of the strategic review referred to above and (iii) the
one-year anniversary of the grant date. The exercise period for the options shall commence on the vesting date and continue until the three-year anniversary of the vesting date.
All of the cash compensation set forth above was paid on February 1, 2019.
Edge Related-Party Transactions Policy
Edge’s audit committee is charged with the responsibility of
reviewing and approving all related person transactions (as defined in SEC regulations), and periodically reassessing any related person transaction entered into by Edge to ensure continued appropriateness. Under SEC rules, related-party
transactions are those transactions to which Edge is or may be a party in which the amount involved exceeds $120,000, and in which any of Edge’s directors or executive officers
or any other related person had or will have a direct or indirect material interest, excluding, among other things, compensation arrangements with respect to employment and board membership. Edge’s audit committee could approve a related-party transaction if it determines that the transaction is in Edge’s best interests. In addition, Edge’s audit committee will review these transactions under Edge’s Code of Conduct, which governs conflicts of
interests, among other matters, and is applicable to Edge employees, officers and directors. Edge’s directors are required to disclose to the Edge audit committee or the Edge
Board any potential conflict of interest or personal interest in a transaction that the Edge Board is considering. Edge’s executive officers are required to disclose any
potential conflict of interest or personal interest in a transaction to Edge’s audit committee. Edge also polls its directors and executive officers on an annual basis with
respect to related-party transactions and their service as an officer or director of other entities. Any director involved in a related-party transaction that is being reviewed or approved must recuse himself or herself from participation in any
related deliberation or decision. Whenever possible, the transaction is approved in advance and if not approved in advance, must be submitted for ratification as promptly as practical.
Principal Accountant Fees and Services
The following table represents aggregate fees billed to us for the fiscal years ended December 31, 2018 and 2017 by KPMG LLP, our
independent registered public accounting firm.
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Audit fees
|
$
|
398,000
|
$
|
398,000
|
||||
|
Audit-related fees
|
58,450
|
15,000
|
||||||
| Tax fees |
–
|
97,650 |
||||||
| All Other Fees |
–
|
–
|
||||||
|
Total
|
$
|
456,450
|
$
|
510,650
|
||||
Audit fees: Audit fees consist of fees
associated with the annual audit of our financial statements, the reviews of our interim financial statements, and all services that are normally provided by the accounting firm in connection with statutory and regulatory filings or engagements.
Audit-related fees: Audit-related fees
consist of fees incurred in connection with the issuance of consent and comfort letters in connection with registration statement filings with the SEC.
Tax fees: Tax fees consist of fees for tax
services, including tax compliance, and related expenses.
All KPMG LLP services and fees in the fiscal years ended December 31, 2018 and December 31, 2017 were pre-approved by the Audit
Committee or its properly delegated authority.
Pre-approval Policies and Procedures
The Audit Committee pre-approves audit and non-audit services rendered by our independent registered public accounting firm, KPMG
LLP. The Audit Committee pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee’s approval of
the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit
Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.
If KPMG LLP renders services other than audit services to us, the Audit Committee will determine whether the rendering of these services
is compatible with maintaining KPMG LLP’s independence.
PART IV
| (a) |
The following documents are filed as part of this report:
|
(1) Financial Statements:
Report of Independent Registered Public Accounting Firm
Balance Sheets
Statements of Operations and Comprehensive Loss
Statements of Convertible Preferred Stock and Changes in Stockholders’ Equity (Deficit)
Statements of Cash Flows
Notes to Consolidated Financial Statements
(2) Financial Statement Schedules:
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial
statements or the notes thereto.
(3) Exhibits. The exhibits filed as part of this Annual Report are set forth on the Exhibit Index immediately following our consolidated
financial statements. The Exhibit Index is incorporated herein by reference.
None.
|
Exhibit
Number
|
Exhibit Description
|
|
|
2.1
|
Agreement and Plan of Merger and Reorganization, dated November 23, 2018, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS
Biotechnology Corporation (filed as exhibit 2.1 to the Company’s Current Report on Form 8-K filed on November 26, 2018, and incorporated by reference
herein).
|
|
|
2.2
|
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated January 24, 2019, by and among Edge Therapeutics, Inc., Echos
Merger Sub, Inc. and PDS Biotechnology Corporation (filed as exhibit 2.1 to the
Company’s Current Report on Form 8-K filed on January 30, 2019, and incorporated by reference herein).
|
|
|
2.3
|
Form of Support Agreement by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of PDS
Biotechnology Corporation’s directors, officers and stockholders (filed as exhibit 2.2 to the Company’s Current Report on Form 8-K filed on November 26,
2018, and incorporated by reference herein).
|
|
|
2.4
|
Form of Support Agreement by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of Edge
Therapeutics, Inc.’s directors, officers and stockholders (filed as exhibit 2.3 to the Company’s Current Report on Form 8-K filed on November 26, 2018, and
incorporated by reference herein).
|
|
|
3.1
|
Eighth Amended and Restated Certificate of Incorporation of Edge Therapeutics, Inc. (filed as exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 6, 2015, and incorporated by reference herein).
|
|
|
3.2
|
Second Amended and Restated Bylaws of Edge Therapeutics, Inc. (filed as exhibit 3.2 to the Company’s Current Report on Form 8-K filed on October 6, 2015, and incorporated by reference herein).
|
|
|
4.1
|
Form of Certificate of Common Stock. (filed as exhibit 4.1 to the Company’s Pre-Effective Amendment No. 1 to the registration statement on Form
S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
4.2
|
Warrant to Purchase 16,667 Shares of Capital Stock Issued to New Jersey Economic Development Authority, dated as of May 3, 2010. (filed as
exhibit 4.2 to the Company’s Registration Statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
4.3
|
First Amendment to Warrant Issued to New Jersey Economic Development Authority, dated October 9, 2013 (filed as exhibit 4.3 to the Company’s
Registration Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.4
|
Form of Warrant Issued to Series B-1 Stockholders. (filed as exhibit 4.4 to the Company’s Registration Statement on Form S-1 (File No. 333-
206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.5
|
Form of Warrant to Purchase Series C Preferred Stock issued to Maxim Group LLC. (filed as exhibit 4.5 to the Company’s Registration Statement on
Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.6
|
Warrant Agreement, dated as of August 28, 2014, by and between the Company and Hercules. (filed as exhibit 4.6 to the Company’s Registration
Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.7
|
Form of Warrant to Purchase Series C-1 Preferred Stock issued to Maxim Group LLC. (filed as exhibit 4.7 to the Company’s Registration Statement
on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.8
|
Investors’ Rights Agreement, dated as of April 6, 2015, by and among the Company and the Investors named therein. (filed as exhibit 4.8 to the
Company’s Registration Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
4.9
|
Warrant to Purchase 18,000 Shares of Common Stock issued to Maxim Partners LLC, dated as of October 6, 2015. (filed as exhibit 4.1 to the Company’s
Quarterly Report on Form 10-Q filed on November 6, 2015, and incorporated by reference herein).
|
|
10.1 *
|
Licensing Agreement by and between the Company and Evonik Industries (as successor in interest to SurModics Pharmaceuticals, Inc.), dated as of October 20, 2010. (filed as exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
10.2 *
|
Amendment No. 1 to the License Agreement, effective as of September 21, 2015, by and between the Company and Evonik Corporation. (filed as
exhibit 10.15 to the Company’s Pre-Effective Amendment No. 1 to the registration statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
10.3 **
|
Amended and Restated Master Formulation Development Agreement, by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017 (filed as
exhibit 10.1 to the Company’s Form 10-Q for the quarter ended June 30, 2017 and incorporated by reference herein).
|
|
|
10.4 **
|
Manufacturing and Supply Agreement, by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017 (filed as Exhibit 10.2 to the
Company’s Form 10-Q for the quarter ended June 30, 2017 and incorporated by reference herein).
|
|
|
10.5**+
|
Edge Therapeutics, Inc. 2010 Equity Incentive Plan and forms of agreement thereunder. (filed as exhibit 10.2 to the Company’s Pre-Effective
Amendment No. 1 to the registration statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
10.6+
|
Amendment to the Edge Therapeutics, Inc. 2010 Equity Incentive Plan, dated June 30, 2014 (filed as exhibit 10.11 to the Company’s Registration
Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
10.7+
|
Edge Therapeutics, Inc. 2012 Equity Incentive Plan and forms of agreement thereunder. (filed as exhibit 10.3 to the Company’s Pre-Effective
Amendment No. 1 to the registration statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
10.8+
|
Edge Therapeutics, Inc. 2014 Equity Incentive Plan and forms of agreement thereunder. (filed as exhibit 10.4 to the Company’s Pre-Effective
Amendment No. 1 to the registration statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
10.9+
|
Second Amended and Restated Employment Agreement by and between Brian A. Leuthner and the Company dated as of June 10, 2015. (filed as exhibit
10.5 to the Company’s Registration Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
10.10+
|
Second Amended and Restated Employment Agreement by and between Albert N. Marchio, II and the Company dated as of June 8, 2015 (filed as exhibit
10.8 to the Company’s Registration Statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
10.11+
|
Amended and Restated Employment Agreement by and between Herbert J. Faleck and the Company dated as of August 11, 2015 (filed as exhibit 10.13
to the Company’s registration statement on Form S-1 (File No. 333- 206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
10.12+
|
Second Amended and Restated Employment Agreement by and between Dr. R. Loch Macdonald and the Company dated September 21, 2015 (filed as exhibit
10.14 to the Company’s Pre-Effective Amendment No. 1 to the registration statement on Form S-1 (File No. 333- 206416) filed on September 21, 2015, and incorporated by reference herein).
|
|
|
10.13+
|
Executive Employment Agreement by and between W. Bradford Middlekauff and the Company dated as of October 30, 2015 (filed as exhibit 10.1 to the
Company’s Current Report on Form 8-K filed on November 5, 2015, and incorporated by reference herein).
|
|
|
10.14+
|
Employment Agreement by and between Daniel Brennan and the Company, dated as of October 17, 2016 (filed as exhibit 10.1 to the Company’s Current Report on
Form 8-K filed on October 18, 2016, and incorporated by reference herein).
|
|
|
10.15+
|
Executive Employment Agreement by and between Andrew Saik and the Company dated as of October 31, 2017 (filed as exhibit 10.1 to the Company’s
Current Report on Form 8-K filed November 1, 2017, and incorporated by reference herein).
|
|
|
10.15
|
Form of Indemnification Agreement for officers and directors (filed as exhibit 10.9 to the Company’s Registration Statement on Form S-1 (File
No. 333-206416) filed on August 14, 2015, and incorporated by reference herein).
|
|
|
10.17
|
Form of Executive Stock Option Agreement (filed
as Exhibit 10.17 to the Company’s Annual Report on Form 10-K filed on March 2, 2017, and incorporated by reference herein)
|
|
10.18
|
Form of Employee Stock Option Agreement (filed
as Exhibit 10.18 to the Company’s Annual Report on Form 10-K filed on March 2, 2017, and incorporated by reference herein)
|
|
|
10.19
|
Lease, dated February 18, 2016, between The Connell Company and Edge Therapeutics, Inc. (filed as exhibit 10.1 to the Company’s Quarterly Report on Form
10-Q filed on May 3, 2016, and incorporated by reference herein).
|
|
|
10.20
|
Letter Agreement, dated February 3, 2019, by and among Edge Therapeutics, Inc., PDS Biotechnology Corporation and Brian A. Leuthner (filed as
exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 4, 2019, and incorporated by reference herein)
|
|
|
23.1
|
Consent of KPMG LLP
(filed herewith).
|
|
|
31.1
|
||
|
31.2
|
||
|
32.1 (1)
|
||
|
32.2 (1)
|
||
|
101.INS
|
XBRL Instance Document
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
| (1) |
This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed
incorporated by reference into any filing under the Securities Act or the Exchange Act.
|
| + |
Indicates management contract or compensatory plan.
|
| * |
Confidential Treatment has been granted with respect to certain portions of this Exhibit. Omitted portions have been filed separately with the Securities and Exchange
Commission.
|
| ** |
Confidential Treatment has been requested with respect to certain portions of this Exhibit. Omitted portions have been filed separately with the Securities and Exchange
Commission.
|
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Form 10-K to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
Edge Therapeutics, Inc.
|
||
|
February 21, 2019
|
By:
|
/s/ Brian A. Leuthner
|
|
Brian A. Leuthner
|
||
|
President and Chief Executive Officer
|
||
|
(Principal Executive Officer)
|
||
|
February 21, 2019
|
By:
|
/s/ Andrew Saik
|
|
Andrew Saik
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial Officer)
|
||
Pursuant to the requirements of the Securities Exchange Act of 1934, this Form 10-K has been signed by the following persons in the capacities indicated
below and on the dates indicated:
|
Signature
|
Title
|
Date
|
||
|
/s/ Brian A. Leuthner
|
President and Chief Executive Officer and Director
|
February 21, 2019
|
||
|
Brian A. Leuthner
|
(Principal Executive Officer)
|
|||
|
/s/ Andrew Saik
|
Chief Financial Officer
|
February 21, 2019
|
||
|
Andrew Saik
|
(Principal Financial Officer)
|
|||
|
/s/ Sol Barer
|
Chairman, Board of Directors
|
February 21, 2019
|
||
|
Sol Barer, Ph.D.
|
||||
|
/s/ Isaac Blech
|
Vice Chairman, Board of Directors
|
February 21, 2019
|
||
|
Isaac Blech
|
||||
|
/s/ Rosemary A. Crane
|
Director
|
February 21, 2019
|
||
|
Rosemary A. Crane
|
||||
|
/s/ James Loughlin
|
Director
|
February 21, 2019
|
||
|
James Loughlin
|
||||
|
/s/ R. Loch Macdonald
|
Director
|
February 21, 2019
|
||
|
R. Loch Macdonald, M.D., Ph.D.
|
||||
|
/s/ Liam Ratcliffe
|
Director
|
February 21, 2019
|
||
|
Liam Ratcliffe, M.D., Ph.D.
|
||||
|
/s/ Robert Spiegel
|
Director
|
February 21, 2019
|
||
|
Robert Spiegel, M.D.
|
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Edge Therapeutics, Inc.:
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Edge Therapeutics,
Inc. (the Company) as of December 31, 2018 and 2017, and the related statements of operations and comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2018 and the related notes (collectively, the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over
financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ KPMG LLP
We have served as the Company’s auditor since 2014.
Short Hills, New Jersey
February 21, 2019
EDGE THERAPEUTICS, INC.
Balance Sheets
|
December 31,
2018
|
December 31,
2017
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
34,645,549
|
$
|
88,067,647
|
||||
|
Prepaid expenses and other current assets
|
1,005,589
|
986,680
|
||||||
|
Total current assets
|
35,651,138
|
89,054,327
|
||||||
|
Property and equipment, net
|
426,952
|
3,423,880
|
||||||
|
Other assets
|
142,870
|
142,870
|
||||||
|
Total assets
|
$
|
36,220,960
|
$
|
92,621,077
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
LIABILITIES
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
399,447
|
$
|
4,369,133
|
||||
|
Accrued expenses
|
419,119
|
5,422,205
|
||||||
|
Restructuring reserve
|
5,563,186
|
-
|
||||||
|
Short term debt
|
–
|
3,075,421
|
||||||
|
Total current liabilities
|
6,381,752
|
12,866,759
|
||||||
|
Noncurrent liability:
|
||||||||
|
Long term debt
|
–
|
17,382,907
|
||||||
|
STOCKHOLDERS’ EQUITY
|
||||||||
|
Preferred stock, 5,000,000 shares authorized at December 31, 2018 and 2017, zero outstanding
|
–
|
–
|
||||||
|
Common stock, $0.00033 par value, 75,000,000 shares authorized at December 31, 2018 and December 31, 2017,
31,449,989 shares and 30,869,205 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively
|
10,591
|
10,400
|
||||||
|
Additional paid-in capital
|
222,644,982
|
214,309,370
|
||||||
|
Accumulated deficit
|
(192,816,365
|
)
|
(151,948,359
|
)
|
||||
|
Total stockholders’ equity
|
29,839,208
|
62,371,411
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
36,220,960
|
$
|
92,621,077
|
||||
See accompanying notes to the financial statements.
EDGE THERAPEUTICS, INC.
Statements of Operations and Comprehensive Loss
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Operating expenses:
|
||||||||
|
Research and development expenses
|
$
|
16,068,769
|
$
|
34,311,650
|
||||
|
General and administrative expenses
|
14,291,008
|
17,654,970
|
||||||
|
Restructuring expenses
|
9,914,209
|
–
|
||||||
|
Impairment charges
|
2,822,581
|
–
|
||||||
|
Total operating expenses
|
43,096,567
|
51,966,620
|
||||||
|
Loss from operations
|
(43,096,567
|
)
|
(51,966,620
|
)
|
||||
|
Other income (expense):
|
||||||||
|
Interest income
|
871,879
|
700,903
|
||||||
|
Interest expense
|
(1,425,255
|
)
|
(2,180,143
|
)
|
||||
|
Loss before income taxes
|
(43,649,943
|
)
|
(53,445,860
|
)
|
||||
|
Benefit for income taxes
|
2,781,937
|
2,586,057
|
||||||
|
Net loss and comprehensive loss
|
$
|
(40,868,006
|
)
|
$
|
(50,859,803
|
)
|
||
|
Loss per share attributable to common stockholders basic and diluted
|
$
|
(1.31
|
)
|
$
|
(1.67
|
)
|
||
|
Weighted average common shares outstanding basic and diluted
|
31,242,176
|
30,393,952
|
||||||
See accompanying notes to the financial statements.
EDGE THERAPEUTICS, INC.
Statements of Changes in Stockholders’ Equity (Deficit)
|
Common Stock
|
||||||||||||||||||||
|
Shares
Issued
|
Amount
|
Additional
Paid-in Capital
|
Deficit
Accumulated
|
Total
|
||||||||||||||||
|
Balance - December 31, 2016
|
28,918,516
|
$
|
9,756
|
$
|
190,341,769
|
$
|
(101,074,968
|
)
|
$
|
89,276,557
|
||||||||||
|
Stock based compensation expense
|
–
|
–
|
6,182,841
|
–
|
6,182,841
|
|||||||||||||||
|
Issuance of common stock, net of issuance costs
|
1,800,000
|
594
|
17,382,349
|
–
|
17,382,943
|
|||||||||||||||
|
Issuance of common stock from exercise of stock options
|
35,366
|
12
|
118,176
|
–
|
118,188
|
|||||||||||||||
|
Issuance of common stock from exercise of warrants
|
94,200
|
31
|
53,118
|
–
|
53,149
|
|||||||||||||||
|
Issuance of common stock from 401K match
|
21,123
|
7
|
217,529
|
–
|
217,536
|
|||||||||||||||
|
Cumulative-effect of new share-based compensation guidance
|
–
|
–
|
13,588
|
(13,588
|
)
|
–
|
||||||||||||||
|
Net loss
|
–
|
–
|
–
|
(50,859,803
|
)
|
(50,859,803
|
)
|
|||||||||||||
|
Balance - December 31, 2017
|
30,869,205
|
10,400
|
214,309,370
|
(151,948,359
|
)
|
62,371,411
|
||||||||||||||
|
Stock based compensation expense
|
–
|
–
|
7,469,441
|
–
|
7,469,441
|
|||||||||||||||
|
Issuance of common stock from exercise of stock options
|
198,300
|
65
|
721,130
|
–
|
721,195
|
|||||||||||||||
|
Issuance of common stock from exercise of warrants
|
175,999
|
58
|
(58
|
)
|
–
|
–
|
||||||||||||||
|
Issuance of common stock from vesting of RSUs
|
91,432
|
30
|
(30
|
)
|
–
|
–
|
||||||||||||||
|
Issuance of common stock from 401K match
|
115,053
|
38
|
145,129
|
–
|
145,167
|
|||||||||||||||
|
Net loss
|
–
|
–
|
–
|
(40,868,006
|
)
|
(40,868,006
|
)
|
|||||||||||||
|
Balance - December 31, 2018
|
31,449,989
|
$
|
10,591
|
$
|
222,644,982
|
$
|
(192,816,365
|
)
|
$
|
29,839,208
|
||||||||||
See accompanying notes to the financial statements.
EDGE THERAPEUTICS, INC.
Statements of Cash Flows
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(40,868,006
|
)
|
$
|
(50,859,803
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Stock-based compensation expense
|
7,469,442
|
6,182,841
|
||||||
|
Stock-based 401K company common match
|
145,167
|
217,536
|
||||||
|
Depreciation expense
|
174,347
|
182,918
|
||||||
|
Impairment of machinery and equipment
|
2,822,581
|
–
|
||||||
|
Amortization of debt discount
|
1,039
|
32,869
|
||||||
|
Amortization of debt issuance costs
|
125,355
|
108,407
|
||||||
|
Non-cash interest expense
|
405,278
|
363,909
|
||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other assets
|
(18,909
|
)
|
(32,099
|
)
|
||||
|
Accounts payable
|
(3,969,686
|
)
|
898,101
|
|||||
|
Accrued expenses
|
(5,003,087
|
)
|
2,208,490
|
|||||
|
Restructuring reserve
|
5,563,186
|
–
|
||||||
|
Net cash used in operating activities
|
(33,153,293
|
)
|
(40,696,831
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
–
|
(188,721
|
)
|
|||||
|
Net cash used in investing activities
|
–
|
(188,721
|
)
|
|||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from issuance of debt
|
–
|
5,000,000
|
||||||
|
Proceeds from exercise of stock options
|
721,195
|
118,188
|
||||||
|
Proceeds from exercise of warrants
|
–
|
53,149
|
||||||
|
Payments for debt back end fees
|
(990,000
|
)
|
–
|
|||||
|
Repayment of debt
|
(20,000,000
|
)
|
–
|
|||||
|
Proceeds from issuance of common stock, net of underwriting costs
|
–
|
17,382,943
|
||||||
|
Net cash (used) provided by financing activities
|
(20,268,805
|
)
|
22,554,280
|
|||||
|
Net decrease in cash
|
(53,422,098
|
)
|
(18,331,272
|
)
|
||||
|
Cash and cash equivalents at beginning of period
|
88,067,647
|
106,398,919
|
||||||
|
Cash and cash equivalents at end of period
|
$
|
34,645,549
|
$
|
88,067,647
|
||||
|
Supplemental disclosure of cash flow information:
|
||||||||
|
Cash paid for:
|
||||||||
|
Interest
|
$
|
1,051,167
|
$
|
1,635,562
|
||||
See accompanying notes to the financial statements.
Edge Therapeutics, Inc.
Notes to Financial Statements
Note 1 – Nature of Operations
Edge Therapeutics, Inc. (the “Company” or “Edge”) is a clinical-stage biotechnology company that seeks to discover, develop and
commercialize novel therapies capable of transforming treatment paradigms in the management of medical conditions. On March 28, 2018, the Company announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first
210 subjects randomized and treated in the Phase 3 multi-center, randomized, double-blind, placebo-controlled NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage demonstrated a low probability of achieving a statistically
significant difference compared to the standard of care in the study’s primary endpoint, if the study were to be fully enrolled. The independent Data Monitoring Committee (“DMC”) for the NEWTON 2 study recommended that the study be stopped based
on this demonstration. The DMC also reported that there were no safety concerns attributed to EG-1962.
Based on the DMC recommendation, the Company decided to discontinue the NEWTON 2 study and took steps to notify health authorities and
clinical investigators participating in the study.
On April 30, 2018, the Company announced that it was exploring strategic alternatives, which might have included, without limitation, an
acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the assets of the Company, a sale of stock, a strategic merger or other business
combination transaction or other transaction between the Company and a third party. The Company retained Piper Jaffray & Co. to serve as the financial advisor to its Board of Directors in certain aspects of the process.
On November 23, 2018, Edge, Merger Sub and PDS, a privately-held clinical-stage cancer immunotherapy company, entered into an Agreement
and Plan of Merger and Reorganization, or the Merger Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into PDS, with PDS
surviving the merger as the wholly-owned subsidiary of the combined company.
If the merger is completed, the business of Edge will become the business of PDS. If the merger is not completed, Edge will reconsider
its strategic alternatives and may pursue one of the following courses of action, which Edge currently believes are the most likely alternatives if the merger with PDS is not completed:
| ● |
Pursue another strategic transaction similar to the merger. Edge may resume its process of evaluating other companies interested in pursuing a strategic transaction with
Edge and, if a candidate is identified, focus its attention on negotiating and completing such a transaction with such candidate.
|
| ● |
Dissolve and liquidate its assets. If Edge is unable, or does not believe that it is able, to find a suitable candidate for another strategic transaction, Edge may dissolve
and liquidate its assets. In the event of dissolution, Edge would be required to pay all of its debts and contractual obligations and to set aside certain reserves for potential future claims. If Edge dissolves and liquidates its
assets, there can be no assurance as to the amount or timing of available cash that will remain for distribution to Edge’ stockholders after paying Edge’ debts and other obligations and setting aside funds for its reserves.
|
In the second quarter of 2018, the Company recorded an initial restructuring charge of $6.3 million. The components of the restructuring
charge included expenses of $4.0 million for severance benefits and $2.3 million for financial advisor fees, as well as ongoing legal fees expensed as incurred, and accrued retention compensation related to the restructuring of the organization.
The restructuring activity during 2018 is as follows:
|
Restructuring reserve at December 31, 2017
|
$
|
–
|
||
|
Initial restructuring charge
|
6,276,563
|
|||
|
Incurred legal fees
|
1,447,079
|
|||
|
Severance revisions
|
259,529
|
|||
|
Retention compensation
|
1,201,568
|
|||
|
Restructuring expenses to date (1)
|
9,184,739
|
|||
|
Payment of legal fees
|
(493,404
|
)
|
||
|
Payment of retention compensation
|
(56,925
|
)
|
||
|
Payment of advisor fees
|
(500,000
|
)
|
||
|
Payment of severance benefits
|
(2,571,224
|
)
|
||
|
Restructuring reserve as of December 31, 2018
|
$
|
5,563,186
|
| (1) |
Excludes non-cash stock based retention compensation of $729,470 expensed to date through restructuring expenses.
|
From the Company’s inception, it has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing
and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital. The Company’s future operations are highly dependent on the success of the merger with PDS.
Note 2 – Summary of Significant Accounting Policies
| (A) |
Use of estimates:
|
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates.
| (B) |
Significant risks and uncertainties:
|
The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors
include, but are not limited to: the Company’s ability to consummate the merger with PDS, the Company’s ability to preserve its cash resources, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property,
competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing
agreements for its products, and the Company’s ability to raise capital.
The Company currently has no commercially approved products and has ceased all research and development activities related to EG-1962
and suspended research for its other product candidates. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires
significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies.
| (C) |
Cash equivalents and concentration of cash balance:
|
The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents.
The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.
| (D) |
Property and equipment:
|
Property and equipment is recorded at cost. Depreciation is recorded for property and equipment using the straight-line method over the
estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life or term of the underlying lease. The Company reviews the recoverability of all long-lived assets, including the
related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.
| (E) |
Research and development:
|
Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to
use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion
of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may
differ from the pattern of costs incurred.
Following the DMC’s recommendation that the NEWTON 2 Trial for EG-1962 be stopped, the Company decided to discontinue the NEWTON 2 study
and took steps to notify health authorities and clinical investigators participating in the study. The Company has ceased all further research and development activities for EG-1962 and suspended research for its other product candidates and
implemented operating cost reductions and organizational restructurings, including a reduction in the Company’s workforce, to preserve its cash resources and better align the organization with its current operating plan. The estimated costs
associated with the study discontinuance have been accrued as of December 31, 2018.
| (F) |
Patent costs:
|
The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying
statements of operations and comprehensive loss. In light of the Company’s cessation of all further research and development activities for EG-1962 and suspension of research for its other product candidates, the Company has substantially scaled
back its patent prosecution activities.
| (G) |
Stock-based compensation:
|
The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a
straight-line basis over the vesting period of the award.
Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions, including, for stock options,
the expected life of the option, and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent
management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different
for future awards.
The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to
develop reasonable expectations about future exercise patterns and employment duration for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price
volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of options grants. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life
of the option.
| (H) |
Net loss per common share:
|
Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted
average common shares outstanding during the period. For all periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive.
Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.
The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as
they would be anti-dilutive:
|
As of December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Stock options to purchase Common Stock
|
7,043,825
|
6,462,795
|
||||||
|
Unvested Restricted Stock Units
|
509,962
|
-
|
||||||
|
Warrants to purchase Common Stock
|
78,596
|
374,653
|
||||||
|
Total
|
7,632,383
|
6,837,448
|
||||||
| (I) |
Income taxes:
|
The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets and liabilities
to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities. Deferred tax assets are
reduced if necessary by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.
| (J) |
Fair value of financial instruments:
|
Financial Accounting Standards Board (“FASB”) guidance specifies a hierarchy of valuation techniques based on whether the inputs to
those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
The three levels of the fair value hierarchy are as follows:
| ● |
Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level
1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
|
| ● |
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of
similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation
methodologies.
|
| ● |
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models,
discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.
|
| (K) |
Subsequent events:
|
Subsequent events have been evaluated through the date these financial statements were issued.
| (L) |
New accounting standards not yet adopted:
|
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases
(Topic 842).” The new standard requires organizations that lease assets—referred to as “lessees”—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases (see Note 9). This standard is
effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The standard requires a modified retroactive approach, but use of certain practical expedients is
permitted as per ASU 2018-11. The Company expects to use the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing
leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company
adopted this ASU on January 1, 2019. The impact of adoption on its financial statements will be to record a Right to Use Asset and Lease Liability of $1.5 million.
(M) New accounting standards adopted:
In March 2016, the FASB issued ASU No. 2016-09 which simplifies several aspects of the accounting for share-based payment transactions,
including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Public companies will be required to adopt this standard in annual reporting periods beginning after
December 15, 2016, and interim periods within those annual periods. The Company adopted this ASU on January 1, 2017.
The impact of adopting ASU 2016-09 resulted in the following:
| ● |
The Company recognized $84,786 of tax benefit along with a full valuation allowance as of the adoption date related to the historical excess tax benefits from historical
option exercises related to employee equity award activity.
|
| ● |
The Company elected to recognize forfeitures as they occur. The cumulative effect adjustment as a result of the adoption of this amendment on a modified retrospective basis
was not material.
|
There were no other material impacts to our consolidated financial statements as a result of adopting this updated standard.
Note 3 – Fair Value of Financial Instruments
|
Fair Value Measurements at Reporting Date Using
|
||||||||||||||||
|
Total
|
Quoted Prices in
Active Markets
(Level 1)
|
Quoted Prices in
Inactive Markets
(Level 2)
|
Significant
Unobservable Inputs
(Level 3)
|
|||||||||||||
|
As of December 31, 2018:
|
||||||||||||||||
|
Cash and cash equivalents
|
$
|
34,645,549
|
$
|
34,645,549
|
$
|
–
|
$
|
–
|
||||||||
|
As of December 31, 2017:
|
||||||||||||||||
|
Cash and cash equivalents
|
$
|
88,067,647
|
$
|
88,067,647
|
$
|
–
|
$
|
–
|
||||||||
There were no transfers between Levels 1, 2, or 3 during 2018 or 2017.
Note 4 – Property and Equipment
Property and equipment is summarized as follows:
|
December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Furniture and equipment
|
$
|
439,620
|
$
|
564,596
|
||||
|
Leasehold Improvements
|
438,996
|
438,996
|
||||||
|
Construction in Process
|
-
|
2,725,569
|
||||||
|
878,616
|
3,729,161
|
|||||||
|
Less accumulated depreciation
|
(451,664
|
)
|
(305,281
|
)
|
||||
|
Property and equipment, net
|
$
|
426,952
|
$
|
3,423,880
|
||||
In March 2018, following the recommendation of the Data Monitoring Committee, the Company made the decision to close down the EG-1962
NEWTON 2 study. The Company believes that it would be highly unlikely that the Company would be able to use the manufacturing equipment associated with EG-1962 for future use. As a result, the Company has recorded a full equipment impairment
charge in 2018 of $2,822,581.
Note 5 – Accrued Expenses
Accrued expenses and other liabilities consist of the following:
|
December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Accrued research and development costs
|
$
|
76,600
|
$
|
2,857,025
|
||||
|
Accrued professional fees
|
69,083
|
267,646
|
||||||
|
Accrued compensation
|
27,405
|
1,886,638
|
||||||
|
Accrued other
|
213,074
|
385,896
|
||||||
|
Deferred rent
|
32,957
|
25,000
|
||||||
|
Total
|
$
|
419,119
|
$
|
5,422,205
|
||||
Note 6 – Stock Warrants
In connection with certain of our preferred stock sales and debt issuances, we issued warrants to the placement agent and lender for
preferred stock. The warrants were recorded as liabilities with changes in fair value being recorded in the statement of operations and are calculated utilizing the Black-Scholes option pricing model. At the closing of the IPO date on October 6,
2015, these warrants become exercisable for shares of our common stock. These warrants were exercisable for 600,184 shares of common stock at exercise prices ranging from $5.79 to $12.10 and expire at various dates through 2020. During 2018, 2017
and 2016, 296,057, 166,762 and 58,769 warrants were exercised resulting in the issuance of 175,999, 94,200 and 44,032 shares of common stock, respectively. As of December 31, 2018, 78,596 warrants were exercisable.
Note 7 – Stock Options
The Company has three equity compensation plans: the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan and the 2014 Equity
Incentive Plan (the “Plans”). Originally, the Company was able to grant up to 548,206 and 1,096,411 shares of Common Stock as both incentive stock options (“ISOs”) and nonqualified stock options (“NQs”) under the 2010 Equity Incentive Plan and the
2012 Equity Incentive Plan, respectively. In 2013, the Company’s stockholders approved an increase to 1,279,146 shares authorized for issuance under the 2010 Equity Incentive Plan. In 2014, the Board of Directors of the Company (the “Board”)
approved an increase to 1,350,412 shares authorized for issuance under the 2010 Equity Incentive Plan.
In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 1,827,351
shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter prior to the termination of the 2014 Equity Incentive Plan,
pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as
the Board of Directors may determine in its discretion. On January 1, 2016, 2017 and 2018 the Plan Limit was increased to 3,047,323 shares, 4,204,063 shares and 5,438,831 shares, respectively.
Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the
option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four year term and NQs generally vest over a one, three or four year term. Unless terminated by the Board, the Plans shall continue to remain
effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding.
The Company issued the following non-qualified options to purchase shares of common stock to its newly appointed executives who are
still employed by the Company. The awards were granted outside of the Company’s 2014 Equity Incentive Plan and vest over four years with 25% vesting one year following the date of hire, and the remaining 75% vesting in 36 equal monthly installments
thereafter, subject to continued service to the Company through each vesting date and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the applicable option agreement and employment agreement. The grant
awards were made pursuant to the Nasdaq inducement grant exception as a material component of employment compensation.
|
Issue Date
|
25% Vesting Date
|
Executive
|
Number of Options
|
|||
|
November 16, 2015
|
October 30, 2016
|
SVP, General Counsel and Secretary
|
80,000
|
|||
|
November 1, 2017
|
October 31, 2018
|
Chief Financial Officer
|
200,000
|
The Company’s stock-based compensation expense was recognized in operating expense as follows:
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Stock-Based Compensation
|
||||||||
|
Research and development
|
$
|
2,503,889
|
$
|
2,687,975
|
||||
|
General and administrative
|
4,236,083
|
3,494,866
|
||||||
|
Retention compensation
|
729,470
|
–
|
||||||
|
Total
|
$
|
7,469,442
|
$
|
6,182,841
|
||||
The fair value of options granted during the years ended December 31, 2018 and 2017 was estimated using the Black-Scholes option
valuation model utilizing the following assumptions:
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Weighted
Average
|
Weighted
Average
|
|||||||
|
Volatility
|
86.33
|
%
|
88.87
|
%
|
||||
|
Risk-Free Interest Rate
|
2.23
|
%
|
1.88
|
%
|
||||
|
Expected Term in Years
|
6.00
|
6.00
|
||||||
|
Dividend Rate
|
0.00
|
%
|
0.00
|
%
|
||||
|
Fair Value of Option on Grant Date
|
$
|
5.08
|
$
|
6.93
|
||||
The following table summarizes the number of options outstanding and the weighted average exercise price:
|
Number
of Shares
|
Weighted Average
Exercise Price
|
Weighted Average Remaining
Contractual Life in Years
|
Aggregate
Intrinsic Value
|
|||||||||||||
|
Options outstanding at January 1, 2017
|
5,316,511
|
$
|
5.84
|
|||||||||||||
|
Granted
|
1,365,400
|
9.39
|
||||||||||||||
|
Exercised
|
(35,366
|
)
|
3.34
|
|||||||||||||
|
Forfeited
|
(183,750
|
)
|
9.46
|
|||||||||||||
|
Options outstanding at December 31, 2017
|
6,462,795
|
$
|
6.50
|
7.13
|
$
|
20,467,335
|
||||||||||
|
Vested and expected to vest at December 31, 2017
|
6,462,795
|
$
|
6.50
|
7.13
|
$
|
20,467,335
|
||||||||||
|
Exercisable at December 31, 2017
|
4,066,066
|
$
|
5.14
|
6.21
|
$
|
18,100,589
|
||||||||||
|
Options outstanding at December 31, 2017
|
6,462,795
|
$
|
6.50
|
|||||||||||||
|
Granted
|
2,322,906
|
7.52
|
||||||||||||||
|
Exercised
|
(198,300
|
)
|
3.64
|
|||||||||||||
|
Forfeited
|
(1,543,576
|
)
|
10.30
|
|||||||||||||
|
Options outstanding at December 31, 2018
|
7,043,825
|
$
|
6.09
|
5.84
|
$
|
3,977
|
||||||||||
|
Vested and expected to vest at December 31, 2018
|
7,043,825
|
$
|
6.09
|
5.84
|
$
|
3,977
|
||||||||||
|
Exercisable at December 31, 2018
|
5,001,465
|
$
|
5.71
|
5.67
|
$
|
3,977
|
||||||||||
At December 31, 2018 there was approximately $8,725,126 of unamortized stock compensation expense, which is expected to be recognized
over a remaining average vesting period of 2.52 years.
The Company may grant RSUs to eligible employees, including its executives, and non-employee directors.
RSUs represent a right to receive one share of the Company’s common stock, upon the completion of a specific period of continued service
or achievement of a certain milestone. RSU awards are valued at the market price of the Company’s common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RSU awards on a straight-line
basis over the requisite service period of these awards.
The following table summarizes the number of RSUs outstanding and the weighted average grant price:
|
Number
of RSUs
|
Weighted Average
Grant Price
|
|||||||
|
RSUs outstanding at December 31, 2017
|
–
|
$
|
–
|
|||||
|
Granted
|
601,394
|
0.85
|
||||||
|
Released
|
(91,432
|
)
|
0.85
|
|||||
|
Forfeited
|
–
|
–
|
||||||
|
RSUs outstanding at December 31, 2018
|
509,962
|
$
|
0.85
|
|||||
At December 31, 2018, there was approximately $236,534 of unamortized RSU compensation expense, which is expected to be recognized over
a remaining average vesting period of 0.62 years.
Note 8 – Income Taxes
A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows:
|
Year Ended December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Federal statutory rate
|
21.0
|
%
|
34.0
|
%
|
||||
|
State taxes
|
0.4
|
%
|
1.1
|
%
|
||||
|
Change in Statutory Rate
|
–
|
(25.6
|
)%
|
|||||
|
Permanent differences
|
(5.4
|
)%
|
(11.0
|
)%
|
||||
|
Research and development
|
6.3
|
%
|
21.2
|
%
|
||||
|
State taxes/ sale of NOL
|
6.4
|
%
|
4.8
|
%
|
||||
|
Valuation allowance
|
(22.3
|
)%
|
(19.7
|
)%
|
||||
|
Effective tax rate
|
6.4
|
%
|
4.8
|
%
|
||||
The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows:
|
December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Federal net operating losses
|
$
|
27,011,760
|
$
|
21,312,121
|
||||
|
State net operating losses
|
1,929,997
|
2,268,249
|
||||||
|
Stock options
|
1,847,546
|
1,608,750
|
||||||
|
Federal tax credit
|
26,815,998
|
24,060,243
|
||||||
|
State tax credits
|
506,752
|
384,740
|
||||||
|
Amortization
|
229,065
|
612,878
|
||||||
|
Accrued expense
|
813,073
|
7,027
|
||||||
|
Depreciation
|
826,109
|
18,498 |
||||||
|
Other
|
17,993
|
12,501
|
||||||
|
Total gross deferred tax assets
|
59,998,293
|
50,285,007
|
||||||
|
Less valuation allowance
|
(59,998,293
|
)
|
(50,285,007
|
)
|
||||
|
Net deferred tax assets
|
$
|
–
|
$
|
–
|
||||
In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to
determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient
taxable income prior to the expiration of the net operating loss carryforwards. There was a full valuation allowance against the net deferred tax assets as of December 31, 2018 and December 31, 2017.
At December 31, 2018, the Company had federal net operating loss (“NOL”) carryforwards of approximately $101.5 million which expire
between 2029 and 2037. NOLs of $27.1 million generated in 2018 have an indefinite carryforward period. At December 31, 2018, the Company had federal research and development
credits carryforwards of approximately $2.4 million and an orphan drug credit carryover of approximately $24.4 million. The Company may be subject to the net operating loss utilization provisions of Section 382 of the Internal Revenue Code. The
effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before
the change, changes to the Company’s capital during a specified period prior to the change, and the federal published interest rate. Although the Company has not completed an analysis under Section 382 of the Code, it is likely that the utilization
of the NOLs will be limited.
At December 31, 2018, the Company had approximately $27.1 million of
State of New Jersey NOLs which expire between 2030 and 2038. At December 31, 2018, the Company had approximately $0.6 million of the State of New Jersey research development credits carryforwards. The State of New Jersey has enacted legislation
permitting certain corporations located in New Jersey to sell state tax loss carryforwards and state research and development credits, or net loss carryforwards. The Technology Business Tax Certificate Transfer Program enables qualified,
unprofitable NJ-based technology or biotechnology companies with fewer than 225 US employees (including parent company and all subsidiaries) to sell a percentage of New Jersey NOLs and research and development (“R&D”) tax credits to unrelated
profitable corporations. In 2018, the Company sold $31,689,956 of State of New Jersey NOLs and $131,214
of State of New Jersey R&D Credits for $2,824,228. In 2017, the Company sold $26,097,607 of State of New Jersey NOLs and $424,466 of State of New Jersey R&D Credits for $2,586,057.
Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax
returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2018, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception in 2009 and as such,
tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. In September 2017, the IRS
concluded auditing the Company’s 2015 tax year resulting in a no change letter. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax
benefits and has not accrued any interest or penalties for 2018.
On December 22, 2017, H.R. 1 (also, known as the Tax Cuts and Jobs Act (the “Tax Act”)) was signed into law. Among its numerous changes
to the Internal Revenue Code, the Tax Act reduces U.S. federal corporate tax rate to 21%. As a result, the most significant impact on its financial statements was the reduction of approximately $13.6 million for the deferred tax assets related to
net operating losses and other assets. Such reduction was offset by changes to the Company’s valuation allowance as of December 31, 2017. We previously provided a provisional estimate of the effect
of the Tax Act in our financial statements. In the fourth quarter of 2018, we completed our analysis to determine there was no additional effect of the Tax Act as of December 31, 2018.
On July 1, 2018, the New Jersey governor signed into law a bill which included significant changes to the New Jersey taxation of
corporations. Chiefly, this legislation imposes a 2.5% surtax on taxpayers with allocated net income over $1 million for 2018 and 2019, and a 1.5% surtax for taxpayers with allocated net income over $1 million for 2020 and 2021. In addition, the
state is changing its filing requirements from separate entity reporting to combined reporting on a water’s edge basis. Further, there are changes to the state’s computation of its dividend received deduction and application of IRC section
163(j). The Company has considered these changes and does not believe this change in law will have a material impact due to availability of significant New Jersey NOL carried forward to set off against future taxable income and a full valuation
allowance against the net deferred tax assets.
Note 9 – Commitments and Contingencies
Evonik
The Company entered into an agreement with SurModics Pharmaceuticals, Inc. (“SurModics”) in October 2010 for the exclusive worldwide
licensing of certain technology, patent rights and know-how rights related to the production of EG-1962, (the “Evonik Agreement”). This agreement was later transferred to Evonik Industries AG (“Evonik”) when it purchased substantially all the
assets of SurModics.
Pursuant to the Evonik Agreement, in exchange for the license, the Company agreed to make milestone payments totaling up to $14.75
million upon the achievement of certain development, regulatory and sales milestones detailed in the Evonik Agreement. The Company paid $0.25 million upon execution of the Evonik Agreement. In August 2016, the Company paid a milestone of $1.0
million after the first patient in the Phase 3 clinical trial of EG-1962 was dosed. In addition, the Evonik Agreement calls for the Company to pay royalties on sales of certain products based on a mid-single digit percentage of net sales. The
Evonik Agreement provides for the reduction of royalties in certain limited circumstances.
The term of the Evonik Agreement will continue until the expiration of the Company’s obligation to pay royalties to Evonik. Either party
may terminate the Evonik Agreement due to material breach by the other party. Evonik may terminate the Evonik Agreement or convert it to a non-exclusive license, in either case upon giving the Company written notice, if the Company fails to use
commercially reasonable efforts to hit certain specified development, regulatory and commercial milestones.
Following the discontinuation of the NEWTON 2 trial for EG-1962, the Company has ceased all research and development efforts related to
EG-1962 and suspended efforts on its other product candidates. As such, unless the Company resumes such development activities, it is unlikely that the Company will have any additional milestone or royalty obligations to Evonik in the future.
Oakwood Amended and Restated Master Formulation Development Agreement
In June 2017, the Company entered into an Amended and Restated Master Formulation Development Agreement (the “Restated Development
Agreement”) with Oakwood Laboratories, L.L.C. (“Oakwood”), pursuant to which Oakwood agreed to continue to provide the Company with certain drug formulation development and non-commercial manufacturing services for EG-1962, in accordance with
project plans that may be entered into from time to time.
Under the Restated Development Agreement, the Company agreed to pay Oakwood to perform services under agreed upon project plans and to
pay Oakwood up to an aggregate of $4.5 million. In July 2017 and April 2018, the Company paid $1.5 million and $0.5 million, respectively, of such aggregate amount in connection with entering into the Restated Development Agreement. The remaining
$2.5 million was payable no later than April 1, 2019. The remaining payment was discounted to $2.375 million and paid pursuant to an accelerated payment agreement entered into in August 2018. As of December 31, 2018, there are no remaining
payments under the Restated Development Agreement.
As additional consideration for performance under the Restated Development Agreement and the Supply Agreement (as defined below), the
Company agreed to pay Oakwood a royalty, during the Royalty Term, in an amount equal to a low single digit percentage of net sales of EG-1962, regardless of the manufacturer or supplier thereof. The “Royalty Term” is the period commencing upon the
commercial launch of EG-1962 by the Company and continuing until twelve (12) years following such launch.
The term of the Restated Development Agreement continues until the expiration or termination of the Supply Agreement, unless earlier
terminated (the “Term”). The Company has the right to terminate project plans upon the occurrence of various circumstances described in the Restated Development Agreement. In the event that the Company terminates the most recent project plan
prior to completion (which would include the Company’s decision to discontinue the development or commercialization of EG-1962), the Company must pay to Oakwood a termination fee for work completed. There are no payments due as of December 31,
2018.
Oakwood Manufacturing and Supply Agreement
Concurrent with its entry into the Restated Development Agreement, on June 30, 2017, the Company entered into a Manufacturing and Supply
Agreement with Oakwood (the “Supply Agreement”), pursuant to which Oakwood agreed to manufacture and supply, and the Company agreed to purchase from Oakwood, EG-1962 in commercial quantities following the commercial launch of the product.
Pursuant to the Supply Agreement, the Company agreed to pay Oakwood milestone payments that could total up to an aggregate of $2.25
million upon the achievement of certain development and regulatory milestones.
The term of the Supply Agreement will terminate automatically upon the termination of the Restated Development Agreement for any
reason. Additionally, either party may terminate the Supply Agreement upon a material breach by the other party that fails to be cured in the applicable cure period.
Following the discontinuation of the NEWTON 2 trial for EG-1962, the Company has ceased all research and development efforts related to
EG-1962 and suspended efforts on its other product candidates. As such, the Company may terminate the Supply Agreement immediately upon notice to Oakwood (which will also result in the automatic termination of the Restated Development Agreement);
provided, that if it chooses to do so prior to completion of the most recent project plan attached to the Restated Development Agreement, the Company must pay to Oakwood a termination fee. While certain of the Company’s milestone payments to
Oakwood will remain outstanding (including the termination fee in the event the Restated Development Agreement is terminated), unless the Company resumes such development activities, it is unlikely that the Company will be required to pay
additional milestone or royalty payments to Oakwood in the future pursuant to the Restated Development Agreement or the Supply Agreement.
Class Action Civil Litigation
On April 23, 2018, a purported securities class action complaint was filed against Edge, Brian Leuthner (Edge’s President and Chief
Executive Officer) and Andrew Saik (Edge’s Chief Financial Officer) in the United States District Court for the District of New Jersey, captioned Sanfilippo v. Edge Therapeutics, Inc., Case No. 2:18-cv-8236. The complaint alleged that Edge, Mr.
Leuthner and Mr. Saik violated Section 10(b) of the Securities Exchange Act of 1934 by making false and misleading statements concerning Edge’s business, operations and prospects by failing to disclose that Edge’s developmental product EG-1962
allegedly would likely fail a futility analysis. The complaint also asserted a “control” person claim against Mr. Leuthner and Mr. Saik pursuant to Section 20(a) of the Exchange Act. The complaint was brought on behalf of all purchasers of Edge’s
common stock between December 27, 2017, and March 27, 2018, and sought unspecified damages. On December 7, 2018, the court appointed Sam Kirkpatrick and Amos Bakouple lead plaintiffs for the putative class and appointed the firm Glancy, Prongay
& Murray LLP lead counsel for the putative class. On February 14, 2019, lead plaintiffs voluntarily dismissed the action, without prejudice, as to all defendants.
Edge and the Edge Board have been named as defendants in two individual lawsuits and two putative class action lawsuits regarding the
merger, each of which alleges that the registration statement on Form S-4 (Registration No. 333-228937) filed by Edge on December 21, 2018 omitted material information with respect to the proposed transaction, which rendered the registration
statement on Form S-4 false or misleading. The case captioned Michael Condon v. Edge Therapeutics et al., case no. 2:19-cv-00152, or the Condon Action, was filed on January 4, 2019 in the United States District Court for the District of New Jersey.
The case captioned Adam Franchi et al. v. Edge Therapeutics et al., case no. 1:19-cv-00058-UNA, or the Franchi Action, was filed on January 9, 2019 in the United States District Court for the District of Delaware. The case captioned Jeffrey L.
Prince v. Edge Therapeutics et al., case no. 1:19-cv-00280, or the Prince Action, was filed on January 10, 2019 in the United States District Court for the Southern District of New York. The case captioned Brian Foldenauer et al. v. Edge
Therapeutics et al., case no. 1:19-cv-00280, or the Foldenauer Action, was filed on January 22, 2019 in the United States District Court for the District of Delaware.
The causes of action set forth in each of the Condon Action, the Franchi Action, the Prince Action and the Foldenauer Action are (i) a
claim against Edge and the Board for violations of Section 14(a) of the Exchange Act, as well as (ii) a claim against the Board for violations of Section 20(a) of the Exchange Act. In the Franchi Action, PDS was also named as a defendant in respect
of the claim regarding violations of Section 20(a) of the Exchange Act. In each case, the plaintiffs seek, among other things, injunctive relief, rescissory damages, and an award of attorneys’ fees and expenses.
Edge has voluntarily accepted service of process in the Franchi Action and Prince Action, but has not yet been served with process in
the Condon Action or the Foldenauer Action. On January 18, 2019, the plaintiffs in the Prince Action filed a motion for a preliminary injunction barring any stockholder vote on the proposed merger until revised disclosures are made to Edge’s
stockholders, and withdrew the motion for a preliminary injunction on February 1, 2019. Edge believes the litigation is without merit and in any event has been rendered moot by the final S-4 and subsequent disclosures. This litigation remains in
the initial pleadings phase.
Employment Matters
The Company has entered into employment agreements with each of its executive officers. The agreements generally provide for, among
other things, salary, bonus and severance payments. The employment agreements generally provide for between 12 months and 18 months of severance benefits to be paid to an executive (as well as certain potential bonus, COBRA and equity award
benefits), subject to the effectiveness of a general release of claims, if the executive terminates his or her employment for good reason or if the Company terminates the executive’s employment without cause. Such severance payments may be
provided for as long as 24 months in connection with a termination following a change of control. The continued provision of severance benefits is conditioned on each executive’s compliance with the terms of the Company’s confidentiality and
invention and assignment agreement as well as his or her release of claims.
On April 30, 2018, the Company initiated a corporate realignment to focus its efforts and resources on its ongoing operations and future
plans that include a reduction in its workforce. This realignment was initiated following the Company’s announcement that it was discontinuing the Phase 3 NEWTON 2 study, based on the recommendation of an independent Data Monitoring Committee (the
“DMC”) that the Company stop its Phase 3 NEWTON 2 study. The DMC recommendation was based on its conclusion that the study had a low probability of meeting its primary endpoint.
During 2018, the Company reduced its workforce from 37 employees to 10 employees. In addition, the Company anticipates completing the
payment of certain employee severance and benefits and certain retention compensation, as approved by the Compensation Committee of the Board of Directors, by the fourth quarter of fiscal year 2019.
Leases
Effective December 13, 2013, the Company entered into a 63 month lease for approximately 8,000 square feet of office space in Berkeley
Heights, New Jersey. On February 18, 2016, the Company entered into a new 63 month lease for approximately 20,410 square feet of office space within the same office complex in Berkeley Heights, New Jersey. The terms of the new lease were
structured so that the termination date of the December 13, 2013 lease coincided with the commencement date of the new lease on August 13, 2016. As a result of the lease termination, the Company wrote off $67,118 of leasehold improvements.
Rent expense is recognized on a straight line basis where there are escalating payments, and was approximately $598,037 and $602,925 for
the years ended December 31, 2018 and 2017, respectively.
The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining
non-cancelable lease terms in excess of one year as of December 31, 2018:
|
Year Ended December 31,
|
||||
|
2019
|
$
|
604,541
|
||
|
2020
|
603,371
|
|||
|
2021
|
530,385
|
|||
|
2022 and after
|
–
|
|||
|
Total minimum payments required
|
$
|
1,738,297
|
||
Note 10 – Debt
On August 1, 2016, the Company entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”) with
Hercules Capital, Inc., formerly known as Hercules Technology Growth Capital, Inc. (“Hercules”). Pursuant to the Amended Loan Agreement, the Company was able to borrow up to $20,000,000. At closing, the Company borrowed $15,000,000 of the amount
available for draw under the Amended Loan Agreement (and received proceeds net of the amount then outstanding under the Original Loan Agreement, fees and expenses). On May 23, 2017, the Company elected to draw down the second tranche of $5
million. Pursuant to the Amended Loan Agreement, in March 2018, the Company made a payment of $90,000, which is equal to 1.5% of the total amounts funded under the Original Loan Agreement.
In June 2018, the Company paid off its entire outstanding debt under the Amended Loan Agreement. The payment consisted of $20.0 million
for the principal amount, an additional $0.9 million in back-end fees and $0.1 million in accrued and unpaid interest.
As of December 31, 2018, the Company has no outstanding debt.
Note 11 – Retirement Plan
The Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees
subject to IRS-imposed limitations. The 401K employer contribution for the 2018 and 2017 plan years were $159,559 and $258,383 respectively.
Page | 75